Development and application of genus-specific peptide arrays for kinome analysis by Arsenault, Ryan
  
 
 
 
 
 
 
Development and Application of Genus-Specific  
Peptide Arrays for Kinome Analysis 
 
 
 
 
 
 
 
A Thesis 
Submitted to the College of Graduate Studies and Research  
In Partial Fulfillment of the Requirements 
For the Degree of Doctor of Philosophy 
In the Department of Biochemistry  
University of Saskatchewan 
By 
Ryan Joseph Arsenault 
 
 
 
 
 
© Copyright Ryan J. Arsenault, December 2011 All Rights Reserved
i 
 
PERMISSION TO USE 
In presenting this thesis/dissertation in partial fulfillment of the requirements for a 
Postgraduate degree from the University of Saskatchewan, I agree that the Libraries of this 
University may make it freely available for inspection. I further agree that permission for 
copying of this thesis/dissertation in any manner, in whole or in part, for scholarly purposes 
may be granted by the professor or professors who supervised my thesis/dissertation work or, 
in their absence, by the Head of the Department or the Dean of the College in which my thesis 
work was done. It is understood that any copying or publication or use of this 
thesis/dissertation or parts thereof for financial gain shall not be allowed without my written 
permission. It is also understood that due recognition shall be given to me and to the 
University of Saskatchewan in any scholarly use which may be made of any material in my 
thesis/dissertation. 
 
DISCLAIMER 
Reference  in this thesis/dissertation  to any specific commercial products, process, or service 
by trade name, trademark, manufacturer, or otherwise, does not constitute or imply its 
endorsement, recommendation, or favoring by the University of Saskatchewan. The views 
and opinions of the author expressed herein do not state or reflect those of the University of 
Saskatchewan, and shall not be used for advertising or product endorsement purposes. 
 
Requests for permission to copy or to make other uses of materials in this thesis/dissertation 
in whole or part should be addressed to: 
 
 Head of the Department of Biochemistry 
 University of Saskatchewan 
 Saskatoon, Saskatchewan S7N 5E5 Canada 
 
 OR 
 
 Dean 
 College of Graduate Studies and Research 
 University of Saskatchewan 
 107 Administration Place 
 Saskatoon, Saskatchewan  S7N 5A2 Canada 
 
ii 
 
ABSTRACT 
Phosphorylation represents a central mechanism to regulate cell function. Protein 
phosphorylation is catalyzed by a class of enzymes called kinases, the cellular complement of 
which is referred to as its kinome. The study of the kinome has led to the development of 
peptide arrays as a high throughput tool. Though the approach was effective, it was limited to 
genera with characterized phosphoproteomes, as well as by the practice of interpreting 
emerging data through platforms designed for gene expression data. Within this thesis, these 
pivotal roadblocks are addressed through the presentation of 1) an approach for the 
development of custom-designed genus-specific arrays based on proteomic information and 
2) a data analysis pipeline, Platform for Integrated, Intelligent Kinome Analysis (PIIKA), 
developed specifically for peptide array kinome data. The utility of these advances is 
demonstrated through the creation of the customized peptide arrays and subsequent 
confirmation of PIIKA-enhanced data transformation and mining. These techniques (custom 
array and PIIKA) were then applied to two complex host-pathogen interactions: prion 
diseases and Mycobacterium avium subsp. paratuberculosis (MAP) infection.  
 Prion diseases result from the misfolding of the widely expressed and highly 
conserved cellular prion protein (PrPC) into an infectious and pathological scrapie-like 
conformation (PrPSc). Little is known about the function of PrPC in either the normal or 
diseased states, although a role in signal transduction has been suggested. Two PrPC protein-
specific ligands, PrP 106-126 prion fragment and the prion-specific monoclonal antibody 
6H4, were used to induce signalling in neuronal cells. Kinome analysis revealed distinct 
signalling pathways and varied signalling responses for each PrPC ligand. This observation is 
consistent with the emerging concept that PrPC interacts with multiple cellular proteins and 
plays a multifunctional role in regulating cellular responses.   
MAP is the causative agent of Johne’s disease in cattle. MAP establishes a persistent 
infection and has the ability to evade immune responses while replicating inside macrophages. 
Kinome analysis indicated that MAP is able to inhibit the interferon gamma (IFNγ)-induced 
JAK-STAT signalling pathway, eliminating the activation of downstream effectors. Further 
analysis indicated that the JAK-STAT pathway was blocked at the level of the IFNγ receptor, 
and JAK-STAT suppressor molecules known as SOCS were activated, both novel findings in 
the field of MAP pathogenesis.  
Collectively, these investigations highlight the use of custom-designed and genus-
specific peptide arrays to address complex biology in distinct genera. 
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1.0 LITERATURE REVIEW 
 
1.1 Phosphorylation-Mediated Cellular Signalling 
1.1.1 Kinases 
In the mid 1950s, Edwin G. Krebs and Edmond H. Fischer described a means of 
enzymatic regulation based on the post-translational modification of proteins through 
phosphorylation. Protein phosphorylation was reversible and had a direct effect on enzymatic 
activity (Krebs and Fischer, 1955; Fischer and Krebs, 1955). It was subsequently determined 
that this phosphorylation-based protein modification was not limited to modulating enzymatic 
activity but affected a broad range of protein functions (Rubin and Rosen, 1975). For their 
role in this important advancement in cell biology, Krebs and Fischer were awarded the Nobel 
Prize in Physiology or Medicine in 1992. Protein kinases are now recognized as one of the 
largest and most important enzyme classes. Consisting of over 500 members (Figure 1.1), 
human protein kinases are responsible for modifying an estimated one third of the human 
proteome (protein complement of the cell) (Hunter, 1995; Manning, et al., 2002). The 
reversibility of protein phosphorylation and the generation of functional isoforms of an 
individual protein through complex patterns of phosphorylation at multiple sites add 
considerable functional diversity and complexity to the proteome.  
 Eukaryotic kinases catalyze the transfer of the γ-phosphate of adenosine triphosphate 
(ATP) or guanosine triphosphate (GTP) to hydroxyl groups. This transfer of phosphate groups 
generates phosphate monoesters in the case of serine- and threonine-containing proteins, or 
phenolic groups in the case of tyrosine-containing proteins (Hanks and Hunter, 1995). Several 
kinases have been found to have the capacity to utilize both ATP and GTP: ectoprotein kinase 
(Mastro and Sniezek, 1982), casein kinase 2 (Niefind, et al., 1999) and calcium/calmodulin-
dependent protein kinase II (CaMKII) (Bostrom, et al., 2009). The amino acid residues that 
most commonly undergo phosphorylation, serine, threonine and tyrosine, do so at a ratio of 
1,000:100:1 (Hunter, 1995). Protein kinases form a family of enzymes which are related due 
to the presence of conserved kinase domains. These domains are composed of approximately 
250-300 amino acid residues and form the catalytic site. The kinase domains carry out three 
separate functions: 1) binding and orientation of the ATP (or GTP) phosphate donor in 
complex with a divalent cation, usually involving Mg2+ or Mn2+, 2) binding and orientation of 
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the substrate, and 3) transferring the γ-phosphate from ATP (or GTP) to the acceptor-
hydroxyl containing residue of the substrate.  
Another common type of kinase is the histidine protein kinase (HPK) which is found 
widely outside of the animal kingdom (Wolanin, et al., 2002). HPKs are transmembrane 
receptors which autophosphorylate a conserved histidine residue within the kinase. This 
phosphate group is then transferred to an aspartate residue in the receiver domain of a 
different protein, which carries out downstream signalling effects. Histidine kinases are part 
of the two-component signalling systems found in bacteria, plants and many other eukaryotes.  
According to Kinbase, the online kinase database maintained by the Salk Institute and 
the biotechnology company SUGEN (www.kinase.com/kinbase), there are nine eukaryotic 
protein kinase groups: cAMP-dependent protein kinase/protein kinase G/protein kinase C 
extended (AGC), Calcium/Calmodulin regulated kinases (CAMK), Cell Kinase I (CK1), 
Cyclin-dependent Kinases and other close relatives (CMGC), Receptor Guanylate Cyclases 
(RGC), MAP Kinase cascade kinases (STE), Protein Tyrosine Kinase (TK), Tyrosine Kinase 
Like (TKL), and atypical protein kinases (Atypical). A tenth informal group, named Other, is 
made up of kinases which are not readily classified into any of the other established groups 
and is comprised of at least several hundred kinases (Figure 1.1). 
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Figure 1.1. Human kinome dendrogram. The complement of kinases within the human 
genome as determined by Manning, et al., (2002) is shown. The dendrogram shows the 
sequence similarity between catalytic domains. The distance along the branches between two 
kinases is proportional to the divergence between their sequences. Major groups of kinases 
are labelled and coloured distinctly. cAMP-dependent protein kinase/protein kinase G/protein 
kinase C extended (AGC), Calcium/Calmodulin regulated kinases (CAMK), Cell Kinase I 
(CK1), Cyclin-dependent Kinases and other close relatives (CMGC), MAP Kinase cascade 
kinases (STE), Protein Tyrosine Kinase (TK), Tyrosine Kinase Like (TKL), and Guanylate 
Cyclase kinases (GYC) (not considered an official kinase group). This illustration is 
reproduced courtesy of Cell Signalling Technology, Inc. (www.cellsignal.com).  
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1.1.2 Protein Kinases in Disease and as Therapeutic Targets 
 The disruption of phosphorylation-mediated cellular signalling is associated with a 
broad range of diseases including cancer, inflammation, neurological disorders and diabetes 
(Manning and Caenepeel, 2005). Of the approximately 500 protein kinases found in the 
human genome, over 250 map to disease loci (Knuutila, et al., 1998). The involvement of 
kinases in disease is often the result of improper expression/localization/activity or mutations 
in the protein sequence which alters any of the kinases’ inherent characteristics. As will be 
discussed later, some pathogens produce their own enzymes to disrupt the natural pattern of 
host phosphorylation as a mechanism to subvert host defences (Section 1.5.2.3). 
The important role of kinases in many diseases, as well as their regulatory role for 
cellular function, makes them potential targets for drug therapy (Cohen, 2002). Each kinase 
has a conserved active site with sufficient unique characteristics to allow for rational drug 
design targeting individual kinases or kinase groups (Hopkins and Groom, 2002). There are 
estimates that approximately 20-25% of the druggable genome is comprised of kinases (Keri, 
et al., 2006). Kinase inhibitor treatment is seen as a more precise means of drug therapy than 
genetic manipulation, which activates or suppresses given genes. Unlike the disruption of 
gene expression, kinase inhibition acts proximal to the final cellular effectors; therefore, any 
unintended consequences can be more easily observed and managed. The central role of 
kinases in a variety of diseases, especially cancers, has led to considerable investment in the 
development of specific kinase inhibitors. Kinases are the most frequently targeted gene class 
in cancer therapy, and they are second only to G protein-coupled receptors in all therapeutic 
targets (Cohen, 2002; Hopkins and Groom, 2002).    
 Kinase inhibitors are an important class of drugs, and numerous examples have been 
employed for the treatment of a broad range of disorders. Gleevac® (imatinib), an inhibitor of 
the constitutively active breakpoint cluster region - Abelson murine leukemia viral oncogene 
homolog 1 (BCR-ABL) fusion protein, is approved for the treatment of leukemia and 
gastrointestinal stromal tumours (Druker, et al., 1996; Druker, et al., 2001). Other protein 
kinase inhibitors, such as the epidermal growth factor receptor (EGFR) inhibitors Tarceva® 
and IressaTM, have either received FDA approval or are in late-stage clinical development to 
treat various cancers (Nobel, et al., 2004; Eglen and Reisine, 2009). However, kinase 
inhibitors have not only been developed for the treatment of cancer (Eglen and Reisine, 
5 
 
2009). Other examples include ruboxistaurin to treat diabetic retinopathy, safingol (a protein 
kinase C inhibitor) for the treatment of atopical dermatitis and fasudil which has received 
approval in Japan for treatment of cerebral ischemia (Sasaki, et al., 2002; Ying, et al., 2006). 
Anti-inflammatory drugs which suppress tumour necrosis factor (TNF)α and interleukin (IL)-
1β expression function through kinase inhibition (Lee, et al., 1994). Kinase involvement was 
determined through the study of the anti-inflammatory activity of pyridinyl-imidazole 
compounds. These compounds were shown to function through the inhibition of proteins 
referred to as cytokine-suppressive anti-inflammatory drug-binding proteins. These binding 
proteins were kinases which activated inflammatory cytokine responses; the kinases are now 
referred to as isoforms of mitogen-activated protein kinase (MAPK)14 (Gene Database, 
ncbi.nlm.nih.gov/gene). Two immunosuppressive drugs, cyclosporine A and rapamycin, 
function through broad non-specific modulation of the phosphorylation status of the cell: 
cyclosporine A through inhibition of phosphatases (Liu, et al., 1991) and rapamycin through 
inhibition of kinases (Heitman, et al., 1991). This disruption of the entire kinase or 
phosphatase class of enzyme inhibits not only immune response but also various other 
functions modulated by protein phosphorylation; thus, kinase inhibitors with broad activity 
can have extensive side effects. A partial listing of potential therapeutic kinase inhibitors and 
their current stage of development is presented in Table 1.1. 
In addition to their important role as therapeutics, these kinase inhibitors are valuable 
experimental tools for enhancing our understanding of basic biology, cellular function, cell 
signalling and pathway cascades. 
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Table 1.1.  Select therapeutic kinase inhibitors both approved and undergoing clinical 
trials.  
 
Drug Target Kinase Status Disease/Disorder 
Avastin VEGFR Approved 
Metastatic carcinoma, non-small cell lung cancer, 
breast cancer 
Erbitux EGFR Approved Metastatic colorectal cancer 
Fasudil Rho kinase Approved Cerebral vasospasm following surgery 
Fostamatinib 
Multikinase 
Inhibitor Phase II 
Colorectal, non-small cell lung, head and neck 
hepatocellular and renal cancer 
Gleevac 
ABL, KIT, 
PDGFR Approved 
Gastrointestinal stromal tumours, chronic 
myelogenous leukemia 
GSK2118436 BRAF kinase Phase II Non-small cell lung cancer 
Herceptin Her-2 Approved Her-2 positive breast cancer 
Iressa EGFR Approved Non-small cell lung cancer 
MLN8237 Aurora A Phase II Stage III-IV melanoma 
Nexavar 
Multikinase 
Inhibitor Approved Renal cell carcinoma 
P1446A-05 
Cyclin dependent 
kinase Phase I Hematologic malignancy 
Rapamune mTOR kinase Approved Organ rejection in renal transplants 
SB-681323 p38 MAPK Phase II Neuropathic pain, nerve trauma 
Sprycel TK Inhibitor Approved 
Chronic myelogenous leukemia, acute 
lymphoblastic leukemia 
Sutent 
VEGFR2, PDGFR, 
FLT3, KIT Approved Kidney cancer, gastrointestinal stromal tumours 
Tarceva EGFR Approved Metastatic non-small cell lung cancer 
Tasigna Abl Approved Chronic myelogenous leukemia 
Tivozanib VEGFR, TK  Phase II Renal cell carcinoma 
TORISEL mTOR kinase Approved Advanced renal cell carcinoma 
Tykerb Her-2, others Approved Advanced breast cancer 
Vandetanib VEGFR, EGFR Approved Medullary thyroid cancer 
Vectibix EGFR Approved Colorectal cancer 
 
Data sourced from Eglen and Reisine (2009), www.fda.gov and www.clinictrials.gov. 
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1.1.3 Phosphatases 
 The importance of protein phosphorylation to cellular function and its nature as a 
reversible post-translational modification means that the addition of phosphate groups, via the 
kinase, and removal, via the phosphatase, are equally important (Hunter, 1995).  Interestingly, 
while Fischer and Krebs (1955) discovered the kinase and the chemical nature of the reaction 
involving inorganic phosphate (Krebs and Fischer, 1956), the phosphatase that catalyzes the 
reverse reaction had been reported over a decade earlier (Cori and Green, 1943). Phosphatases 
dephosphorylate specific amino acids much the same way as kinases phosphorylate specific 
residues. Phosphatases can be tyrosine-specific (Alonso, et al., 2004), serine/threonine-
specific (Shi, 2009), histidine-specific (Kim, et al., 1993), have dual specificity (tyrosine and 
serine) (Camps et al., 2000) or dephosphorylate lipids (Maehama, et al., 2004). Tyrosine 
phosphatases are organized into four families: class I cysteine-based, class II cysteine-based, 
class III cysteine-based and aspartate-based (Alonso, et al., 2004). Serine/threonine 
phosphatases are organized into three families: phosphoprotein phosphatases, metal-
dependent protein phosphatases and aspartate-based phosphatases (Shi, 2009). While the 
number of tyrosine kinases and tyrosine phosphatases approximately match, the number of 
serine/threonine phosphatases is less than a tenth of the number of serine/threonine kinases. 
The human genome encodes 518 kinases in total (Manning, et al., 2002). There are 107 
protein tyrosine phosphatases (Alonso, et al., 2004) and approximately 30 serine/threonine 
phosphatases (Shi, 2009). Serine/threonine phosphatases are able to maintain specificity equal 
to that of kinases despite their smaller numbers due to their ability to share catalytic subunits 
among different phosphatases regulated by a number of regulatory subunits. While 
traditionally kinases, rather than phosphatases, have been the target of therapeutic 
intervention, there is emerging appreciation of the role of phosphatases in disease (Alonso, et 
al., 2004). One of the first studies which linked phosphatase activity with disease found the 
involvement of protein tyrosine phosphatase-1B in diabetic insulin sensitivity (Elchebly, et 
al., 1999). Since that study, at least 13 phosphatases have been implicated in disease (Alonso, 
et al., 2004).      
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  1.1.4 “Omics” from Genes to Kinases 
At the turn of this century, there was a strong focus on a genetic approach to the study 
of biological systems, from the individual cell to an entire complex multicellular organism. 
Indeed, the human genome project, which involved determining the entire DNA sequence of 
humans, was heralded as the means to elucidate the mechanism of nearly every human disease 
and condition (Collins and McKusick, 2001). When considering the complete genome 
sequence, functions are difficult to determine. A more focused approach that considers the 
transcriptionally active subset of the complete genome is a common means of studying 
genetics. The transcriptionally active portion of the genome in a cell is referred to as its 
transcriptome; transcriptomics is the most mature of the “omic” disciplines and is a widely 
applied technique for the global analysis of cellular responses. One of the limitations of 
transcriptional analysis is its inability to consider post-transcriptional events which may be 
important in the final phenotypic response of the cell. Specifically, transcription-based 
approaches are unable to consider events such as gene silencing, mRNA stability, 
translational efficiencies, protein turnover, sequestration of enzymes from substrates and the 
activation/deactivation tuning by a multitude of post-translation modifications, of which 
phosphorylation is a major class.  
 Intuitively, the transition from genetics to cellular responses closer to final effectors 
will reduce complicating intermediate factors. This allows a more accurate picture of what 
functionally relevant changes are occurring within the cell. For example, a gene encoding a 
protein may be transcribed but not translated; thus, it may not carry out any function within 
the cell. From this perspective, protein kinases may be an advantageous area to study as they 
are the core of signal transduction with a central role in the regulation of nearly every aspect 
of cellular behaviour (Manning, et al., 2002). Through their ability to modulate protein 
conformation and functional characteristics, kinases control diverse processes such as 
metabolism, transcription, cell cycle progression, cytoskeletal rearrangement and cell 
movement, apoptosis, and cell differentiation. Considering this, an understanding of host 
cellular responses at the level of phosphorylation-mediated signal transduction has the 
potential to offer insight into cell biology that has thus far eluded the transcription-based 
approaches. 
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1.1.5 The Phosphoproteome and Kinome 
Investigations of cellular phosphorylation can be divided into two broad categories: 
the kinome and the phosphoproteome (Jalal, et al., 2007). Kinome analysis considers a cell’s 
complement of kinases and subsequent phosphorylation of proteins. Phosphoproteome 
analysis considers the phosphorylation state of a cell’s complement of protein. The 
phosphoproteome and kinome are intimately related since the phosphoproteome represents 
the total activity of the kinome as well as that of the protein phosphatases. The techniques to 
study the kinome and phosphoproteome are quite experimentally distinct, though the kinome 
and phosphoproteome are closely related biologically.  
Phosphoproteome analysis is an attempt to define the subpopulation of the proteome 
which is modified by phosphorylation. Comprehensive characterization of the 
phosphoproteome involves defining which proteins undergo phosphorylation, at which 
residue, and the ensuing biology associated with the modification. Specific phosphorylation 
sites on a given protein can affect the protein’s function in different ways; for example, 
phosphorylation at one site can activate a protein’s enzymatic activity while phosphorylation 
at another site may inhibit this activity. A challenge to phosphoproteome analysis is that while 
the fraction of the proteome that undergoes phosphorylation is significant, the individual 
proteins involved in signal transduction are often expressed at very low levels (Mann, et al., 
2002). Furthermore, within the subpopulation of phosphorylated proteins, it is estimated that 
only 1-2% of the cellular complement of a given protein is phosphorylated at any one time. 
Phosphorylation of a protein can be difficult to measure due to the overwhelming amount of 
protein that may interfere with detection of the fraction which has undergone phosphorylation. 
These difficulties restrict some methods used to study the phosphoproteome. The three most 
common methods involve phosphospecific antibodies (Kalume, et al., 2004), two-dimensional 
electrophoresis (Gorg, et al., 2004) and mass spectroscopy (Mann, et al., 2002). These 
methods can also be used in combination. Limitations of these techniques include availability 
and specificity of reagents, identification of proteins, cost, and difficulty of analysis.    
 The study of the kinome suffers from fewer limitations than those faced when 
studying the phosphoproteome. Investigation of enzymatic activities is a well-established area 
in biochemistry and has a greater potential for specific and sensitive analysis. The well- 
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defined, highly conserved chemistry of enzymatic phosphorylation allows for the 
characterization of kinase activity, substrate specificity and kinase targeting. 
 
1.2 Peptide Arrays for Kinome Analysis 
Peptide arrays for kinome analysis are based on the use of peptides representing 
protein phosphorylation target sequences, which are synthesized and spotted onto an array 
surface (Houseman, et al., 2002). A sample containing an active kinase or kinases, such as in 
a cellular lysate, is applied to the array. These kinases phosphorylate their respective target 
sequences using the γ-phosphate from ATP, which has been added to the reaction mixture as 
the phosphate source. Any phosphatase activity which may inhibit or reverse peptide 
phosphorylation is reduced by the addition of a number of phosphatase inhibitors. These 
phosphorylation events are then visualized using one of a number of methods including 
phosphorylation-specific antibodies, radioactivity, a labelled chelator or phosphospecific 
stains. Quantification of the extent of phosphorylation of a given peptide target provides a 
measure of kinase activity within a sample. From this, the extent of phosphorylation of the 
represented protein can be inferred.  
The distinction between a kinome array and a phosphoproteome array depends on 
what is being measured: the phosphorylation of array peptides by active kinases or the 
phosphorylation state of the endogenous cellular protein substrate acted upon by kinases and 
phosphatases. Thus, kinase activity in kinome analysis or phosphorylation state of protein in 
phosphoproteome analysis is measured. In the case of peptide arrays for kinome analysis, the 
data are analyzed by observing the phosphorylation state of the peptide on the array. This 
peptide has been phosphorylated by the active kinases applied. In the case of 
phosphoproteome analysis, phosphorylated proteins within a cell at a given time point are 
observed. In both cases, the direct measurement is the extent of peptide/protein 
phosphorylation. However, the distinctions are the context in which the phosphorylation 
occurs, on the array or within the cell, and the method of measuring, either measuring peptide 
phosphorylation or capturing phosphorylated protein from within the cell. A disadvantage of 
the peptide array technique is the assumption that the phosphorylation state of the peptide on 
the array is a match for the protein of interest present in a cell. 
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A large number of peptide arrays for kinome analysis are commercially available. 
These arrays range in size from dozens to thousands of peptides, representing defined 
phosphorylation sites. A listing of commercial peptide arrays which are currently available for 
kinome analysis is presented in Table 1.2. 
 
 
 
Table 1.2. Commercially available peptide arrays.  
 
Name Technology Company 
Number of 
Substrates 
Visualization 
Method 
PepScan Spotted peptide array 
PepScan 
Therapeutics 
10,000-
100,000 Variable 
PepStar Custom spotted peptide array 
JPT Peptide 
Technologies 100-1,000 Variable 
PamChip 
Immobilized peptide on 
porous surface Pamgene 50-150 Fluorescence 
Peptide 
Array Unbound 96 well array ChemPep 96 Radiolabel 
CelluSpots 
Custom spotted peptide array 
cellulose membrane Intavis AG 1-384 Variable 
Reverse- 
phase 
Protein 
Microarray  
Sample blotting peptide 
array 
Theranostics 
Health 100s Fluorescence 
 
 
 
  1.2.1 Peptides as Kinase Substrates 
While utilizing the complete protein as the substrate for a given kinase would allow 
investigation of the reaction under scrutiny, synthesizing the full length protein is a significant 
task, and proteins are often unstable in an array environment. In addition, proteins can be 
phosphorylated at different sites, resulting in distinct phenotypes (Sridevi, et al., 2007; Smith, 
et al., 2009). If a full-length protein were printed onto an array, it would not be possible to 
determine which site is being targeted. Looking at the individual site of phosphorylation 
rather than the phosphorylation state of a protein allows a better characterization of functional 
changes due to the phosphorylation. For many protein kinases, the specificity of their 
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substrate recognition is determined by the residues immediately surrounding the 
phosphorylation site rather than higher-order protein structure. Specifically, the core 
phosphorylated amino acid plus the four amino acids flanking each side of the phosphorylated 
residue is the most common recognition site (Kreegipuu, et al., 1998). Synthetic peptides 
modelled on the phosphorylation site have been shown to be appropriate substrates with Vmax 
and Km values approaching that of the intact full-length protein (Zhu, et al., 2000). Using 
short peptide sequences rather than full length proteins is cost-effective, displays high 
stability, provides site specific information and is amenable to array technologies (Ouyang, et 
al., 2003). In addition, peptides can be custom designed to match the recognition sequence of 
nearly any kinase. 
 
  1.2.2 Peptide Array Design 
   1.2.2.1 Selection of Peptide Targets 
A large number of proteins undergo phosphorylation, many of these at multiple sites. 
It is estimated that there are 100,000 unique phosphorylation events within the human 
proteome (Zhang, et al., 2002) as compared to a current best calculation of 22,333 total 
translated human genes (Pertea and Salzberg, 2010). PhosphoSite (www.phosphosite.org) and 
Phospho.ELM (phospho.elm.eu.org) are publically available online databases that contain 
information on manually curated, literature-based serine, threonine and tyrosine 
phosphorylation sites. The information contained within these databases is predominantly 
human and mouse phosphorylation events. Search results for a specific protein return short 
peptide sequences corresponding to characterized phosphorylation sites. Where available, 
information on the corresponding kinase and descriptions of the biological function of the 
specific modification are listed. These databases have been used in the design of peptide 
arrays for kinase study (Diks, et al., 2004). Once the selection process is complete, peptide 
synthesis and array printing can be done. If this cannot be done in-house, a number of 
commercially available, pre-designed and custom-designed arrays are available (Table 1.2).   
 
   1.2.2.2 Genus-Specific Arrays 
 There are techniques, tools and reagents available to conduct kinome work on the 
most commonly studied genera, such as human or mouse, but these resources are limited or 
13 
 
non-existent for other genera. The phosphorylation annotation databases are heavily biased 
toward human and mouse, with phosphorylation-specific reagents, like antibodies, generated 
predominantly to be species-specific. The limited options for kinome analysis of other genera 
were the impetus for the development of genus-specific peptide arrays for kinome analysis 
(Jalal, et al., 2009). Based on the concept that specific sites of protein phosphorylation and 
biological activity are conserved across genera, information collected from human studies 
could be applied to other genera. In the initial study, the degree of amino acid sequence 
conservation surrounding human and bovine phosphorylation sites was investigated (Jalal, et 
al., 2009). The investigation was done by searching nearly a thousand peptides of 15 amino 
acids in length, representing human phosphorylation sites, against the National Centre for 
Biotechnology Information (NCBI) non-redundant protein database using the Blastp program 
to generate orthologous bovine peptides. These results revealed that approximately half of the 
bovine sequences had 100% identity to the query sequences, and the majority of the 
remaining peptides had limited sequence divergence (Table 1.3). It was subsequently 
confirmed that these bovine peptides matched the orthologous protein found in humans.  
These results indicated that while a human peptide array would have substantial cross-
reactivity with bovine kinases, there would be many peptide target sequences that may not 
match sufficiently for kinase recognition. This would limit the information generated when 
using human peptide arrays to analyze bovine samples.  
The degree of difference in the kinase recognition sequences of the phylogenically 
similar human and bovine appears greater than their genetic differences (Zimin, et al., 2009). 
These kinase recognition sequence differences indicate that human-sequence based arrays 
would be of less utility for more evolutionarily distinct genera. Interestingly, other labs have 
utilized human-based peptide arrays for genera as evolutionarily distant as the plant 
Arabidopsis (Ritsema, et al., 2007), avoiding the challenge of designing a genus-specific 
array. Of the 184 kinase target sites on the array used by Ritsema, et al. (2007), only 15 
showed statistically significant phosphorylation. This was considered a significant cross-
reaction success. However, the relevance of kinome data based on a cross-reaction between 
human peptide targets and plant kinases should be interpreted with reservations. Emerging 
databases for economically important plant genera such as the Rice Kinase Database 
(phylomics.ucdavis.edu/kinase/) are simplifying the task of developing a plant-based array. 
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Given the availability of kinomic information found in these databases, the genus-specific 
design technique pioneered by our group, and the large evolutionary divergence between 
plants and humans, the design of genus-specific arrays for plant kinome work should be 
considered a more appropriate approach. Kinome analysis could be used to characterize plant 
responses to disease resistance/susceptibility, drought tolerance, nutrient utilization and many 
other important economic traits.  As additional kinomic information on an increasing number 
of genera becomes available, the potential application of the technology is not limited to just 
animals and plants; rather, it is applicable to bacteria and others that use phosphorylation as a 
means of cellular regulation.       
 
 
 
Table 1.3 Bovine/human phosphorylation target site comparison.  
 
 
This table shows the Blastp results against the NCBI non-redundant protein records of 880 
human peptides to find orthologous bovine proteins. The number of sequence differences 
between human and bovine is indicated (*). The human sequences were collected from 
PhosphoSite and Phospho.ELM and compared to bovine peptide sequences. Of the 880 
human sequences, the percent that displayed the indicated number (*) of sequence differences 
is shown (†). The Peptides on Array column indicates the percent of peptides which showed 
the indicated sequence similarity and were ultimately printed on the first-generation bovine 
array (‡). Some peptides with significant sequence differences between human and bovine 
matched a different protein between human and bovine. Whether the protein description 
matched (same name, function) between human and bovine is shown in the last column (§). 
This table is sourced from Jalal, et al., 2009 and used with permission.      
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  1.2.3 Detection of Phosphorylation Events 
A number of techniques are available for the detection of protein phosphorylation 
status. These techniques can be used to determine the status and extent of phosphorylation of 
a given peptide on an array. These detection methods include the use of radioisotopes, 
phosphospecific antibodies, labelled chelators and phosphospecific stains (Figure 1.2).   
 
 
 
Figure 1.2. Methods of detecting phosphorylated peptides. Kinases specific for their target 
peptide sequence phosphorylate the appropriate residue on the array. A) The gamma 
phosphate group of ATP, which is the phosphate donor for the kinase, is radioactive. Its 
emissions can be visualized and quantified. B) Direct detection of phospho-peptides through 
the use of a labelled antibody specific to the phosphorylated form of the peptide is shown. The 
antibody can be labelled with a fluorophore. C) Indirect detection of the phospho-peptide 
through the use of a phosphospecific antibody which is then visualized by a secondary 
labelled anti-immunoglobulin antibody is shown. D) A labelled phospho-amino acid chelator 
is added after the kinase reaction. E) Fluorescent phosphospecific stain, which only binds 
phosphorylated peptide, can be used to directly detect the phosphorylated residues present on 
the array following completion of the kinase reaction. This figure was adapted from Jalal et 
al., 2007 and used with permission. 
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   1.2.3.1 Radioisotope Detection 
 The earliest detection method to be applied to phosphorylation-based peptide arrays 
was gamma phosphorous-32 (γ32P) ATP. Kinases catalyze the transfer of the γ32P group to the 
hydroxyl of threonine-, serine- or tyrosine-containing peptides spotted onto the array 
(MacBeath and Schreiber, 2000; Falsey et al., 2001; Diks et al., 2004). This phosphorylation 
event can be visualized by using a phosphorimager screen to capture the radioactive emission 
which can then be scanned for signal quantification (Falsey et al., 2001; Diks et al., 2004) 
(Figure 1.3). 
 The main disadvantages of using radioisotopes are the cost, time, health risks and 
special safety precautions required when handling these reagents. For example, it can take up 
to a week of exposure to an array for the phosphorimager screen to capture sufficient 
emissions to be detected by the scanner (Jalal, et al., 2009). These factors have led many 
researchers to pursue alternative detection methods.  
   
 
 
 
 
Figure 1.3. Radioisotope peptide array scan. An image of a peptide array scanned from a 
phosphorimager screen is shown. Bovine monocytes treated with LPS were lysed, then 
incubated on an array along with γ32P-ATP. The array was exposed to a phosphorimager 
screen for one week and then scanned. 
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   1.2.3.2 Antibodies 
 Shortly after the initial studies involving peptide arrays for kinome analysis, an 
alternative method of signal detection was developed using phosphospecific antibodies. The 
antibodies were generated to be specific for epitopes representing phosphorylated sites on 
protein (Lesaicherre, et al., 2002). Use of these antibodies avoided the disadvantages of 
working with radioactivity. Following antibody binding to the phosphorylation site of the 
protein, the interaction was then visualized through the use of a fluorescence tag or a 
chemiluminescent system, such as those based on peroxidase activity (Schutowski, et al., 
2005). Generally, the phosphospecific antibody can be directly labelled with either a 
fluorochrome or an enzyme as indicated above (Lesaicherre, et al., 2002), or a labelled 
secondary anti-immunoglobin can be utilized to further amplify the signal (Houseman, et al., 
2002) (Figure 1.2 B and C). 
 Antibody-based detection of protein phosphorylation eliminates the safety and time 
concerns of radioisotope use. In addition, antibody binding is very sensitive. In the context of 
a phosphorylated peptide array spot, 0.1 pmol of phosphorylated peptide is easily detectable 
with the potential to go 10-100 times lower in concentration (Lesaicherre, et al., 2002). This 
sensitivity is within the range of the radioisotope γ 32P system (Povey and Cooper, 1995). The 
major disadvantage of using antibody detection is specificity. While phosphotyrosine 
antibodies are generally specific, phosphoserine antibodies have at times given high rates of 
false positives, and phosphothreonine antibodies display high rates of cross-reactivity with 
phosphoserine residues (Panse, et al., 2004).  
    
   1.2.3.3 Labelled Chelator 
 Metal-bound cyclic ring structures can be designed to specifically bind to covalently 
bonded phosphate groups. These are called chelators because they form a metal incorporated 
ring structure. It is possible to bind a fluorophore or chemiluminescent effector such as 
peroxidase to this chelator and expose it to a phosphorylated peptide array.  
 One of the disadvantages of chelators is that their binding affinity can be low, 
especially at physiological pH and in aqueous solution (Kinoshita, et al., 2004). However, 
some groups have designed constructs which behave as phosphorylation sensors under 
physiological conditions. These constructs include an alkoxide-bridged dinuclear zinc(II) 
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complex (Kinoshita, et al., 2004) and an anthracene zinc(II)-dipicolylamine derivative. The 
latter auto-fluoresces following binding to the phosphate group which induces a 
conformational change (Ojida, et al., 2002).     
    
   1.2.3.4 Phosphospecific Stain 
 A small molecule fluorophore which specifically binds to phosphorylated peptides or 
proteins can be used to probe peptide arrays or Western blots. Extensive studies have been 
carried out to generally characterize these phosphospecific stains (Steinberg, et al., 2003; 
Schulenberg, et al., 2004) and specifically characterize them in the context of peptide arrays 
in comparison to both γ32P-ATP and antibody detection (Martin, et al. 2003a, 2003b). The 
stain was found to have better sensitivity than radioactivity and was more broadly applicable 
than antibodies, which must be generated for each phosphorylated peptide epitope and are 
generally species-specific. Importantly, the study determined that a phosphorylated protein 
concentration of 312-625 fg and a spot diameter of 100 µm could be detected (Martin, et al., 
2003a). This is well within the range of peptide array specifications. In addition, along with 
antibody and labelled chelator-based detection methods, phosphospecific stain has the 
potential to detect phosphorylation using GTP as the phosphate donor.  
One disadvantage of phosphospecific stain is that it can non-specifically bind to the 
array surface. This can result in background fluorescence. Care must be taken to destain the 
array as much as possible, leaving only phosphorylated peptides/proteins stained. In addition, 
appropriate background correction can be conducted during data analysis to subtract 
background fluorescence from the peptide/protein signal. Figure 1.4 shows a scan of a bovine 
peptide array labelled with phosphospecific stain. 
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Figure 1.4. Phosphospecific stain peptide array scan. An image of a peptide array scanned 
using a microarray scanner at 532 nm wavelength is shown. Lysate from bovine monocytes 
treated with interferon gamma was incubated on an array before exposing the array to 
phosphospecific stain. The array was then washed and scanned for green fluorescence. 
 
 
 
  1.2.4 Data Analysis 
   1.2.4.1 Use of DNA Microarray Analysis Methods 
 Genomics, a field which adopted high throughput microarray techniques early, has 
dominated the development of array technology. Consequently, upon the introduction of 
peptide arrays for kinomic analysis, the majority of the statistical manipulation and data 
analysis tools developed for genomic array work were simply ported into kinome array 
analysis (Diks, et al., 2004; van Baal, et al., 2006; Schrage, et al., 2009; Arsenault, et al., 
2009). However, peptide array data have a number of unique attributes that limit the utility of 
this analysis approach.   
 
1.2.4.2 Differences Between Nucleotide and Peptide Arrays 
 There is concern that the tools for genomic analysis may have limitations when 
applied to peptide arrays, in particular phosphorylation-based peptide arrays. The two 
techniques are fundamentally different. A statistical analysis method should account for these 
differences; otherwise, data normalization will not be optimum. In the case of nucleotide 
arrays, a hybridization reaction takes place; with peptide arrays, the enzymatic transfer of a 
phosphate group occurs. The enzymatic process results in a signal response from zero to many 
multiples of the control. While a nucleotide array signal is limited by the number of matching 
nucleotides in a sample, the peptide array is limited only by the number of peptide sequences 
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printed on a given spot. Phosphate levels are at saturation, and the ample incubation time 
means a highly active kinase could theoretically phosphorylate every target sequence 
available virtually regardless of the number of sequences printed on the array. This makes it 
difficult to determine where a positive reaction cut-off should be set. Also, the variance in 
signal is affected by this dynamic range of phosphorylation. This makes statistical 
manipulations difficult when assumption of a constant variance is required, such as for 
Student’s t-test, analysis of variance and some regression models. Data normalization is 
required before statistical tests can be performed; however, normalization procedures are 
based primarily on nucleotide microarray data and may not be the most appropriate for 
kinome data. Significance calculations should also be considered as the number of kinase 
target sequences is usually much lower than the number of nucleotide chains spotted onto an 
array, potentially as much as 100 times fewer. This means that each individual spot is of much 
greater consequence when trying to achieve coverage of a given cellular process or response. 
The indiscriminate discarding of data points by inappropriate statistical significance 
calculations is thus highly undesirable. Statistical calculations should take these differences 
into account when being applied to kinome data analysis.   
 
   1.2.4.3 Data Transformation 
 Variance stabilization (VSN) is a method of data transformation which calibrates all of 
the background-corrected data to a positive scale, alleviating mean-variance-dependence 
while maintaining the structure within the dataset (Huber, et al., 2002). Mean-variance-
dependence occurs when variance for individual data points is not independent of signal 
intensity. This is a common characteristic of peptide array kinome data as phosphorylation of 
peptides is not a binary signal but rather a scale increasing from zero. Because a consistent 
signal of zero will have a variance of zero, a replicate signal of zero phosphorylation will have 
no variance. Replicates with a strong signal may be relatively consistent but include a broader 
variance having a large absolute signal intensity value. For example, triplicate signal 
intensities of 0.00, 0.00 and 0.00 display no variance; signals of 25,000, 33,000 and 27,000 
display much more broad variance but are relatively similar considering that the dynamic 
range can extend to zero. In addition to dealing with the mean-variance-dependence problem, 
VSN facilitates scaling of datasets to a relatively consistent value to enable comparisons 
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between datasets. This is important when various experiments, treatments or cell types are 
being compared.   
 
   1.2.4.4 Visualization Techniques  
   1.2.4.4.1 Hierarchical Data Clustering 
Hierarchical clustering is a useful tool to organize multiple datasets based on degree of 
similarity. Broadly, each treatment/dataset is considered a singleton (a cluster with a single 
element) at the initial stage of clustering. The two most similar clusters are determined and 
then merged. Then, the degree of distance between this newly merged cluster and the next 
most similar cluster is determined. This process continues iteratively until all clusters are 
considered.  
For hierarchical clustering, three popular independent combinations of clustering 
methods and distance measurement are implemented: Average Linkage + (1-Pearson 
Correlation), Complete Linkage + Euclidean Distance and McQuitty. The calculations of 
similarity/distance between the clusters and the update step are algorithm-specific. These 
calculations are performed on complete kinome datasets. For example, an array containing 
three-hundred peptides will be considered a single element; this will then be compared to a 
second array. The “Average Linkage + (1 - Pearson Correlation)” takes the average of the 
merged (i.e., the most correlated) kinome profiles and updates the distances between the 
merged clusters and other clusters by recalculating the correlations between them (Pearson, 
1896; Eisen et al., 1998). In “Complete Linkage + Euclidean Distance”, the distance between 
any two clusters is considered as the Euclidean distance between the two farthest data points 
in the two clusters (Everitt, 1974; Hartigan, 1975). Finally, the “McQuitty” method updates 
the distance between the two clusters in such a way that, upon merging clusters XC  and YC  
into a new cluster XYC , the distance between XYC  and each of the remaining clusters, 
labelled , is calculated taking into account the sizes of  and  (McQuitty, 1966). If 
three arrays are to be clustered, the two most similar arrays will be merged, creating a new set 
representing both. This new representative set will then be compared to the third. A relative 
similarity/difference output will then be provided for all three arrays. 
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    1.2.4.4.2 Principal Component Analysis 
Briefly, Principal Component Analysis (PCA) is a variable reduction procedure. For 
example, if a dataset contains three variables between data points, PCA can reduce that to one 
or two variables, making the relationships between points easier to observe. The calculation 
performed is a singular value decomposition of the centered and scaled data matrix (Mardia, 
et al., 1979). As a result, PCA transforms a number of possibly correlated variables into a 
smaller number of uncorrelated or literally orthogonal variables (i.e., principal components). 
An example of this is seen in Figure 1.5, where a hypothetical dataset is converted into two 
principal components by bisecting the data, thus simplifying the variables between the points. 
The first principal component accounts for the most variability in the data, and each 
succeeding component accounts for as much of the remaining variability as possible. Usually, 
the first three components account for more than 50% of the variability in the data and can be 
used as a set of the most important coordinates in a 3D plot to reveal the structure of the data. 
 
1.2.4.5 Pathway Analysis  
 A number of pathway analysis databases have been developed with the goal of 
associating gene expression data with signalling pathways. InnateDB was originally designed 
for innate immune gene expression analysis but has since been significantly expanded to 
become a comprehensive database (Lynn, et al., 2008). Kyoto Encyclopedia of Genes and 
Genomes (KEGG) (Kanehisa and Goto, 2000) accepts high throughput genomic data and 
outputs relevant pathway information. It is possible to apply these databases to peptide array 
kinomic data. Inputting normalized, background-corrected and comparative peptide array data 
produces pathways which are represented by the phosphorylated peptides on the array. This 
allows organization of data by functionality and provides a clearer overview of the data 
collected than only considering individual peptide phosphorylation events. 
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Figure 1.5. PCA example: A simplified example of how PCA works on a hypothetical 
dataset is shown. A) A hypothetical scatter plot of mean subtracted data with eigenvectors 
roughly drawn is shown. Eigenvectors are normally calculated from the covariance matrix of 
the dataset. Each eigenvector provides information about the patterns in the data. The vector 
with the positive slope through the dots shows how the data points relate along that line. The 
vector running perpendicular to the first provides another, less important pattern in the data. 
This second vector shows that the data are offset from the centre of the first line. The two 
lines together characterize the data. The vector with the highest eigenvalue, also calculated 
from the covariance matrix of the dataset, is the principal component. In this case, the 
principal component is the vector with the positive slope. B) A plot of the dataset in Plot A 
with the eigenvectors used as axes is shown. The data are now separated into two principal 
components by the X and Y axes. If PCA, a variable reduction procedure was used, then the 
values of the Y-axis could be eliminated. This is because the Y-axis in Plot B corresponds to 
the eigenvector with the lowest value. Eliminating this will maintain most of the information 
in the dataset while reducing the variables under consideration. Plot B would then appear as 
only the X-axis with all of the data points falling upon it.    
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  1.2.5 Peptide Array Kinome Studies 
 The development and use of peptide arrays for kinomic studies is relatively new. 
Despite this, there have been a number of studies employing the technology which have 
produced novel biological insight. A number of studies employing peptide array technology 
for kinomic research are described below.  
 
   1.2.5.1 LPS Signal Transduction in Human PBMCs 
 The original study which evaluated and confirmed the efficacy of peptide arrays for 
kinomic analysis involved human peripheral blood mononuclear cells (PBMCs) stimulated 
with bacterial-derived lipopolysaccharide (LPS) (Diks, et al., 2004). LPS was used since it 
was a well-characterized inducer of innate immune response kinases and allowed a 
comparison of peptide array data against known signalling events. Various peptide substrates, 
corresponding to proteins known to be involved in LPS-induced signaling, were found to 
display increased phosphorylation on the array including p44/42 MAPK, signal transducers 
and activators of transcription (STAT)-1α/β, nuclear factor kappa-light-chain-enhancer of 
activated B-cells (NFκB), Bruton’s tyrosine kinase (Btk), and Tec kinase. A time course 
involving stimulation at 5 min, 15 min, 30 min and 60 min allowed a characterization of the 
time of activation of the kinases. The results were subsequently confirmed with western blot. 
In addition, the cells were treated with the MAPK inhibitors PD 98059 and SB 203580, and 
array analysis was conducted to confirm that MAPK signalling had been eliminated by the 
addition of inhibitors. Indeed, MAPK phosphorylation which had been observed in LPS- 
treated PBMCs was entirely ablated by the addition of these inhibitors.  
While the goal main of this study was mainly to prove the usefulness of studying 
kinases using peptide arrays, novel biological results were also produced. Prior to this study, 
the means of activation of the Raf/MAPK kinase (MEK)/p42/p44 MAPK signalling cascade 
by LPS had been unknown (Diks, et al., 2004). Two means of activating this pathway were 
considered potential options: one via p21Ras and the other by phospholipase C (PLC)β1 and 
protein kinase C (PKC)α/β. Peptide array data indicated an increase in the phosphorylation of 
peptides corresponding to proteins downstream of activated p21Ras. A subsequent p21Ras 
activation assay confirmed p21Ras activation. This study was the first direct identification of 
p21Ras activation following stimulation of a member of the Toll-like receptor (TLR) family. 
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This result demonstrated the utility of this technology for analyzing cell signalling events and 
discovering novel biology. 
 
1.2.5.2 Glucocorticoid Receptor-Dependent Non-Genomic 
Inhibition of Insulin Signalling 
 Glucocorticoids are used as immunosuppressive agents that work in a transcriptional 
dependent manner through the glucocorticoid receptor (Lowenberg, et al., 2006). The 
problem with glucocorticoid therapy is that it has resulted in insulin resistance. The 
mechanism by which this resistance occurs had been unknown. Evidence pointed to a rapid, 
genome-independent, process. Lowenberg, et al. (2006) attempted to uncover this mechanism 
by using peptide array kinome analysis to describe the cellular non-genomic effects of 
glucocorticoids. Their analysis indicated that several insulin-signalling intermediates were 
involved: p70S6k, glycogen synthase kinase-3 and Fyn. These signalling molecules were 
affected by the glucocorticoid dexamethasone (DEX) (all subsequently confirmed by western 
blot). DEX also activated Jun N-terminal kinase (JNK) signalling, an inhibitor of insulin 
signalling. To confirm that the insulin signalling inhibition induced by DEX was not due to a 
reduction in gene expression of the insulin receptor or insulin signalling intermediates, gene 
expression was measured and no expression-level differences were found. It was also 
determined that DEX was exerting its effects through the glucocorticoid receptor. The 
inhibition of the receptor by antibody binding eliminated the DEX dependent insulin 
signalling inhibition. Thus, this study uncovered the means by which glucocorticoids result in 
insulin resistance by a non-genomic mechanism. The hope is that this knowledge can lead to 
the design of immunosuppressive glucocorticoids that will not affect insulin signalling.       
 
1.2.5.3 Chondrosarcoma with Src Activity Indicates Dasatinib as 
Treatment 
 Kinome profiling can also be used to determine the most effective treatment for 
various cancers by identifying specific signalling pathways that are differentially activated or 
inhibited in cancer cells. The activated pathways can be determined by measuring the activity 
of the constituent kinases within the tumour or cancerous cell. Schrage, et al. (2009) used this 
approach in the study of chondrosarcoma cancers. Treatment of chondrosarcoma of the bone 
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was historically restricted to surgery since the tumour was highly resistant to conventional 
therapies. Therefore, the only means of treatment for high grade chondrosarcomas was large-
scale bone resection or amputation. Published evidence indicated that kinase inhibitors were 
ineffective as a means of treating conventional chondrosarcomas, which constitute over 85% 
of cases (Gelderblom, et al., 2007). Kinome analysis of 13 chondrosarcoma samples was 
performed and combined to produce a representative kinome profile. Two of the top pathways 
indicated by the array data were platelet-derived growth factor receptor (PDGFR)B signalling 
and the sarcoma (Src) pathway. Two inhibitors that target these respective pathways were 
tested: imatinib for PDGFRB and dasatinib for Src. Imatinib had no effect on cultured 
chondrosarcoma cells, while it did have an effect on the positive control gastrointestinal 
stromal tumour cell line GIST882. Dasatinib reduced the cell viability in seven of the nine 
chondrosarcoma cell lines tested. Western blot analysis confirmed that dasatinib acted by 
inhibiting the phosphorylation of Src but had no affect either on the total level of Src protein 
or the activation of pro-apoptotic effector caspase-3, the mode of action of dasatinib which 
had been observed in other cancers. This analysis revealed the reason that Src inhibitors may 
not have been considered as a therapeutic treatment for chondrosarcomas: genomic and 
proteomic studies would not have indicated a change in the Src pathway. Src expression and 
total Src protein level were unchanged. Thus, peptide array kinome analysis pointed toward a 
potential therapy for patients suffering from chondrosarcoma where none was previously 
available.     
 
  1.2.6 Genus-Specific Peptide Array Kinome Studies 
 The use of peptide arrays for kinome analysis is still relatively new; thus, custom-
designed arrays for genera such as cattle were unavailable until our group designed and 
validated the first bovine array in 2009 (Jalal, et al., 2009). The utility of kinome technology 
was understood by a number of groups and was quickly applied to a variety of biological 
problems. While the research was outside the scope of my doctoral project, the following 
sections contain a review of published investigations in which I was involved, either within 
Dr. Napper’s group or with collaborators. 
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   1.2.6.1 Expanding Knowledge of Defined Ligand Signalling 
 During the development of the first custom-designed genus-specific peptide array, it 
was important to confirm the biological relevance of the data generated. This was first done 
by investigating signalling responses to ligands by receptors which activated well-defined 
signalling pathways. The model chosen to validate the bovine-specific arrays was purified 
bovine monocytes stimulated with two well characterized TLR ligands: cytosine-
phosphodiester-guanine oligodeoxynucleotides (CpG) and LPS (Arsenault, et al., 2009). 
TLRs are a family of pathogen recognition receptors ranging from TLR 1-10 in bovine that 
bind to pathogen-associated molecular patterns and initiate innate immune responses within 
the cell (McGuire, et al., 2006). In this specific study, signalling by TLR4, which recognizes 
LPS, and TLR9, which recognizes CpG, were investigated. These ligands induce well-defined 
signalling responses and are of biological and medical interest. LPS is a causative agent of 
sepsis, and CpGs are immunomodulating agents investigated for use in immunotherapy and as 
vaccine adjuvants. The results from our kinomic investigation of monocyte signalling 
following stimulation with TLR ligands were in close agreement with signalling pathways 
established through alternative techniques and reported in the literature (Arsenault, et al., 
2009).  
In addition to confirming the established TLR signalling pathways, other signalling 
events were identified which had not been previously described. For example, tyrosine 40 of 
epithelial and endothelial tyrosine kinase (Etk) (also known as Bmx) was phosphorylated in 
response to LPS but not CpG stimulation. This response was subsequently confirmed through 
the use of phosphospecific antibody and western blot analysis of human monocytes (Figure 
1.6). Etk phosphorylation was confirmed in human monocytes because the antibody to 
phosphotyrosine 40 was unavailable for bovine. This lack of a bovine reagent highlights the 
need for an alternative kinome analysis method in non-human genera. In addition to Etk, the 
phosphorylation pattern of peptides corresponding to p40phox and p47phox proteins indicated 
that oxidative burst was activated following CpG but not LPS stimulation. A functional assay 
based on the production of superoxide radicals was conducted, and this bioassay confirmed 
the kinome data (Figure 1.7). Through the use of independent assays, we were able to 
confirm the accuracy of custom-designed bovine array data and elucidate novel ligand 
activities. In addition, the study using human peptide arrays to uncover human PBMC 
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response to LPS had been conducted previously (Diks, et al., 2004), enabling a comparison of 
the conservation of TLR4 signalling responses in bovine and human cells. The strong level of 
similarity observed between bovine and human responses provided further validation of the 
bovine array results.     
 
 
 
Figure 1.6. Etk phosphorylation following stimulation. An image of a western blot is 
shown. Monocytes were treated with CpG, LPS or media control. The cell extracts were 
separated by SDS-PAGE and immunoblotted using Etk Tyr40 phosphospecific antibody 
(Arsenault, et al., 2009).  
 
 
 
 
Figure 1.7. Superoxide production. The figure shows the results of a superoxide radical 
production assay. Monocytes were treated as indicated, and superoxide radical production was 
measured and calculated relative to media control (Arsenault, et al., 2009).  
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1.2.6.2 Characterizing Phenotypically Similar But Mechanistically 
Distinct Signalling Events 
 The cytokines IL-32 and IL-17 are both involved in chronic inflammation and 
autoimmune disorders. It was speculated that the mechanisms by which IL-32 and IL-17 carry 
out their cellular effects are differentially dependent on the TNF receptor and its pathway 
(Turner-Brannen, et al., 2011). Peptide array kinome analysis determined that a peptide 
corresponding to TNF receptor 1 (R1) was phosphorylated upon cell stimulation with IL-32 
but not IL-17. This result was then validated through the use of an antibody to TNF-R1 used 
to block any TNF-R1 ligand binding, which suppressed IL-32 but not IL-17 responses. This 
IL-32 blockage confirmed that while IL-32 and IL-17 have similar phenotypic effects, these 
effects are produced by distinct cell signalling events at the level of cell surface receptors. 
This differential dependence may have therapeutic implications since the treatment of 
inflammation and cytokine induced autoimmune disorders would be ineffective if based on 
the suppression of the TNF-R1 rather than targeting a common downstream effector.   
 Considering that distinct receptors are utilized by the two cytokines but similar 
phenotypes are observed, similar signalling intermediates may be involved. Peptide array data 
indicated that p300 and death-associated protein kinase-1 (DAPK-1) were common 
phosphorylation targets for both IL-32 and IL-17. These phosphorylation events were 
subsequently confirmed by immunoblots. Known downstream responses of p300 and DAPK-
1 were altered in response to both cytokines as well including activation of NFκB and the 
induction of chemokine production. These results allowed for the conclusion that p300 and 
DAPK-1 are nodes of conversion for signalling responses to IL-32 and IL-17. These nodes 
may be targets to disrupt the activity of both cytokines for treating chronic inflammation and 
autoimmunity.  
 
   1.2.6.3 Understanding the Source of Phenotypic Variability 
 Closely related cells may respond differently to the same stimulus producing two 
distinct phenotypes, but the mechanism for this differential response can be difficult to 
determine. For example, intestinal Peyer’s patch (PP) cluster of differentiation (CD)21+ 
regulatory B cells (Bregs) fail to show detectable TLR9-induced immune responses. By 
contrast, CD21+ B cells from blood display a robust response to TLR9 stimulation (Booth, et 
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al., 2010). The apparent failure to respond to TLR9 stimulation occurs despite PP CD21+ 
Bregs expressing high levels of TLR9 mRNA and detectable TLR9 protein being present. It 
was hypothesized that CpG was unable to induce a TLR9-dependent response because of a 
disruption in the TLR9 signalling pathway. This hypothesis was tested by kinome analysis 
which showed that following stimulation with CpG, phosphorylation of downstream TLR 
pathway proteins was increased in blood CD21+ B cells but remained unchanged in PP 
CD21+ Bregs. The TLR pathway intermediates included interleukin-1 receptor-associated 
kinase 1 (IRAK1), mitogen-activated protein kinase kinase kinase 7 (TAK1), IκB kinase 
(IKK), and NF-κB-p65 (Figure 1.8). These results confirmed the lack of TLR9 signalling in 
PP CD21+ Bregs and revealed that this signalling was disrupted at or near the level of the 
receptor. This information could not have been determined with genetic techniques or would 
have been time-consuming with standard phosphorylation-based techniques.  
 
1.2.6.4 Cancer Cell/Tumour Profiling 
 As described previously, cancer is very important in the field of kinome research and 
vice versa. Research on kinase drug discovery is also dominated by cancer. A large part of 
this research involves cancer models used to test various molecules and compounds for effect 
on kinases. Thus, it is of critical importance that the animal or cell model being used 
accurately reflects the kinase activity of the cancer under scrutiny. The development of 
custom-designed bovine arrays and their application along with a Bovine Leukemia Virus 
leukemia cancer model in sheep made it possible to study changes in kinase activities 
associated with B cell transformation (Van den Broke, et al., 2011). It is common practice to 
isolate cancerous cells from a host, establish a cell line tissue culture and then use the cell 
lines for in vitro cancer research. However, our study indicated that the removal of cancer 
cells from the ovine host and passage of cells in tissue culture significantly altered 
phosphorylation patterns in these cells. Changes between host-derived and cultured cells 
occurred in pathways key to cancer such as growth, apoptosis and cell cycle. Thus, the 
external environment of these cells had a profound impact on many cell signalling pathways. 
This finding is one that must be considered in the fields of cancer research and drug 
discovery. If a cell line is used to screen potential cancer treatments, it must be a cell line 
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where key cancer-specific pathways or cell signalling proteins have not been significantly 
altered due to passage in tissue culture. 
 
 
 
Figure 1.8. TLR9 signalling differences in related cell types. Peptide array results indicated 
blood derived bovine CD21+ B cells had increased activation of the TLR9 pathway upon 
CpG treatment. Ovine PP-derived CD21+ Bregs showed no increase in TLR9 signalling 
pathway phosphorylation following treatment with CpG. The red spots indicate the sites of 
differential phosphorylation along the pathway between the two cell types. The blood-derived 
CD21+ B cells displayed increased phosphorylation at these sites, and the PP-derived CD21+ 
Bregs displayed a lack of phosphorylation. This figure was adapted from Booth et al., 2010 
and is used with permission.      
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1.3 Host-Pathogen Interactions Involving Cell Signalling 
Much of the initial work in researching the kinome, many of the kinase inhibitors and 
other drug discoveries developed from this work has been in the field of cancer research 
(Knight, et al., 2010). At times perhaps overshadowed by the large role that cancer research 
plays in the kinome field, the importance of kinases, kinase inhibitors and cell signalling in 
infectious disease has been well-documented for decades (Rosenshine, et al., 1992). The 
study of host-pathogen interactions at a cell signalling level is difficult due to the complexity 
of the cellular signalling networks and the challenge of separating general host stress 
responses from those induced by the pathogen. These responses may also include pathogen 
signalling events especially when studying intracellular pathogens. Despite these difficulties, 
the technique has provided useful insight into the biological responses to pathogen-associated 
ligands, CpG (Booth, et al., 2010) and LPS (Diks, et al., 2004; Arsenault, et al., 2009).  
The two infectious diseases studied in this project are uniquely suited for kinomic 
study: prion disease and Mycobacterium avium subspecies paratuberculosis (MAP). Prion 
diseases are not caused by a bacterium, virus or genetic disorder; rather, they are caused by a 
host protein misfolding event which is disruptive and contagious (Prusiner, 1982). The 
symptoms of the disease are entirely induced by a self protein and there appears to be no 
genetic component. Moreover, there is evidence that the prion protein has a cell signalling 
function. As such, a kinomic approach should be an effective technique for the study of this 
disease.    
The second infectious disease that likely has a strong signalling component is 
infection where the pathogens disrupt or influence host-signalling events. MAP establishes a 
persistent infection which subverts host immune response, both innate and acquired. 
Signalling studies may provide useful information about treating these infections. In fact, 
some pathogens have been shown to specifically target host phosphorylation-mediated signal 
transduction pathways (Zachos, et al., 2001; Koul, et al., 2004). A fascinating example of this 
is the mycobacteria which produce eukaryotic-like phosphorylation effector molecules. These 
molecules enter the host cell and directly affect specific sites of phosphorylation (Alber, 
2009). These pathogen-produced eukaryotic phosphorylation effectors have been identified as 
possible therapeutic targets (Schreiber, et al., 2009).       
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1.4 Prions  
Prions were discovered due to their involvement in diseases known as Transmissible 
Spongiform Encephalopathies (TSEs). TSEs include Creutzfeldt-Jakob disease and Kuru in 
humans, bovine spongiform encephalopathy (BSE) in cattle, scrapie in sheep, and chronic 
wasting disease (CWD) in deer and elk. These diseases represent the first class of infectious 
disease characterized as being mediated exclusively by a protein agent (Prusiner, 1982). TSEs 
result from the conversion of endogenous, cellular prion protein (PrPC) to a misfolded, 
infectious, scrapie-like conformation (PrPSc) by a template-directed autocatalytic mechanism. 
This novel means of infection was first proposed in the early 1980s; however, fundamental 
questions remain regarding the physiological role of PrPC, the mode of PrPSc transmission and 
the pathogenesis of prion disease. Considering the fact that PrPC is so highly conserved, 
having been found in nearly every species studied (Strumbo, et al., 2001), its physiological 
role must be important for such evolutionary fidelity to be maintained. In addition, PrPC may 
play a variety of roles as it is found on various cell types and tissues. A key question in 
understanding TSE pathogenesis is to understand how the misfolding from PrPC to PrPSc 
alters the protein’s natural function, be it a gain, loss or subversion of normal function.      
 
  1.4.1 Proposed Functions of the Prion Protein 
In spite of years of intensive investigation, there has been limited progress in defining 
the physiological function of PrPC. PrPC knock-out animals show minimal phenotypic effects 
besides a resistance to prion disease (Bueler, et al., 1992). This means that researchers have 
been forced to look more closely at the molecular basis of prion activity. Efforts to uncover 
the physiological role of the protein have produced evidence of numerous and varied 
functions including neuronal protection (Roucou, et al., 2005), copper metabolism (Brown, et 
al., 1997), long-term memory creation (Shorter and Lindquist, 2005) and bone marrow 
renewal (Zhang, et al., 2006). While questions remain about the function of PrPC, there is a 
strong impetus to look into its disorder of function, which occurs upon misfolding to the PrPSc 
conformation, and to understand the pathogenesis of this infectious disease. The protein’s 
ability to function in two conformations adds complexity to determining function since it is 
not clear whether normal or disease-related activity is being studied. For example, it can be 
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unclear for a given PrPC signalling model if the induced signalling is related to normal 
function or misfolded disease-state function. 
 
  1.4.2 The Prion as a Cell Signalling Molecule 
PrPC is a glycophosphotidylinositol (GPI)-anchored protein associated with lipid rafts, 
indicating that PrPC is a cell-surface signalling molecule. Lipid rafts are functional hubs of 
cell-surface signal transduction, and GPI-anchored proteins are often part of multicomplex 
signalling receptors (Simons, et al., 2000). PrPC does not contain a transmembrane domain; 
therefore, it cannot communicate directly to the interior of the cell. This is why many GPI- 
anchored proteins associate with secondary proteins containing a transmembrane domain 
(Pike, 2005). To confirm the lipid raft anchoring necessity for PrPC function, as well as the 
disease potential of PrPSc, a soluble version of PrPC was created via the removal of the GPI 
anchor. Removal of the GPI anchor and misfolding to the PrPSc isoform resulted in plaque 
formation, however, without the neuronal pathology normally observed in TSEs (Chesebro, et 
al., 2005). This observation dissociates the protein aggregation often observed in TSEs with 
the cell death and neuropathological symptoms of disease. It appears that pathology is a result 
of some type of disruption of the information transferred through the PrPC following 
misfolding to PrPSc, not a disruption of cell function due to plaque deposition. The dual 
requirement for conversion to PrPSc and PrPC association with lipid rafts points to a 
subversion of function based on alterations of cellular signalling events (Aguzzi, 2005).   
Subsequent investigations of PrPC and PrPSc from the perspective of signalling 
analysis have implicated a number of intracellular kinases and signalling pathways including 
Src (Nixon, 2005), MAPK (Lee et al., 2005; Marella, et al. 2005), phosphoinositide-3 kinase 
(PI3K)/RAC-alpha serine/threonine protein kinase (Akt) (Vassallo, et al., 2005), JNK 
(Carimalo, et al., 2005) and extracellular signal-regulated kinase (Erk) (Monnet, et al., 2004). 
It is clear that PrP influences intracellular kinase activity, though the specific details of how 
and for what purpose have yet to be elucidated. The diversity of conflicting functions that 
have been ascribed to the PrPC/Sc protein may be partially due to the limited scope of the 
investigations carried out thus far. This may also reflect the functional diversity of the PrPC/Sc 
protein. When undertaking a prion signalling/function study, experimental design is 
complicated by numerous variables including species, cell type, primary or cultured cell, 
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conformational isomer, and the interacting partner/ligand chosen. It is essential to achieve as 
broad a cellular picture as possible to eliminate the biases and limitations inherent in studying 
a complex protein such as this.  
 
   1.4.2.1 Putative Prion Interacting Partners 
 The PrPC protein is GPI-anchored, and its apparent ability to influence cell signalling 
suggests that PrPC must have cell surface interacting partners that contain transmembrane 
domains. Alternatively, PrPC may interact with intracellular partners during protein trafficking 
to enable the transmission of signals from the PrPC to the intracellular environment. No fewer 
than 45 potential interacting partners have been proposed for the prion protein (Aguzzi, et al., 
2008). Some well-cited examples of proposed PrPC interacting partners are shown in Table 
1.4.  
 
 
 
Table 1.4. Putative prion interacting partners. 
Interacting 
Partner 
Subcellular 
Localization 
Interaction 
Detection Method Reference 
Hsp60 Mitochondria Yeast-2-hybrid Edenhofer, et al., 1996 
Laminin Extracellular Binding assay Graner, et al., 2000 
N-CAM Plasma membrane 
Formaldehyde 
cross-linking 
Schmitt-Ulms et al., 2001; Maness 
and Schachner, 2007 
STI-1 
Cytoplasm, plasma 
membrane Co-IP 
Chiarini, et al., 2002; Zanata et al., 
2002 
Fyn kinase Cytoplasm Co-IP 
Mouillet-Richard, et al., 2000; Mattei 
et al., 2004 
Insulin 
Receptor Plasma membrane 
Co-IP, Equilibrium 
Binding Ostlund, et al., 2001 
NMDA Plasma membrane Co-IP Khosravani, et al., 2008 
 
    
 
   1.4.2.2 Ligands for Inducing a Prion Signalling Event 
While there are many theories, there are no definitive conclusions about the interacting 
partners of PrPC or PrPSc. To study the intracellular effects produced by the prion protein, two 
characteristics are essential: 1) the ligand or interacting molecule must be prion-specific in 
that it must bind to the prion protein to the exclusion of all other cell surface proteins, and 2) 
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it must induce a response within the cell. Prion-specific antibodies and prion peptide 
fragments are two types of prion ligands that are available and do not have the negative side 
effect of producing protease-resistant infectious prions. Research groups have used prion 
antibody to dimerize PrPC on the cell surface inducing intracellular signalling events 
(Mouillet-Richard, et al., 2000; Schneider, et al., 2003; Solforosi, et al., 2004). The prion 
peptide fragment composed of amino acids 106-126 (PrP 106-126) is a well characterized in 
vitro model for inducing TSE-like effects on cultured cells (Tagliavini, et al., 1993; Fabrizi, et 
al., 2001; O’Donovan, et al., 2001; Thellung, et al., 2002; Carimalo, et al., 2005; Pietri, et al., 
2006). Numerous studies have confirmed that this peptide interacts with PrPC and induces 
cellular effects strikingly similar to infection with scrapie material. Therefore, antibody cross-
linking may be considered a model for endogenous PrPC signaling, while peptide binding may 
model the disease-like effects of PrPSc infectious material.       
 
1.5 Mycobacterium avium subspecies paratuberculosis  
  1.5.1 MAP and Johne’s Disease  
Mycobacterium avium subsp. paratuberculosis (MAP) is a gram-positive, acid fast 
organism that is the causative agent of Johne’s disease, a severe gastroenteric disorder in 
ruminant animals. The disease has been known to veterinary medicine for well over a hundred 
years; H.A. Johne and L. Frothingham initially reported the disease in Germany in 1894. It 
wasn’t until 1910 that MAP was proven to be the causative agent when F.W. Trowt fulfilled 
Koch’s postulates (Chiodini, et al., 1984). Johne’s disease is extremely important to the dairy 
industry since it is responsible for estimated losses of over $1.5 billion per year to the United 
States industry alone (Stabel, 1998). MAP is the cause of the highest production losses among 
the five major production-limiting diseases (Chi, et al., 2002). There have been reports that 
MAP is also the cause, trigger or an aggravating factor in a number of human diseases 
including Crohn’s disease (Eltholth, et al., 2009; Olsen, et al., 2009; Shin, et al., 2010), type-
1 diabetes (Rani, et al., 2010) and ulcerative colitis (Pierce, 2010). Evidence for a causal link 
with these diseases remains circumstantial. Despite the amount of time MAP has been under 
scientific scrutiny and the economic imperative for an effective treatment, limited success has 
been achieved in controlling MAP infections. The intracellular survival and the chronic nature 
of MAP infection are thought to be a result of substantial immune evasion abilities.    
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  1.5.2 Immune Evasion Capabilities of MAP 
MAP invades the host through M cells of the ileal Peyer’s Patch (PP) where it 
subsequently enters macrophage cells of the immune system (Momotani, et al., 1988). This 
invasion via M cells is through the formation of a fibronectin bridge with host integrins 
(Secott, et al., 2004). There is evidence indicating that MAP can invade the intestinal mucosa 
without PP through enterocytes, but even these studies indicate that the preferred invasion 
route of MAP is through the M cells (Siguroardottir, et al., 2005). It is in the macrophages 
that MAP resides and proliferates, effectively shielded from the host immune system. 
Macrophages’ normal function is to internalize and destroy bacteria as well as present antigen 
to the immune system. For MAP to be able to invade and survive within these cells, it must 
disrupt normal immune functions (Woo, et al., 2007; Weiss and Souza, 2008). A number of 
mechanisms have been described which explain how MAP evades the natural immune 
defences. MAP is able to block the maturation of phagolysosomes (Fratti, 2001). It is believed 
that components of the Mycobacterium cell wall have immune-evasion and immune-
disruption properties (Karakousis, et al., 2004). The bacterium is also able to interfere with 
other immune defences related to pathogen clearance including the blocking of interferon 
gamma (IFNγ)-induced immune signalling events (Robertson and Andrew, 1991). In addition, 
MAP is known to produce tyrosine phosphatases. Since the MAP genome encodes no tyrosine 
kinases and its intracellular phosphorylation dependent signalling is serine/threonine-based, it 
is believed the role of these phosphatases is to disrupt host signalling (Koul, et al., 2000; 
Singh, et al., 2003).          
 
   1.5.2.1 The Phagolysosome 
 Phagolysosomes are acidic organelles that are rich in hydrolytic enzymes which digest 
bacteria and other particles (Koul, et al., 2004). Phagosomes, which engulf extracellular 
particles or bacteria, merge with lysosomes containing acid hydrolysases to form the 
phagolysosome. Mycobacteria are able to inhibit the merger of phagosome and lysosome 
protecting the bacteria from hydrolysis and other immune effector molecules such as 
oxidases. There have been several proposed mechanisms by which mycobacteria are thought 
to disrupt membrane fusion. One proposed mechanism involves tryptophan aspartate-
containing coat protein (TACO) which is released from the membrane of the phagosome and 
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allows fusion with the lysosome (Ferrari, et al., 1999). In mycobacteria-infected cells, the 
TACO protein is not released from the phagosome; thus, membrane fusion is inhibited. A 
mechanism discovered in Mycobacterium tuberculosis, but may equally apply to other 
mycobacteria species due to the conserved genes involved, is the use of the lipid phosphatase 
SapM to hydrolyze phosphatidylinositol 3-phosphate (PI3P) (Vergne, et al., 2005). In normal 
phagosome development, PI3P is an essential membrane-trafficking regulatory lipid which 
allows for phagosomal acquisition of lysosomal constituents. It was found that PI3P was 
retained in cells infected with dead bacteria, but PI3P is continuously eliminated by the action 
of SapM in cells infected with live bacteria. This mechanism may be shared with MAP since 
the MAP genome encodes a phosphoesterase protein very similar in amino acid sequence to 
SapM (based on NCBI-NR Blastp results). Whatever the mechanism(s) used, MAP is able to 
survive within the phagosome and replicate without elimination by normal immune effector 
molecules, allowing for establishment of a chronic infection.  
 
   1.5.2.2 Cell Wall 
 Components of the mycobacterial cell wall are potent immune modulators affecting 
the responses of both the innate and adaptive immune systems (Karakousis, et al, 2003). The 
four main components of the bacterial cell wall that have immune modulating activity are 
mannosylated lipoarabinomannan (ManLAM), sulpholipids, mycolic acid-containing 
glycolipid trehalose-6-6’-dimycolate (TDM) and the 19 kDa lipoprotein.  
In the case of ManLAM, there is evidence that it may directly inhibit macrophage 
activity and promote intracellular survival. Specifically, ManLAM attenuates TNFα and IL-12 
expression and induces host expression of Src homology region 2 domain-containing 
phosphatase-1 (SHP-1), a tyrosine phosphatase that down-regulates macrophage immune 
responses (Knutson, et al., 1998). ManLAM is also able to inhibit the expression of IL-12 in 
dendritic cells (Nigou, et al., 2001). In experiments involving isolated M. tuberculosis and M. 
Bovis bacille Calmette-Guérin, when cells were exposed to ManLAM, there was no detectale 
TLR-dependent activation (Means, et al., 1999). The failure to activate TLR responses and 
the down-regulation of IL-12, thus T-cell activation, may be a key strategy for immune 
avoidance by mycobacteria. ManLAM also has been found to inhibit IFNγ-mediated 
macrophage activation (Adams, et al., 1993) and induce transforming growth factor (TGF)β 
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production (Takeuchi, et al., 1998). This may inhibit macrophage and T-cell activation and 
lead to a switch from a Type 1 helper T-cell (Th1) immune response to a Th2 immune 
response, which is ineffective against mycobacteria (Takeuchi, et al., 1998).   
 Sulpholipid immune modulation has been linked to the inhibition of phagosome 
activation (Goren, et al., 1987), a key step in the ability of macrophage to destroy intracellular 
bacteria. Purified sulpholipids of mycobacteria were found to block priming of human 
monocytes by LPS or IFNγ, resulting in no detectable increase in superoxide production as 
compared to control cells (Pabst, et al., 1988; Zhang, et al., 1988).    
 Evidence for the role of TDM in mycobacteria immune evasion and survival came 
from a study involving the delipidation of M. tuberculosis. When delipidated M. tuberculosis 
was used to infect macrophages, bacterial survival was severely impaired. However, upon 
reconstitution with TDM, bacterial survival was restored, indicating a role for TDM in 
intracellular macrophage survival (Indrigo, et al., 2002). It has been speculated that this 
survival enhancement has something to do with TDM’s role in the arrest of phagosome 
development (Karakousis, et al, 2003).  
 The 19 kDa lipoprotein has been linked to reduced production of TNF-α and IL-12 
(Post, et al., 2001) and the inhibition of major histocompatibility complex class-II (MHC-II) 
molecule expression (Noss, et al., 2001). The mechanism by which MHC-II levels are 
reduced is through the 19 kDa lipoprotein-dependent activation of TLR2, which inhibits IFNγ 
receptor signalling by down regulating human leukocyte antigen (HLA)-DR. This results in 
decreased MHC-II processing and reduced recognition of antigens by CD4+ T cells (Gehring, 
et al., 2003), potentially allowing the bacteria to actively evade the adaptive immune 
surveillance systems and maintain chronic infection.         
 
   1.5.2.3 Disruption of Host Cell Signalling 
    1.5.2.3.1 IFNγ Response 
IFNγ is a key cytokine involved in the immune response to a number of intracellular 
pathogens including mycobacteria (Dorman and Holland, 1998; Doffinger, et al., 2000). Mice 
deficient in IFNγ display increased susceptibility to intracellular pathogens (Cooper, et al., 
1993; Dalton, et al., 1993). Humans with mutations in the IFNγ receptor display an increased 
prevalence to infection with low-virulence environmental mycobacterial strains and suffer 
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from recurrent bouts of tuberculosis (Jouanguy, et al., 1999; Dupuis, et al., 2000). IFNγ is 
released from T cells and natural killer cells to activate target cells through a high-affinity 
receptor composed of two chains: IFNγ receptor 1 (IFNGR1) and IFNγ receptor 2 (IFNGR2).  
Signal transduction by IFNγ is most commonly associated with the Janus family kinase 
(JAK)-STAT signalling cascade (Bach, et al., 1997; Darnell, 1997). IFNγ binds to its receptor 
which induces dimerization of the receptor activating JAK1 and JAK2, which phosphorylate 
IFNGR1 (Igarashi, et al., 1994; Bach, et al., 1996). This phosphorylation of IFNGR1 causes 
the recruitment of STAT1, which itself is phosphorylated. Phosphorylated STAT1 
translocates to the nucleus to activate the transcription of IFNγ-inducible genes (Greenlund, et 
al., 1995). One of the main actions of IFNγ is the induction of genes encoding proteins to kill 
intracellular pathogens.  
Since the IFNγ immune response is so important to the clearance of intracellular 
pathogens, a number of viruses and bacteria have evolved means to block cells’ ability to 
respond to IFNγ stimulation. There are a number of points along the IFNγ signalling cascade, 
from receptor-ligand binding to internal signal transduction to gene expression to protein 
activity, which are potential points of disruption. At the level of the receptor, several 
pathogens decrease the expression of one or both of the IFNGR1 and IFNGR2 chains. For 
example, Trypanosoma cruzi (Kierszenbaum, et al., 1995) and Leishmania donovani (Ray, et 
al., 2000) decrease IFNGR1 expression, adenoviruses decrease IFNGR2 expression (Joseph 
and Look, 2001), and Mycobacterium avium decreases expression of both IFNGR1 and 
IFNGR2 (Hussain, et al., 1999). Disruption of intracellular signalling events downstream of 
the IFNGR will also eliminate IFNγ responsiveness. For example, human cytomegalovirus 
targets JAKs for degradation (Miller, et al., 1998), Mumps virus reduces levels of STAT1 
(Fujii, et al., 1999), Varicella-zoster virus reduces levels of JAK2 and STAT1 (Abendroth, et 
al., 2000), and Leishmania donovani activates the protein tyrosine phosphatase SHP-1 to 
dephosphorylate and deactivate JAK2 (Blanchette, et al., 1999). Transcriptional effectors’ 
expression and translation are induced by IFNγ, and these can also be targets for pathogens 
since without effector activity, there is no immune response. Adenovirus inhibits IFNγ-
induced gene expression through a direct interaction with cellular transcription factors 
(Eckner, et al., 1994; Look, et al., 1998).  
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The diverse mechanisms employed to disrupt the IFNγ response clearly demonstrate 
that knowledge of a given pathogen subverting an immune response is not adequate 
information to design an effective treatment. The exact mechanism by which the IFNγ 
response is deactivated must be known. For example, the treatment will be ineffective if a 
given pathogen disrupts the IFNγ response by down-regulating IFNγ receptor expression and 
a treatment is given to stimulate the IFNγ receptor. A rationally designed treatment approach 
based on the specific mechanism of host-pathogen interaction may have a greater chance of 
success.   
It is clear from numerous studies that an IFNγ response is important in Johne’s 
disease. It has been shown that cattle in the excretory, subclinical stage of Johne’s disease 
have increased IFNγ at the site of infection (Sweeney, et al., 1998) and increased IFNγ 
production after in vitro re-stimulation of PBMCs with MAP antigens (Coussens, et al., 
2004). Macrophages pre-treated with IFNγ are able to clear mycobacterial infections (Flynn, 
et al., 1993; Bonecini-Almeida, et al., 1998), while macrophages treated with IFNγ post-
infection are unable to achieve effective bacterial clearance (Denis, et al., 1990; Robertson 
and Andrew, 1991). Taken together, these results indicate that one of the immune evasion 
mechanisms of MAP is to block cellular responses to IFNγ but not the production of IFNγ. To 
date, the mechanism by which MAP blocks the IFNγ response has not been determined.     
 
    1.5.2.3.2 MAP Tyrosine Phosphatases 
Most Mycobacterium genomes contain genes for two proteins which act as functional 
protein tyrosine phosphatases (PTPs): PtpA and PtpB (Koul, et al., 2004). This discovery was 
surprising, considering that mycobacteria do not contain any tyrosine kinases encoded in their 
genome, and their internal cell signalling is based on serine/threonine phosphorylation. Based 
on these observations, it was hypothesized that these phosphatases may be involved in 
disruption of host cell signalling, and the fact that they are secreted from the bacteria 
strengthened this hypothesis. When the mptpB gene of M. tuberculosis was disrupted, it was 
found that the bacteria were as able to survive in macrophages as wild type. However, when 
macrophages were activated with IFNγ, bacterial survival was highly impaired (Singh, et al., 
2003), indicating that PtpB may dephosphorylate key signalling proteins in the active IFNγ 
pathway. Specifically in MAP, PtpA was characterized as an active, secreted phosphatase that 
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carries out its function on defined substrates (Bach, et al., 2006). It was also determined that 
PtpA is actively secreted by MAP in both in vivo and in vitro infection models. MAP PtpA 
had dephosphorylation kinetics similar to the well defined M. tuberculosis PtpA. This 
indicates that the phosphatases may be conserved in both sequence and function across 
mycobacteria species and most likely play an important role in infection. In light of the 
importance of PTPs in Mycobacterium infections, and with the development of more 
phosphatase specific inhibitors, it is believed that a future treatment for Mycobacterium 
infections may involve the use of phosphatase inhibitors specific for one or both of PtpA and 
PtpB. The first species this specific phosphatase inhibitor treatment will be applied to will 
most likely be in M. tuberculosis infections targeting PtpB (Koul, et al., 2004).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
43 
 
2.0 HYPOTHESIS AND OBJECTIVES 
Hypothesis 
Custom-designed genus-specific peptide arrays, in conjunction with customized data analysis 
methods, represent a valuable strategy to determine host signalling responses induced by a 
variety of stimuli, including infection. 
 
Objectives 
1) To develop and validate custom-designed genus-specific peptide arrays for kinome analysis 
2) To develop and validate customized strategies to analyze and interpret peptide array 
kinome data 
3) To apply peptide arrays and associated data analysis methods to understand host signalling 
responses to prion and MAP infection 
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3.0 MATERIALS AND METHODS 
 
 3.1 Reagents and Chemicals 
The chemical reagents required to carry out experiments throughout this thesis are 
listed in Table 3.1.  
 
3.2 Peptide Array Development 
  3.2.1 Protein Selection and Target Site Identification 
 The original bovine peptide array contained peptides corresponding to 
phosphorylation targets of proteins selected on the basis of known cell signalling pathways 
and was biased toward innate immune-related signalling events. Despite this bias, a broad 
range of signalling proteins were chosen to facilitate novel discovery and provide a broad 
overview of signalling events. Many proteins undergo phosphorylation at multiple sites to 
allow discrete control of various aspects of protein function and interactions. Therefore, many 
target proteins were represented more than once on the array by peptides corresponding to 
multiple phosphorylation sites within the protein. This allowed a more detailed exploration of 
cellular response. The first generation bovine array contained a total of 300 phosphorylation 
target sequences corresponding to 194 proteins. A custom-designed human/porcine array, in 
which the majority of peptide sequences were homologous to both genera, contained 300 
phosphorylation target sequences corresponding to 152 proteins. The phosphorylation target 
sites were determined through the use of PhosphoSite (www.phosphosite.org) or 
Phospho.ELM (phosphor.elm.eu.org). 
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Table 3.1 List of selected reagents, chemicals and suppliers.  
 
Reagent/Chemical Supplier 
[5-(4-Fmoc-aminomethyl-3,5-dimethyloxyphenoxy) 
valeric acid]-polyethylene glycol-polystyrene resin 
Applied Biosystems 
Acetonitrile EMD Biosciences, VWR 
Acid destain Sigma Aldrich 
Amino acids VWR 
Anisole: ethylmethyl sulfide: 1,2-ethanedithiol Sigma Aldrich 
Aprotenin Sigma Aldrich 
Adenosine triphosphate (ATP) New England Biolabs 
Beta-mercaptoethanol Qiagen 
Bovine serum albumin (BSA) Biorad Laboratories 
Brij-35 ICN Biomedicals 
Camptothecin Sigma Aldrich 
Carbol fuchsin Sigma Aldrich 
CD14 microbeads Miltenyi Biotec Inc. 
CpG 2007 Merial 
Diethyl ether VWR 
Eagle’s Minimum Essential Medium (EMEM) Cedarlane Laboratories 
Entellen New Rapid Mounting Medium EMD Chemicals 
Ethanol (molecular grade) Sigma Aldrich 
Ethylene glycol tetraacetic acid (EGTA) Sigma Aldrich 
Ethylenediaminetetraacetic acid (EDTA) Sigma Aldrich 
F12K medium Cedarlane Laboratories 
Fetal bovine serum (FBS) Seracare 
Fura-2, AM AnaSpec Inc. 
Gentamicin Gibco, Invitrogen Corp. 
Glycerol GE Healthcare 
Immulon 2 96U plates Thermo Scientific 
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Leupeptin Sigma Aldrich 
Lipopolysaccharide (LPS) Sigma Aldrich 
MACS buffer Miltenyi Biotec Inc. 
Magnesium chloride Sigma Aldrich 
Methylene blue Sigma Aldrich 
Middlebrook 7H9 broth Difco Labs 
Middlebrook 7H10 agar Difco Labs 
Mycobactin J Allied Monitor Inc. 
Oleic acid albumin dextrose complex enrichment 
medium 
Difco Labs 
Para-Nitrophenylphosphate (PNPP) Invitrogen 
Percoll GE Healthcare 
Phenylmethylsulphonyl fluoride (PMSF) Sigma Aldrich 
Piperidine VWR 
Polyoxyethylene lauryl ether (Brij-35) MP Biomedicals 
ProQ Diamond Phosphoprotein Stain Invitrogen 
Recombinant bovine IFNγ Novartis 
Reverse transcriptase buffer Invitrogen 
Reverse transcriptase enzyme Invitrogen 
RNase H (E. coli) Invitrogen 
RNeasy lysis buffer (RLT) Qiagen 
Roswell Park Memorial Institute (RPMI) medium Gibco, Invitrogen Corp. 
Sodium acetate Sigma Aldrich 
Sodium fluoride Sigma Aldrich 
Sodium orthovanadate Sigma Aldrich 
Sodium pyrophosphate Sigma Aldrich 
Streptavidin alkaline phosphatase Jackson ImmunoResearch 
SYBR Green master mix BioRad Laboratories 
Trifluoroacetic acid (TFA) Fischer Scientific 
Tris + Tween 20 (TBST) Sigma Aldrich 
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Gelatin Sigma Aldrich 
Triton X-100 Sigma Aldrich 
Trypan blue Gibco-Invitrogen 
Tween 80 Sigma Aldrich 
Recombinant VEGF  Invitrogen 
Antibodies Supplier 
6H4 Prionics 
Goat anti-mouse (GAM) IgG1 CALTAG Laboratories 
GAM fluorescein isothiocyanate (GAM-FITC) BD Biosciences 
Goat anti rabbit IgG biotin Zymed, Invitrogen 
IgG1 isotype control CALTAG Laboratories 
Kits Supplier 
RNeasy mini kit Qiagen 
Supplier Name Supplier Address 
Allied Monitor Inc Fayette, Missouri, USA 
Applied Biosystems Foster City, California, USA 
Difco Labs Detroit, Michigan, USA 
EMD Biosciences Mississauga, Ontario, Canada 
VWR Mississauga, Ontario, Canada 
Sigma Aldrich Oakville, Ontario, Canada 
Gibco-Invitrogen Corp. Burlington, Ontario, Canada 
New England Biolabs Pickering, Ontario, Canada 
Qiagen Mississauga, Ontario, Canada 
Biorad Laboratories Mississauga, Ontario, Canada 
ICN Biomedicals St. Laurent, Quebec, Canada 
Miltenyi Biotec Inc. Auburn, California, USA 
Merial Baie d’Urfé, Quebec, Canada 
Cedarlane Laboratories Burlington, Ontario, Canada 
EMD Chemicals Mississauga, Ontario, Canada 
Seracare Milford, Massachusetts, USA 
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AnaSpec Inc. Fremont, California, USA 
GE Healthcare Baie d’Urfé, Quebec, Canada 
Thermo Scientific Nepean, Ontario, Canada 
Invitrogen Mississauga, Ontario, Canada 
MP Biomedicals Solon, Ohio, USA 
Novartis Mississauga, Ontario, Canada 
Qiagen Mississauga, Ontario, Canada 
Jackson ImmunoResearch West Grove, Pennsylvania, USA 
Fisher Scientific Ottawa, Ontario, Canada 
Prionics AG Lincoln, Nebraska, USA 
CALTAG Laboratories Mississauga, Ontario, Canada 
BD Biosciences Mississauga, Ontario, Canada 
Zymed, Invitrogen Mississauga, Ontario, Canada 
 
 
 
  3.2.2 Genus Ortholog Identification 
 The PhosphoSite and Phospho.ELM phosphorylation databases contain predominantly 
human or mouse phosphorylation sites. These human sequences were converted to the genus 
of interest, originally bovine. The NCBI program Blastp (blast.ncbi.nlm.nih.gov) was utilized 
to find orthologous target sequences in the genus of interest. The first step in scrutinizing the 
Blastp-generated results was to ensure that the identified protein matched the human query 
protein by ensuring the annotations matched. Then, the number of amino acid differences 
between the human peptide and target was determined by comparing the two 15 amino acid 
sequences, query and match. In the bovine array design, target sites with substantial sequence 
differences between human and bovine were purposely limited. Limiting sequence differences 
meant more confidence that the peptide sequences represented a true kinase target, since the 
human sequences were well characterized. In addition, with fewer sequence differences, more 
cross-reactivity between bovine and human samples could be expected. For the 
human/porcine array, 268 of the 600 human sequences were exact matches with the porcine 
sequence, and the remaining sequences contained at least one amino acid difference. For 
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human and porcine peptides that did contain sequences differences, it was decided that the 
human sequence would be printed on the array. This would allow the array to be used in 
studies with both human and porcine cell lysate since the majority of the sequences were 
100% identical. Of the 300 peptides printed on the array, 206 had 100% homology, and the 
remainder had at most 2 amino acid sequence differences. 
 
  3.2.3 Peptide Synthesis and Spotting 
All peptides were synthesized and printed according to the protocol developed and 
performed by JPT Peptide Technologies (www.jpt.com). Amino-oxy-acetylated peptides were 
synthesized on cellulose membranes in a parallel manner using SPOT synthesis technology 
(Frank, 1992; Wenschuh, et al., 2000). Following side chain deprotection, the solid-phase 
bound peptides were transferred into 96-well microtiter filtration plates (Millipore, Bedford, 
USA) and treated with 200 µL of aqueous triethylamine (0.5 % v/v) to cleave the peptides 
from the cellulose. Peptide-containing triethylamine solution was filtered off, and solvent was 
removed by evaporation under reduced pressure. The resulting peptide derivatives (50 nmol) 
were re-dissolved in 25 µL of printing solution (70% dimethyl sulfoxide (DMSO), 25% 0.2 M 
sodium acetate pH 4.5 and 5% glycerol v/v) and transferred into 384-well microtiter plates. 
Two droplets of 0.5 nL peptide solution were deposited per spot on aldehyde functionalized 
glass slides using the non-contact printer Nanoplotter of GESIM (Großerkmannsdorf, 
Germany) equipped with 8 piezoelectric NanoTips (GESIM, Großerkmannsdorf, Germany). 
Printed peptide microarrays were kept at room temperature for 5 hours, washed with 
deionised water, quenched for 1 hour with 50% aqueous hydroxylamine, washed extensively 
with water followed by ethanol, and dried under a stream of nitrogen. The peptide 
microarrays were then stored at 4°C and maintained reactivity for more than 18 months. To 
determine intra-assay variability in substrate phosphorylation, each block of 300 peptides was 
printed in triplicate. The physical dimensions of the array were 19.5 x 19.5 mm. Each peptide 
spot had a diameter of ~350 µm, and the distance between the peptide spots was 750 µm.  
In the case of the bovine array, a total of 298 bovine peptides and 2 negative control 
peptides of 15 amino acids in length were printed within each block of the array. The layout 
of one block is presented in Figure 3.1 A. Seven positive control proteins (Histone 1-4, 
Myelin basic protein-maltose binding protein bovine and alpha/beta Casein) were printed 
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outside the margins of each block on the array. The layout of the entire array is shown in 
Figure 3.1 B. For the human/porcine array, a total of 297 human/porcine peptides and 3 
negative control peptides were printed in blocks similar to the bovine arrays. The same seven 
positive control proteins were used. Each positive control was a full-length protein which is 
known to be phosphorylated in cells in the presence of ATP. Signals from the controls were 
not included in the peptide array analysis, but these proteins were used to orient the slide for 
visualization and gridding of the blocks. The layout of the human/porcine array was similar to 
that shown in Figure 3.1. 
 
A) 
 
B) 
 
 
Figure 3.1. Peptide array diagram: Shown are representations of a custom peptide array 
from JPT Peptide Technologies. Three hundred peptides are printed within each block which 
is then printed in triplicate. Control spots are printed outside of these blocks to ease array 
orientation and gridding during analysis. A) A single block of peptides is shown. Blue spots 
indicate custom-designed peptides, and black spots indicate positive control proteins. B) 
Shown here is an entire peptide array chip with each block printed in triplicate. Light yellow 
spots containing red indicate custom-designed peptides. Coloured and black spots located 
around the custom-designed spots indicate control proteins. This figure was adapted from the 
JPT schematic.   
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 3.3 Human Neuronal BE(2)M17 Culture 
Human neuronal cells, BE(2)M17, (Cedarlane Laboratories Burlington, ON) were 
maintained in a 1:1 mixture of Eagle’s Minimum Essential Medium (EMEM) (Cedarlane 
Laboratories) containing Earle’s Balanced Salt Solution, non-essential amino acids, 2 mM L-
glutamine, 1 mM sodium pyruvate, and 1500 mg/L sodium bicarbonate, and F12K Medium 
(Cedarlane) containing gentamicin (Gibco-Invitrogen, Burlington, ON) with 10% fetal bovine 
serum (FBS) (Seracare, Milford, MA). The cells were cultured in T-75 culture flasks 
(Corning, Lowell, MA) at 37ºC in an atmosphere of 5% CO2 and 95% air. The cells grew as 
an adherent monolayer and were detached from the plastic with 0.5% trypsin in versene when 
passaged every 3-4 days. 
 
 3.4 Flow Cytometric Analysis of PrPC Expression on BE(2)M17 Cells  
Monoclonal antibody 6H4, specific for PrP, was purchased from Prionics AG 
(Lincoln, NE). Fluorescein isothiocyanate (FITC)-conjugated, isotype specific, goat anti-
mouse Ig antibodies (GAM-FITC) were purchased from BD Biosciences (Mississauga, ON), 
and IgG1 isotype control antibodies were purchased from CALTAG Laboratories 
(Mississauga, ON). One-million cells resuspended in 50 µL phosphate buffered saline (PBS) 
and 50 µL of primary antibody (10 µg/mL) were mixed and incubated on ice for 15 minutes 
before the cells were washed 3 x with 200 µL phosphate buffered saline (PBS). The cells were 
then resuspended in 100 µL secondary GAM-FITC (10 µg/mL) and incubated for 15 minutes 
on ice. The cells were again washed 3 x with 200 µL PBS and resuspended in 200 µL PBS. 
Phenotypic analysis of the cells was performed using a FACSCalibur (Becton Dickinson, San 
Jose, CA) flow cytometer to collect data, and the CellQuest (Becton Dickinson) software 
program was used for data analysis. 
 
3.5 BE(2)M17 Prion Stimulation 
 3.5.1 Peptide Synthesis 
Peptide PrP 106-126, sequence N terminal - KTNMKHMAGAAAAGAVVGGLG – C 
terminal (O’Donovan, et al., 2001), and scramble peptide of identical amino acid 
composition, sequence N terminal – NGAMAKMAGGHAVATVAGKGL – C terminal,  
were synthesized by VIDO Chemistry Services using the following protocol. Peptides were 
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synthesized on a Pioneer solid-phase peptide synthesizer (PerSeptive Biosystems. Foster City, 
CA) using 9-Fluorenylmethyloxycarbonyl (Fmoc) chemistry. The peptide chain was 
synthesized by the addition of amino acids (VWR, Mississauga, ON) from the carboxyl 
terminus to the amino terminus onto [5-(4-Fmoc-aminomethyl-3,5-dimethyloxyphenoxy) 
valeric acid]-polyethylene glycol-polystyrene resin (Applied Biosystems, Foster City, CA). 
The Fmoc protecting group at the amino terminus was deprotected with piperidine (VWR). 
The peptide was cleaved from the resin with concurrent deprotection of the side-chain 
protecting groups by treating the resin-bound peptide with trifluoroacetic acid (TFA) (Fisher 
Scientific, Ottawa, ON) (9.3 parts) in the presence of the scavengers anisole, ethylmethyl 
sulfide and 1,2-ethanedithiol (Sigma Aldrich, Oakville, ON) (3:3:1) for 3 hours. The crude 
peptide was filtered from the resin, and the TFA evaporated. Diethyl ether (VWR) was added 
to the residue to precipitate the crude peptide. The peptide was isolated and purified by high 
performance liquid chromatography on Vydac Protein C-4 column (1.0 x 25 cm) eluting with 
a linear gradient of 15% (water, 0.1% TFA) - 90% B (acetonitrile (VWR):water (90:10), 
0.01% TFA) for 40 minutes at a flow rate of 3 mL/minute. The molecular weight of the 
peptides was measured by matrix-assisted laser desorption/ionization time of flight mass 
spectrometry on PE Biosystems Voyager System 4068 (Plant Biotechnology Institute, 
National Research Council, Saskatoon, SK). 
 
 3.5.2 Peptide Stimulation 
Human neuronal cells were stimulated with a prion protein fragment PrP 106-126, and 
a scrambled peptide of identical amino acid composition was used as a negative control. The 
peptides were dissolved in distilled H2O at a concentration of 5 µg/mL. This solution was then 
added to cultured cells at a final concentration of 80 µM, and the cells were incubated at 37ºC, 
5% CO2 and 95% air for 4 hours. The cells were then harvested as described in Section 
3.11.1. 
 
 3.5.3 Antibody Stimulation 
Antibody cross-linking was done as per the cell phenotyping procedure with the 
following alterations: cells were suspended in culture media, GAM without conjugated FITC 
(CALTAG) was used as the secondary to cross-link the antibody, 5 µg/mL of primary and 2 
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µg/mL of secondary was used, only 1 wash following the addition of the primary was done, 
and no washes were performed after GAM addition. 
 
3.6 MACS Isolation of Bovine Monocytes 
Fifty mL of blood was collected from three 9-month-old Charolais-cross steers, animal 
numbers 89, 136 and 148. Blood was collected by venupuncture into tubes containing 
ethylenediaminetetraacetic acid (EDTA) (Sigma Aldrich, Oakville, ON) as an anti-coagulant 
(performed by VIDO Animal Care staff). Blood was transferred to 50 mL polypropylene 
tubes (Corning) and centrifuged at 1,400 x g for 20 minutes at 20°C. Mononuclear leukocytes 
were isolated from the buffy coat and mixed with phosphate buffered saline without Mg2+ or 
Ca2+ (PBSA) to a final volume of 35 mL. The cell suspension was then layered onto 15 mL of 
54% isotonic Percoll (GE Healthcare, Baie d’Urfe, QC) and centrifuged at 2,000 x g for 20 
minutes at 20°C. Peripheral blood mononuclear cells (PBMC) from the Percoll-PBSA 
interface were then collected and washed three times with ice-cold PBSA. Monocytes were 
purified from isolated PBMCs by MACS purification using anti-CD14 microbeads (Miltenyi 
Biotec, Auburn, CA), as per Miltenyi Biotech Protocol Sheet 130-050-201. Monocytes were 
then plated at 4x106 cells/well in 12-well culture cluster plates (Corning) using RPMI medium 
(Gibco-Invitrogen) supplemented with 10% heat-inactivated FBS (Gibco-Invitrogen) and 
rested overnight at 37ºC in 5% CO2 prior to infection. 
 
3.7 MAP Culture 
MAP K10 was incubated at 37ºC on Middlebrook 7H10 agar (Difco Labs, Detroit, 
MI) with oleic acid albumin dextrose complex enrichment medium (Difco Labs) and 
mycobactin J (Allied Monitor Inc., Fayette, MO). After 3-4 weeks of growth, a large loopful 
of bacteria was collected and transferred to 50 mL Middlebrook 7H9 broth (Difco Labs) 
containing 0.05% Tween 80 (Sigma Aldrich), oleic acid albumin dextrose complex 
enrichment medium and mycobactin J. The culture was incubated at 37ºC with gentle 
agitation for 5 days to achieve log phase growth. A 50 mL tube (Corning) was weighed, and 
bacteria culture was transferred to the tube. The tube was then centrifuged at 3,400 x g for 30 
minutes. The supernatant was decanted, and the pellet was allowed to drain upside down on 
sterile filter paper for 30 minutes. The tube containing the pellet was then weighed. A 
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calculation of colony-forming units (CFU) was then performed (1 mg = 107 CFU) as per 
Hines, et al. (2007). The pellet was resuspended in an appropriate amount of RPMI medium 
(Gibco-Invitrogen) to achieve the desired concentration. 
 
3.8 MAP Infection of Monocytes 
MAP bacteria were added to cultured monocytes at a ratio of 10 bacteria to 1 
monocyte. Following MAP addition, the culture plate (Corning) was centrifuged at 300 x g 
for 2 minutes to ensure contact between the bacteria and monocytes. The monocyte culture 
was then incubated at 37ºC in 5% CO2 for 3 hours. The cells were washed 3 x with fresh 
RPMI (Gibco-Invitrogen) + 10% FBS (Seracare), and if required for the given assay, 
incubated for additional time at 37ºC in 5% CO2.  
 
3.9 Monocyte and MAP Acid Fast Staining 
Following infection, media containing the monocytes was removed. The monocytes 
were lifted from the plastic using 0.5% trypsin in versene. The monocytes were prepared for 
cytospins by centrifugation at 325 x g for 5 minutes. The cells were then resuspended in 200 
µL PBSA + 0.1% EDTA (Sigma Aldrich). Cytospins were performed by adding 100 µL cell 
suspensions to the cytospin cone before centrifuging at 300 x g for 3 minutes to deposit cells 
onto a glass slide. The slides were allowed to dry overnight in a fume hood. The cells were 
heat-fixed to the slides by briefly passing them through flame. The slides were then placed 
over boiling water, stained with carbol fuchsin (Sigma Aldrich) for 5 minutes and rinsed. 
Acid destain (Sigma Aldrich) was briefly added to each slide before rinsing with water. The 
slides were counterstained using methylene blue (Sigma Aldrich) for 1 minute and rinsed with 
water. The slides were dried overnight in the fume hood. The next day, each cytospot was 
fixed using Entellen New Rapid Mounting Medium (EMD Chemicals, Mississauga, ON) with 
a coverslip. The cells were observed under a light microscope using oil immersion (100X 
power). 
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3.10 Treatment of Monocytes 
Purified monocytes (uninfected and MAP-infected) were prepared as described earlier. 
In the case of CpG treated monocytes, 5 µg/mL CpG 2007 (Merial, Baie d’Urfé, QC) was 
added to the well. In the case of LPS treated monocytes, 100 ng/mL of LPS (E. coli 0111:B4) 
(Sigma Aldrich) was added to the well. In the case of recombinant bovine IFNγ treatment, 
IFNγ (Novartis, Mississauga, ON) was added to cultures at a final concentration of 10 ng/mL, 
and the cells were incubated for time required for the individual assays at 37ºC in 5% CO2. 
 
3.11 Peptide Array Technique 
 3.11.1 Cell Harvesting 
Approximately 10x106 cells were stimulated/infected for the desired time period: 4 
hours for prion, CpG, LPS studies and 3 hours for MAP studies. The media was removed and 
discarded. Approximately 1 mL mixture of 0.5% trypsin-versene was added to each well for 
30 seconds. Trypsin-versene was removed and discarded. The cultures were placed in an 
incubator for 5 minutes at 37ºC. To remove adherent cells, the plates were then washed with 
the appropriate media: EMEM-F12K for prion study or RPMI for studies involving 
monocytes. The cells were then collected, spun down and pelleted at 300 x g for 8 minutes. 
The media was removed, and the pellet was frozen in a freezer block at -80ºC overnight. The 
cells were then removed from the block and stored at -80ºC until used in peptide array 
analysis. 
  
 3.11.2 Peptide Array Exposure/Incubation/Washing Procedure 
The cells were thawed and lysed by the addition of 100 µL lysis buffer [20 mM Tris-
HCl pH 7.5, 150 mM NaCl,1 mM EDTA, 1 mM Ethylene glycol tetraacetic acid (EGTA), 1% 
Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM Na3VO4, 1 mM NaF, 1 µg/mL leupeptin, 
1 g/mL aprotinin and 1 mM Phenylmethylsulphonyl fluoride] (all products from Sigma 
Aldrich unless indicated). The cells were incubated on ice for 10 minutes and spun in a 
microcentrifuge at 1,000 x g for 10 minutes at 4ºC. An approximate protein concentration of 
1.3-1.5 mg/mL was present in the 100 µL of lysate. A 70 µl aliquot of this supernatant was 
mixed with 10 µl of activation mix [50% glycerol (GE Healthcare), 500 µM ATP (New 
England Biolabs, Pickering, ON), 60 mM MgCl2, 0.05% v/v Brij-35 (ICN Biomedicals, St. 
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Laurent, QC) and 0.25 mg/mL BSA (BioRad Laboratories, Mississauga, ON)] which was 
incubated on the array for 2 hours at 37ºC. Custom-designed bovine peptide array was used 
for all array experiments. Following incubation, the slides were washed once with PBS-(1%) 
Triton, submerged in stain (ProQ Diamond Phosphoprotein Stain, Invitrogen) and agitated for 
1 hour. Arrays were then washed twice in 50 mL tubes (Corning) containing destain [20% 
acetonitrile (EMD Biosciences, Mississauga, ON) and 50 mM sodium acetate (Sigma 
Aldrich) at pH 4.0] for 10 minutes, with the addition of new destain before each wash. A final 
wash was done with distilled H2O, and the arrays were dried.   
 
 3.11.3 Signal Detection 
The arrays were read using a GenePix Professional 4200A microarray scanner (MDS 
Analytical Technologies, Toronto, ON) at 532-560 nm with a 580 nm filter to detect dye 
fluorescence. Images were collected using the GenePix 6.0 software (MDS). Signal intensity 
values were collected using the GenePix 6.0 Software (MDS) with the following settings: 
scanner saturation level 65535, background calculation done using local feature background, 
signal mean and background mean intensity values used for analysis, local background 
features excludes 2 pixels, and width of background was set to 3 feature diameters. Intensity 
values for the spots and background were collected for each array. 
 
3.12 Peptide Array Data Analysis 
 3.12.1 Statistical Analysis 
The statistical analysis pipeline and data mining steps were developed as a 
collaborative effort with Dr. Tony Kusalik and his student Yue Li of the Department of 
Computer Science, University of Saskatchewan. 
  
  3.12.1.1 Data Pre-Processing 
For all datasets, the specific value for each peptide spot was calculated by subtracting 
local background intensity from foreground intensity. The resulting data were transformed 
using a variance stabilization (VSN) model (Huber, et al., 2002). The transformation 
calibrated all the data to a positive scale while maintaining the structure within the data and 
alleviating mean-variance-dependence. In addition, the data across various experiments were 
57 
 
brought to the same scale by VSN to enable comparison of arrays between experiments, cell 
types or treatments. To facilitate subsequent analysis, the dataset was rearranged so each row 
contained all the replicates of a unique peptide. The R software environment (www.r-
project.org) function vsn2 from the package vsn was used for the VSN transformation (Huber, 
et al., 2003). Only in the subsequent clustering analysis was the average for each of the 
peptide replicates in a single treatment taken, otherwise replicates were left as separate values. 
 
  3.12.1.2 Spot-Spot Variability Analysis 
A chi-squared ( 2Χ ) test was used to examine the variability of each peptide spot 
across technical replicates (Draghici, 2003), that is, replicates on the same chip or multiple 
chips for the same subject under the same treatment.  
For each peptide, the null hypothesis (H0) claimed that there was no difference among 
intensities from the replicate spots, and the alternative hypothesis (HA) stated that there 
existed significant variation among the replicates. The 2Χ  test statistic (TS1) was: 
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where n  is the number of replicates for each peptide in the treatment,  
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is the sample variance of the replicates for each peptide in a treatment,  
 
∑=
M
sM 22 /1σ                                                                                                                    (3.3) 
 
is the mean of all the variances for the replicates of the  peptides in the treatment (i.e., total 
number of distinct peptides included in an array), and 
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The peptides with p-values less than a set threshold were considered inconsistently 
phosphorylated across the array replicates. A confidence level (e.g., 0.01) was used to retain 
as much data as possible. The p- value was calculated using the R function pchisq from the 
stats package.  
If applicable, the remaining intensities induced by the treatments were adjusted by 
subtracting the intensities of the biological control of the same subject. 
 
  3.12.1.3 Subject-Subject Variability Analysis 
Subject-subject variability analysis was done after biological background subtractions 
(if applicable) and was only applied to datasets where there was a concern of animal (subject) 
variation. Thus, subject-subject variability analysis was performed on the MAP peptide array 
data but not the prion array data. For each of the peptides, an F-test was used to determine 
whether there were significant differences among the subjects under the same treatment 
condition. Data for inconsistently phosphorylated peptides were eliminated from subsequent 
analysis. 
As a description, let a be the number of subjects, n the number of intra-array 
replicates, N  the total number of replicates for each peptide for each treatment and iu  the 
mean response of each peptide in the i th subject for each treatment. The null hypothesis (H0) 
claimed that 1u = 2u =…= au , or that the mean phosphorylation intensities elicited by the 
identical peptide among the subjects were the same. The alternative hypothesis (HA) stated 
that not all subject means were equal. The F-statistic ( 2TS ) was calculated as: 
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Above, ii uy ˆ≡  is the sample mean for the i
th
 subject, uy ˆ≡  the grand mean of all the 
subjects and imy  the individual response of the m th replicate in the i th subject. For the p-
value calculation: 
 
p - value = )],1([ 2 aNaFTSP −−>                                                                                      (3.8) 
 
Under the same treatment condition, the peptides with p-value less than a threshold were 
considered inconsistently phosphorylated among the subjects and were eliminated from 
subsequent analysis. A confidence level (e.g., 0.01) was used so that as much data as possible 
was retained. 
 
  3.12.1.4 Treatment-Treatment Variability Analysis 
All peptides identified as having consistent patterns of response to various treatments 
across the subjects were the objects of one-sided paired t-tests. T-tests were conducted to 
compare signal intensities under a treatment condition with those under control conditions. 
The t-test statistic ( 3TS ) was calculated as: 
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where  is the mean of the differences between responses for the same peptides induced by 
two different treatments,  the standard deviation of the differences and N  the number of 
differences between each treatment and control. Finally, 
 
- value =       (phosphorylation)                                                          (3.10) 
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and 
p - value = )]1([ 3 −−< NtTSP     (dephosphorylation)                                                      (3.11)   
 
Thus, each peptide had two p-values: one associated with the peptide being differentially 
phosphorylated and the other with it being dephosphorylated. The peptides with a p-value less 
than a threshold (e.g., 0.1) were considered as differentially (de)phosphorylated and were 
used for the subsequent analyses. To retain as much data as possible, no adjustment (as for 
multiple hypotheses testing) was made to the p-value. The paired t-test was performed using 
the R environment function t.test from the stats package with paired = True. 
The paired t-test was used because it takes into account the interdependence between 
the same peptides under treatment and control conditions. Also, note that the t-test was able to 
account for the variability (in terms of DS ) among the replicates; thus, replicates with 
significant p-value from the 2Χ -tests automatically had insignificant p-value from the t-test. 
However, this did not apply to datasets with multiple subjects because significant variation for 
the same peptide among the subjects under the same treatment condition might have been 
biologically meaningful. It may have confounded the analysis if these peptides were treated as 
if they came from the same source. 
 
  3.12.1.5 Data Visualization 
The results from the treatment-treatment variability analysis were recorded in tables 
and also presented in pseudo-images. The latter were generated based on the p-values from 
the one-sided t-tests for phosphorylation or dephosphorylation of each peptide. Each peptide 
was represented by one small coloured circle. The intensity of the colouration in red and 
green were inversely related to the corresponding p-values. For example, if the p-value for 
phosphorylation was 0.001, then the redness in percentage was 100% x (1 - 0.001) = 99.9%. 
The same rationale was applied to dephosphorylated peptides and the intensity of the green 
colour. Thus, the combined colour intensity of red and green represented the phosphorylation 
status of each peptide in the microarray. In addition, each circle in the plot was partitioned 
into sectors, each of which represented a different treatment. Moreover, the circles were 
arranged in such a way that, going downwards by column from left to right, the consistently 
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phosphorylated peptides across treatments were presented first, and the inconsistent ones 
followed. Within the consistently phosphorylated peptides the ones with the most significant 
p-values for (de)phosphorylation on average over the treatments being compared, were 
presented first, and the less significant ones followed. Similarly, the inconsistent ones with the 
largest p-values when compared to the treatment were presented first, and the smaller p-
values followed. The original numbering for a peptide (i.e., the label below each circle) from 
the physical array layout was unchanged for indexing detailed information of the peptide. The 
plots were generated using R environment functions plot (for plotting the circles in different 
coordinates), rgb (for 13 colouration) and polygon (for drawing sectors to represent 
treatments). This visualization of the results from differential analysis facilitated the 
identification of conspicuous intensities of peptides, or patterns of intensities, across 
treatments. 
 
  3.12.1.6 Cluster Analysis 
Peptides with consistent intensities in technical and biological replicates were 
determined in the previous spot-spot and subject-subject variability analyses. For each such 
peptide, an average intensity was taken over the technical replicates. The averaged data, with 
or without biological control subtractions, was subjected to hierarchical clustering and PCA to 
cluster peptide-response profiles across treatments or subject-treatment combinations. The 
dendrograms from the hierarchical clustering were augmented by heatmaps showing the 
averaged (de)phosphorylation intensities.  
The R environment function heatmap.2 from the gplots package was used for 
hierarchical clustering, and the prcomp function from stats was used for PCA. The 3D plot for 
the PCA using the first three principal components was produced by the R function 
scatterplot3d from package scatterplot3d. 
In the case of the prion dataset, heatmap clustering was based on complete linkage 
plus Euclidean (Everitt, 1974; Hartigan, 1975). The distance between any two clusters was 
considered as the Euclidean distance between the two farthest data points in the two clusters. 
Formally, the Euclidean distance between two animal/treatment vectors, X and Y, was 
calculated as:  
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For the MAP study dataset, the clustering was average linkage plus Pearson 
correlation (Pearson, 1896; Eisen et al., 1998), and the calculation of two vectors of treatment, 
X and Y, were computed as follows: 
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3.12.2 Statistical Method Comparison 
To compare our pipeline, three previously published workflows for microarray 
analyses were implemented in R and applied to the same datasets. Those were percentile 
normalization (PNorm) + fold change (Lowenberg, et al., 2006; van Baal, et al., 2006; Jalal, 
et al., 2009), quantile normalization (QNorm) + Linear Models for Microarray Data (limma) 
(Schrage, et al., 2009) and VSN + limma (Fletcher, et al., 2009). All three methods operated 
on background-corrected data. The PNorm procedure was implemented in R based on the 
algorithm reviewed by Fundel et al. (2008). The 90th percentile was used, as in the kinome 
analysis by Lowenberg et al. (2006). Briefly, after background correction, intensities in each 
array were divided by the 90th percentile of the data points from the same array in order to 
achieve a uniform intensity at the 90th percentile across all the arrays. The QNorm and VSN 
steps were carried out using the R environment limma package function 
NormalizeBetweenArrays by setting the parameter method to quantile and vsn, respectively 
(Smyth and Speed, 2003). Note that the NormalizeBetweenArrays provided the VSN method. 
After VSN, however, the function further scaled the transformed data by taking the logarithm 
to base 2 (log2), which was not carried out in our pipeline. 
In the PNorm + fold change approach, data from the same array with standard 
deviation (SD) larger than 1.96 (approximated as 2 x SD) of the mean were deemed 
inconsistent and excluded from subsequent analysis (Lowenberg, et al., 2006; van Baal, et al., 
2006). In QNorm + limma and VSN + limma, a function called duplicateCorrelation in the 
limma package was used to estimate the correlation between the replicates within an array 
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(Smyth, et al., 2005). The resulting correlations for each peptide were used as a weighting 
factor for the subsequent differential analysis. Finally, an F-test provided by the limma 
package was used to compare the log2 fold change (logFC) of each peptide across biological 
replicates. The log scale ratios given by limma were converted to fold change values by using 
the R function logratio2foldchange from the gtools library. 
In the differential analysis, the PNorm + fold change approach identified differentially 
phosphorylated peptides by comparing their combined fold change to an arbitrary threshold 
(td). The peptides with fold change larger than td were deemed significantly phosphorylated, 
and those with fold change less than td were deemed significantly dephosphorylated. The two 
other comparison methods involving limma used the function eBayes (Schrage, et al., 2009) 
to determine the p-values associated with the moderated t-statistics. A peptide was determined 
as differentially phosphorylated if its p-value was less than 0.1.  
  
3.12.3 Pathway Analysis 
Differentially phosphorylated peptides, as determined by the differential analysis step 
(Section 3.12.1.4), can be used to probe the database InnateDB (Lynn, et al., 2008). Because 
InnateDB requires fold change values as input (with p-values optional), the differences 
between the VSN-transformed intensities under control and treatment were converted to fold 
change values by the formula:  
 
Fold Change = 2d                                                                                                                 (3.14) 
 
where  
 
d=averagetreatment-averagecontrol                                                                                             (3.15) 
 
The fold change value and one of the p-values from the one-sided t-test for each of the 300 
peptides (less those removed during the subject-subject variability analysis) were input into 
InnateDB. If a peptide had a positive calculated fold change value, then the p-value associated 
with phosphorylation was chosen; otherwise, if the calculated fold change value was negative, 
the p-value associated with dephosphorylation was chosen. 
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Other inputs to InnateDB were p-value threshold and fold change threshold. These 
thresholds allow specified cut-offs for the input dataset. InnateDB eliminated from analysis all 
peptides with a p-value greater than the set p-value threshold and fold change values less than 
the set fold change threshold. For the prion and MAP dataset analysis, the p-value threshold 
was set to 0.2, and the fold change threshold was set to 1. The latter threshold is non-selective 
since the fold change values will always be equal to or greater than 1, or equal to or less than -
1. This non-selectivity was a deliberate choice. Since the p-value was a calculation of how 
significant the difference was between treatment and control, it was the preferred basis for 
determining whether a peptide should be included rather than relying on fold change. 
For the comparison methodologies, pathway identification was again performed using 
InnateDB. All peptides except those determined to have inconsistent intensities were 
considered. Thresholds were the same as for our method (p-value of 0.1 and fold change of 1). 
For QNorm + limma and VSN + limma methods, identifiers of the peptides along with p-
values and fold change values were again input. For PNorm + fold change, only peptide 
identifiers and fold change values were input as no p-values were available from this method.  
Pathways identified by InnateDB for each methodology and each dataset were then 
visualized using the Cerebral plugin (Barksy, et al., 2007) for the interaction viewer 
Cytoscape (Shannon, et al., 2003). 
 
3.13 Phosphospecific Antibody Array 
 3.13.1 Cell Preparation 
BE(2)M17 cells (10 x106) were stimulated for 4 hours with 80 µM of the prion protein 
fragment PrP 106-126 or scrambled control peptide in media. The cells were then centrifuged 
at 300 x g for 8 minutes, washed in PBS and centrifuged a second time. The supernatant was 
removed, and the pellet was frozen at -80°C before shipping for commercial analysis. 
 
 3.13.2 Array Procedure 
The antibody array procedure was performed as per Pelech and Zhang (2008) by 
Kinexus Bioinformatics (Vancouver, B.C.). Cell lysates at a protein concentration of 2 
mg/mL were labelled with a fluorescent dye. Unincorporated dye was removed by 
ultrafiltration. Purified, labelled proteins from the control and treatment samples were 
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incubated separately on opposite sides of a Kinex KAM 1.0 antibody microarray. The 
microarray contained two identical fields of antibody grids. Each field contained 604 
antibodies printed in duplicate. Pan-specific and phosphospecific antibodies were printed at a 
concentration of 100 µg/mL at 10 nL per spot. The internal variation for the spot printing 
between chips in the same print run is less than 4%. After antibody binding, arrays were 
scanned using a ScanArray scanner (Perkin-Elmer, Wellesley, MA) with a resolution of 10 
µm. Images were quantified to determine the binding signal using ImaGene software 
(BioDiscovery, El Segundo, CA). The values were the means of the measurements from each 
antibody spot pair. Means were converted to fold change by dividing treatment mean by 
control mean.   
 
3.14 Camptothecin Treatment of BE(2)M17 
 Human neuronal cells were plated in 24-well plates (Corning) in 1 mL of media. Ten 
µM camptothecin (Sigma) was added to the wells which were incubated at 37°C in 5% CO2 
and 95% air overnight. The cells were then harvested and assayed, as indicated in Section 
3.11.1 but without freezing. 
 
3.15 VEGF Treatment of BE(2)M17 
Human neuronal cells were plated in 24-well plates (Corning) in 1 mL of media. 
Fifteen ng/mL recombinant vascular endothelial growth factor (VEGF) (Invitrogen) was 
added to wells which were incubated at 37°C in 5% CO2 and 95% air overnight. The cells 
were then harvested and assayed as indicated in Section 3.11.1, but without freezing.  
 
3.16 Viable Cell Assay 
Neuronal cells (5x105) were plated in triplicate in 24-well plates (Corning) at a 
concentration of 1x106 cells/mL and left overnight. The cells were then treated with peptide or 
antibody as described in Sections 3.5.2 and 3.5.3 respectively, with or without the addition 
VEGF (Invitrogen) (Section 3.15). The cells were left for an additional 24 hours to allow 
stimulation to have effect. The cells were harvested as described in Section 3.11.1, but 
without freezing. Cell viability was determined by trypan blue (Gibco-Invitrogen) dye 
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exclusion, and cell count was determined using a hemocytometer. Fold change and standard 
error of mean were calculated from replicate means. 
 
3.17 Calcium Release 
Triplicate cell samples at a concentration of 1x106/mL were treated with the 
appropriate stimulation for 4 hours, harvested and resuspended at 2x106cells/mL in modified 
Krebs-Ringer-HEPES (KRH) buffer at pH 7.4 containing 0.1% BSA (BioRad), 118 mM 
NaCl, 4.6 mM KCl, 24.9 mM NaHCO3, 1.0 mM KH2PO4, 11.1 mM glucose, 1.1 mM MgSO4, 
5.0 mM HEPES, and 1.0 mM CaCl2 (Sigma Aldrich, unless indicated). The cells were 
incubated with 2 µM Fura-2-acetoxymethyl ester (Fura-2/AM) (AnaSpec Inc., Fremont, CA) 
fluorophore at 37°C in 5% CO2 for 30-40 min. The cells were then centrifuged at 300 x g for 
8 min, resuspended in KRH buffer and incubated for an additional 20 min at a concentration 
of 1x106 cells/mL. Fluorescence was measured at 339 nm excitation and 505 nm emission 
using a Victor3V 1420 Multilabel Counter (PerkinElmer, Woodbridge, ON). 
 
3.18 TNFα ELISA 
Purified monocytes (uninfected and MAP-infected) were prepared as described in 
Section 3.8 and incubated for an additional 24 hours. Recombinant bovine IFNγ (Novartis) 
was added at a final concentration of 10 ng/mL. The cultures were returned to the incubator 
(37°C in 5% CO2 and 95% air) overnight. Supernatant was collected from each well, diluted 
(1:2), and bovine TNFα concentration was quantified using an antibody capture Enzyme-
linked immunosorbent assay (ELISA). 
The ELISA was performed as per Ellis, et al. (1993). Briefly, mouse-anti-bovine 
TNFα antibody (Clone 1D11-13) was diluted 1:1000 in coating buffer (0.1 M PBS). The 
diluted antibody was applied to Immulon 2 96U plates (Thermo Scientific, Nepean, ON) at 
100 µL per well. The plates were left at 4°C overnight and then washed 4 x with Tris-
Buffered Saline and Tween 20 (TBST) (Sigma Aldrich). Samples were serially diluted, and 
100 µL was added per well.  Samples were diluted with TBST + 0.1% gelatin (TBST-g) 
(Sigma Aldrich). Known concentrations of TNFα were added for the establishment of a 
standard curve. The plates were incubated for 2 hours at room temperature and then washed 4 
x with TBST. Rabbit-anti-bovine TNFα Pool 88 was diluted 1/1500 in TBST-g, and 100 µL 
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added per well. The plates were incubated for 1 hour at room temperature and then washed 4 
x with TBST. Goat-anti-rabbit IgG (H+L) biotin (Zymed-Invitrogen, Mississauga, ON) was 
diluted 1/10,000 in TBST-g, and 100 µL was added per well. The plates were incubated for a 
minimum of 1 hour at room temperature and then washed 4 x with TBST. Streptavidin 
alkaline phosphatase (Jackson ImmunoResearch, West Grove, PA) in 50% glycerol was 
diluted 1/5000 in TBST-g, and 100 µL was added per well. The plates were incubated for a 
minimum of 1 hour at room temperature and then washed 4 x with TBST. Para-
Nitrophenylphosphate (PNPP) (Invitrogen) substrate was diluted in PNPP buffer to 1 mg/mL, 
and 100 µL was added per well. The plates were incubated approximately 1 hour at room 
temperature. The reaction was stopped by the addition of 30 µL 0.3 M EDTA (Sigma Aldrich) 
when the optical density (OD) of the first dilution of the standard curve reached an OD of 
approximately 2.00 at a wavelength of 405 nm. The plates were then read at 405 nm, 
reference 490 nm.  The TNFα concentration of the samples was determined from the standard 
curve of known concentrations. 
 
3.19 IFNGR and SOCS RT-PCR 
Purified monocytes (uninfected and MAP-infected) were prepared as described in 
Section 3.8 and incubated for 1 hour or 18 hours. Total RNA extraction was performed as per 
the RNeasy Mini Kit Protocol (Qiagen, Mississauga, ON). Briefly, 1 mL of RNeasy Lysis 
Buffer (RLT) + beta-mercaptoethanol (Qiagen) was added to each well for 5 minutes. The 
cells were collected in a 2 mL tube, vortexed briefly and stored at -80°C until further 
processing. Samples were homogenized by running lysate through a QIAshredder (Qiagen). 
Molecular grade ethanol (Sigma Aldrich) was added to each sample before running the 
sample through an RNeasy mini spin column (Qiagen). DNase treatment was performed on 
each sample by adding a DNase solution (Qiagen) to the column and allowing the solution to 
sit for 15 minutes. Three washes were performed, followed by elution in nuclease-free water. 
Each sample was quantified and checked for purity using a 2100 Bioanalyzer (Agilent 
Technologies, Mississauga, ON). 
RNA (200 ng) was converted to cDNA by adding 8 µL 2 x real-time (RT) buffer and 2 
µL RT Enzyme (Invitrogen) to a total volume of 10 µL. A master mix of buffer and enzyme 
was made to eliminate pipetting error. Samples were placed in a thermocycler under the 
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following conditions: 25°C for 5 minutes, 50°C for 60 minutes and 70°C for 15 minutes. The 
RNA template was removed by adding 1 µL E. coli RNase H (Invitrogen) for 20 minutes. The 
cDNA was stored at -20°C. 
Each reaction for qRT-PCR included 9 µL iQ SYBR Green Master Mix (BioRad 
Laboratories, Mississauga, ON), 3 µL primer mix (3.3uM), 2 µL nuclease-free water and 1 uL 
cDNA, for a total of 15 µL reaction. Thermocycler conditions were as follows: cycle 1 55°C 
for 2 minutes, cycle 2 95°C for 8.5 minutes, cycle 3 step 1 - 95°C for 15 seconds, step 2 - 
55°C for 30 seconds, and step 3 - 72°C for 30 seconds, and cycle 4 55°C for 10 seconds with 
an increased set-point temperature after cycle 2 by 1°C. Results were analyzed using the 2-
∆∆CT
 method described in Applied Biosystems User Bulletin No. 2 (P/N 4303859). 
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4.0 RESULTS 
 4.1 Peptide Array Design 
 In the first generation bovine array (Jalal, et al., 2009), sixty-five percent of the bovine 
peptides exactly matched the orthologous human sequences. This sequence similarity was not 
by design. During the development of the human/porcine array, a different approach was 
utilized. A search was done to specifically identify porcine peptide sequences with exact 
matches to human sequences, and these peptide targets were the majority of sequences 
chosen. Out of the 600 human sequences screened, 268 were exact matches to orthologous 
porcine peptides. The remaining peptides contained at least one amino acid difference (Table 
4.1). In choosing peptides for the human/porcine array, if there were sequence differences, the 
human peptide was chosen rather than the porcine sequence. Of the 300 peptides ultimately 
printed on the array, 206 had 100% homology between human and porcine. The majority of 
the remaining peptides had a maximum of two amino acid sequence differences. As the 
majority of the sequences were 100% identical, the array could be used in human and porcine 
studies. 
Human phosphorylation target sites were compared with those of a number of diverse 
genera. Thousands of human phosphorylation target sites were investigated using the protocol 
described for peptide array design (Section 3.2.2), but the process was computer automated. 
This high-throughput method allowed a comparison of phosphorylation target site sequences 
across several mammalian genera, as well as rice, fruit fly and yeast (Table 4.2). Individual 
peptides showed variable degrees of sequence conservation across genera. The significant 
number of differences observed between genera highlights the importance of designing genus-
specific peptide arrays for evolutionarily divergent genera. 
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Table 4.1. Porcine/human phosphorylation target site comparison.   
Sequence Difference # of Peptides  Human-Porcine Protein Match  
0 268 Same protein 
1 165 Same protein 
2 39 Same protein 
3 29 Same protein 
4 6 Same protein 
5 7 Same protein 
6 4 Same protein 
7 5 Same protein 
8 2 Same protein 
9 4 Same protein 
10 6 Same protein 
11 2 Same protein 
12 1 Same protein 
13 0 N/A 
14 0 N/A 
15 62 Different protein 
 
Six-hundred human peptide sequences were analysed using the Blastp program and the NCBI 
porcine proteome database. Sequence Difference indicates the number of amino acid 
differences when comparing the porcine and human kinase target site sequences. # of Peptides 
indicates the number of peptides out of the 600 human sequences screened. Human-Porcine 
Protein Match indicates whether the porcine protein was identified as being orthologous to the 
human protein by protein name and description. 
 
 
Table 4.2: Phosphorylation target site differences between various genera. 
 % of Proteins vs. Human 
Sequence 
Difference Cow Chicken Mouse Pig Rice Fruit Fly Yeast 
0 34.82% 12.78% 27.29% 26.82% 0.03% 0.54% 0.07% 
1 15.86% 8.56% 15.04% 11.35% 0.03% 0.66% 0.08% 
2 9.66% 6.71% 9.58% 7.07% 0.02% 0.86% 0.16% 
3 6.43% 5.33% 6.39% 4.50% 0.03% 1.00% 0.16% 
4 4.59% 4.62% 4.60% 3.20% 0.04% 1.01% 0.17% 
5 3.09% 3.82% 3.10% 2.41% 0.07% 1.15% 0.19% 
6 1.63% 2.74% 1.61% 1.11% 0.05% 1.10% 0.18% 
7 0.51% 1.33% 0.47% 0.42% 0.02% 0.84% 0.12% 
8 0.08% 0.33% 0.05% 0.08% 0.01% 0.42% 0.03% 
No similarity 23.34% 53.75% 31.88% 43.03% 99.69% 92.31% 98.83% 
 
The table shows the differences in the phosphorylation target site amino acid sequences of 
various genera. Comparison was done between human sequences collected from PhosphoSite 
(www.phosphosite.org) and the proteome of the comparative genera using Blastp. At the time 
of analysis, there were over 100,000 non-redundant phosphorylation sites in the PhosphoSite 
database. 
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 4.2 Standard Array Data Analysis and PIIKA Comparison 
 Often, the data normalization and analysis techniques used for the analysis of peptide 
array kinome data were lifted directly from the processes used to analyze nucleotide arrays. 
Our group questioned whether these previously developed methods were adequate since these 
methods cannot take into account the distinct nature of peptide array data. In conjunction with 
bioinformatics collaborators, Dr. Anthony Kusalik and Yue Li, a new analysis pipeline was 
developed. This pipeline, specifically designed for the data collected from peptide arrays, was 
entitled Platform for Integrated, Intelligent Kinome Analysis (PIIKA) (Figure 4.1). Initial 
results produced with this pipeline appeared to provide superior results: the data displayed 
enhanced statistical significance, the pipeline was able to handle negative values and it did not 
distort the raw data. Despite this early evidence, it was decided that a comprehensive 
comparison between the new analysis pipeline and other established methods based on 
nucleotide arrays was required to objectively evaluate the value of PIIKA.  
 The datasets used to conduct the comparison were collected from three different 
treatment conditions. All experiments were done on bovine monocytes treated with one of 
three different ligands or untreated control samples. Two sets, CpG-treated and LPS-treated, 
were done as a single set of array experiments. The third set of IFNγ-treated monocytes 
contained samples collected from three different animals and was performed as a separate 
experiment. Thus, CpG and LPS datasets contained 300 peptides printed in triplicate on the 
array, totaling 900 data points per treatment. The IFNγ-treated experiment had 300 peptides 
printed in triplicate for three animals, totaling 2,700 data points per treatment.  
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Figure 4.1. PIIKA workflow. Shown is a general workflow of the PIIKA process pipeline. 
The flow chart starts from the top left and follows the arrows. Rectangles represent 
procedures, and ovals represent intermediate results. 
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  4.2.1 Data Processing Prior to Analysis 
 The raw data collected from the scanned array image displayed noticeable signal 
mean-variance-dependence for each phosphorylated spot (Figure 4.2). This dependence was 
observed as an increase in the standard deviation on these plots. This was an important aspect 
of the peptide array data that needed to be taken into account. The peptide array data being a 
measure of target site phosphorylation means that the greater the phosphorylation, the greater 
the variance. Correspondingly, a lack of phosphorylation or signal will display limited or no 
variance. The mean-variance-dependence characterisitic of peptide array data is described 
extensively in Section 1.2.4.3. The goal was to eliminate this mean-variance-dependence by 
using appropriate normalization techniques (Figure 4.2). The relative success of each 
normalization technique was determined by the slope of the line in the plots. Raw data which 
have not undergone normalization had the greatest slope. Following Log2 transformation, a 
jagged line was produced which indicated significant change in the variance of the spots as 
signal increases. As observed by the upward slope of the line in the top right plot, PNorm did 
not eliminate the mean-variance-dependence at the highest levels of signal intensity. QNorm 
caused the opposite effect where the variation was greatest at the lower signal levels, as 
indicated by the negative slope of the line. The VSN transformations, VSN alone and VSN 
with log-scaling provided the best results, as indicated by the limited slope of the lines in the 
VSN plots. PNorm standard deviation increased from approximately 0.25 to 0.75. VSN 
standard deviation increased from approximately 0.6 to 0.8, and VSN log-scaled standard 
deviation stayed at approximately 0.09 across peptides.        
 With any data normalization technique, a key concern was that the final results are not 
skewed by the manipulation. Figure 4.3 shows scatter plots displaying the signal intensities of 
the CpG data compared to their own media control. These plots showed a pattern of response 
matching the raw data in both PNorm and VSN without log-scaling methods (Figure 4.3). 
This pattern can be observed by the location and distribution of the spots along the line of best 
fit. Raw Data, PNorm and VSN displayed a similar pattern, while the other plots, Log2, 
QNorm and VSN (log-scaled), displayed different patterns and did not preserve the 
biologically relevant phosphorylation data. This lack of data preservation can be seen by the 
colour-coded negative or positive spot signal following background subtraction. Only PNorm 
and VSN maintained the distribution of positive and negative spots along the axis seen in the 
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raw data. This negative and positive spot distribution is very important since any 
normalization should maintain the relative signal intensity of a given spot compared to 
another. If negative spot intensities, which indicate no phosphorylation when compared to 
background, are altered to show significant signal following transformation, this altered data 
distribution would significantly skew further data analysis. Considering the signal intensity 
plots, PNorm and VSN appeared to be the best methods to normalize data while not altering 
data relevance. 
 Taking into account both the mean-variance-dependence correction (Figure 4.2) and 
the data preservation ability (Figure 4.3) of the normalization method, VSN transformation 
was the best method. VSN and VSN log-scaled were the best methods for correcting mean-
variance-dependence, while PNorm and VSN were best at preserving raw data patterns. Thus, 
VSN transformation, which was among the best at both, was the better overall method. 
 
 
 
Figure 4.2. Mean-variance-dependence plots. These data plots show before (Raw Data) and 
after normalization by log2 (Log2), percentile normalization (PNorm), quantile normalization 
(QNorm), transformation by variance stabilization (VSN) and transformation by VSN with 
log2 scaling (VSN (log scaled)). Rank of the mean signal intensities was plotted against the 
standard deviation of the corresponding peptide intensities. If there was no variance-mean-
dependence, then the line formed by the dots should display no slope.  
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Figure 4.3. Signal intensity scatter plot. Shown are scatter plots of the signal intensities for 
monocyte responses to CpG against the corresponding intensities in the media control. The 
raw data were preprocessed in the following ways: no processing (top left panel), logarithm to 
base 2 of the positive intensities while discarding the negative signal (top right), QNorm 
(middle left), VSN (log-scaled) (middle right), PNorm (bottom left) VSN (bottom right). The 
dots in each plot represent signal intensities after background subtraction and taking the 
average across intra-slide replicates. If the resulting intensity for treatment was negative, an 
orange dot was used. Otherwise, the average intensity for both conditions was positive, and 
the dot was coloured black.  
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4.2.2 Treatment-Treatment Variability Analysis and Phosphorylation 
Significance 
 When considering normalized peptide array data, the significantly phosphorylated or 
dephosphorylated peptides relative to control are important. The greater number of significant 
peptides, the easier it is to assign pathways and functions to a treatment. Table 4.3 lists the 
number of statistically significant peptides under a given treatment condition for all the 
normalization methods except PNorm. PNorm was not applicable since this method does not 
provide a means of calculating statistical significance for a given peptide. The peptide 
significance cut-off was set at 90% confidence. Given the ligands used in the experiments and 
the design of the array, a large number of peptides were expected to display significant levels 
of phosphorylation relative to control. However, both QNorm (QNorm + limma) and VSN 
log-transformed (VSN + limma) displayed a very limited number of significant peptides for 
each treatment. By contrast, the VSN + paired t-test method (PIIKA) provided a large number 
of peptides considered significant. For a given experiment, the more data considered, the 
more powerful the biological analysis. For example, in the case of VSN log-transformed data, 
only three peptides were indicated as significantly differentially phosphorylated in CpG-
treated cells. With three peptides, no functionality could be assigned to the effect of CpG on 
bovine monocytes. By contrast, VSN + paired t-test (PIIKA) identified 85 significant 
peptides, providing a better overview of phosphorylation events following treatment.  
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Table 4.3. Normalization method comparison. 
 
 
Table shows the number of statistically significant peptides (p-value <0.1) identified by the 
various normalization techniques. The results are generated from peptide array data for bovine 
monocytes treatmented with one of CpG, LPS or IFNγ. ↕ indicates the total number of 
differentially phosphorylated peptides relative to control. ↑ indicates the number of peptides 
with increased phosphorylation. ↓ indicates the number of peptides with decreased 
phosphorylation. The PNorm + fold change method was not included in the above table, since 
it did not allow for a calculation of significance. 
 
 
 
  4.2.3. Pathway Analysis of Normalized Data 
    Previous steps in the analysis generated a list of peptides that were differentially 
phosphorylated under the various treatment conditions. For each of the normalization 
methods, fold change and p-value information from this list of peptides were input into the 
online pathway database InnateDB (Lynn, et al., 2008). The output generated from this 
database was a list of over-represented pathways and associated pathway p-values calculated 
from the input peptide array data. The model pathways for the various treatments, CpG, LPS 
and IFNγ, were TLR (Hemmi, et al., 2000), IL-2 (Holter, et al., 1987) and JAK-STAT 
(Darnell, et al., 1994), respectively. Table 4.4 shows the number of peptides present on the 
array that fit into each of these pathways (Pep), the number of those that were identified by 
the various methods and the significance level for the pathway. Results indicated that our 
custom-designed pipeline increased statistical significance without a considerable loss in 
sensitivity. When comparing PIIKA to the next best method, the improvement in pathway p-
value for the TLR pathway was from 0.019 to 0.008 over QNorm, for the IL-2 pathway from 
0.405 to 0.002 over VSN and for the JAK-STAT pathway from 0.122 to 0.003 over PNorm. 
Part of this improvement may be due to the increased number of peptides deemed 
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significantly differentially phosphorylated by our method versus the others. This, however, is 
not a complete explanation, as the PNorm method generates comparable numbers of peptides 
but lower pathway significance levels. As mentioned previously, the PNorm method does not 
provide individual peptide significance values. Thus, all data that were deemed consistent 
(i.e., without a SD greater than 1.96) were included. In addition, the fold change magnitudes 
and direction generated following transformation were improved by PIIKA. PIIKA generated 
more consistent data when looking for canonical pathways produced by known ligands. This 
is an important factor when hoping to discover novel biology in future experiments. Figures 
4.4 and 4.5 are pathway networks generated from the same data input into InnateDB using the 
Cerebral plugin to Cytoscape. These figures are not intended to be detailed depictions of the 
given pathways or canonical pathway representations; rather, they are intended to be simple 
visual illustrations of the increase in protein representation in the given pathways. Cytoscape 
uses a different method of generating pathway networds than InnateDB. The figures provide a 
contrast between QNorm and PIIKA in their ability to identify representative proteins in a 
given pathway. QNorm was used as the comparative method for these figures, as it was the 
best method at producing canonical pathways while allowing for a calculation of individual 
peptide p-values for input into InnateDB.  
  
Table 4.4. Comparison of pathway results from each data analysis method. 
 
 
 
Based on the differential phosphorylation data, InnateDB indicated the pathways which were 
consistent with published data. Each pathway was assigned a probability value (p) based on 
the number of proteins (corresponding to input peptides) present from that pathway. Output 
included the number of uploaded peptides associated with a particular pathway and the subset 
of those peptides which were differentially phosphorylated. Pep indicates the total number of 
peptides on the array relating to the pathway. ↑ and ↓ show the number of identified peptides 
from the pathway with significantly increased or decreased phosphorylation, respectively, 
relative to control. 
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IL-2 identified by QNorm + limma IL-2 identified by PIIKA (our pipeline) 
 
Figure 4.4. IL-2 signalling networks method comparison. Shown are pathway network 
representations of the identified IL-2 signalling pathway from LPS-treated monocyte data. 
Proteins were identified as belonging to the IL-2 pathway. The nodes in each network 
represent proteins corresponding to peptides identified as being significantly differentially 
phosphorylated. Red colouration of a node indicates an increase in phosphorylation, while 
green indicates a decrease. The non-coloured nodes were identified as either not significantly 
phosphorylated or not on the array. The networks were generated through the use of the 
Cerebral plugin of the interaction viewer Cytoscape. The lines connecting each node are 
putative interactions according to the Cytoscape database. The network on the left was 
derived from QNorm + limma, while the network on the right was from PIIKA. The green 
colouration at the bottom of the networks can be ignored for the purposes of this figure. 
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Figure 4.5. CpG and IFNγ signalling networks method comparison. Shown here are 
network representations of the identified TLR signalling pathway from CpG-treated monocyte 
data (top) and the JAK-STAT pathway identified from IFNγ-treated monocyte data (bottom). 
The nodes in each network represent proteins containing peptides that were identified as being 
significantly differentially phosphorylated. Red colouration of a node indicates an increase in 
phosphorylation, while green indicates a decrease. The non-coloured nodes were identified as 
either not significantly phosphorylated or not on the array. The networks were generated 
through the use of the Cerebral plugin of the interaction viewer Cytoscape. The lines 
connecting each node are putative interactions according to the Cytoscape database. The 
networks on the left were derived from QNorm + limma, while the networks on the right were 
from PIIKA. The green colouration at the bottom of the networks can be ignored for the 
purposes of this figure. 
 
 
 
 
 
 
81 
 
4.3 Prion Signalling Studies 
4.3.1 Flow Cytometric Analysis of PrPC Expression on BE(2)M17 Cells 
To confirm that the human neuronal cell line BE(2)M17 was an appropriate cell line 
for PrPC stimulation studies, the level of cell surface expression of PrPC was determined. Flow 
cytometric analysis using the PrPC-specific antibody 6H4 confirmed cell surface expression of 
PrPC on the majority of the viable cultured cells (Figure 4.6). This indicated that these cells 
were appropriate for studying ligand interactions with PrPC. 
 
 
 
 
 
Figure 4.6. PrP surface expression. Shown above are flow cytometic analyses plots of 
neuronal cells labelled with antibody 6H4. A secondary antibody, GAM-FITC, was used to 
visualize the cells. The plots to the left shows non-specific GAM-FITC binding following 
incubation with an irrelevant isotype control IgG antibody. The plot to the right depicts cell 
fluorescence following incubation with the PrPC-specific antibody 6H4 and the FITC-
conjugated GAM. The % shows the percent of cells which have shifted, indicating 
fluorescence. Media control cell autofluorescence (no antibody added) resulted in 1.05% of 
cells indicating fluorescence (data not shown). 
 
 
 
 
 
 
0.43% 89.8% 
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4.3.2 Peptide Array Experiment 
Human neuronal cells were treated with two PrP-specific stimulants: a prion protein 
fragment of amino acids 106-126 and the PrP-specific antibody 6H4. The peptide response 
served as a model of prion disease-like signalling, while the response to antibody cross-
linking of PrPC modeled the endogenous signalling pathways of PrPC. In addition, three 
controls were used: a peptide of identical amino acid composition to PrP 106-126 but with a 
scrambled sequence, an irrelevant isotype control IgG1 monoclonal antibody and a media 
control. 
 
 4.3.3 Cluster Analysis of Kinome Data 
 Heatmap clustering was done on data from all 300 peptides in each of the various 
prion stimulants and controls. In Figure 4.7 A, the individual stimulants are shown at the 
bottom of the heatmap. The lines above the heatmap indicate the relative similarity between 
the totalities of the signals for each of the stimulants. The plot was generated from the data 
post-normalization without subtracting the individual specificity controls. Without subtracting 
the control signal from the stimulant signal, clustering was first based on the type of 
stimulant. The 6H4 and isotype control antibody stimulants clustered together. The PrP 106-
126 and scramble peptide control stimulants clustered together. The media control sample is 
in the centre between the two stimulant types. This clustering was important as it indicated 
that stimulant-related events were occurring which are not necessarily specific to PrPC. 
Phosphorylation events were detected which were common to the addition of exogenous 
monoclonal antibody to cultured neuronal cells. Similarly, phosphorylation events were 
detected which occured when a peptide was added to cultured neurons. These observations 
underscored the importance of taking into account specificity controls before biological 
significance was assigned to any of the resulting patterns of peptide phosphorylation. In this 
case, comparing the PrP-specific stimulants to their individual controls eliminated non-
specific signalling effects due to the type of stimulant. For example, removing scramble 
control signal from PrP 106-126 signal revealed the signal unique to PrP 106-126. If media 
control signal was removed from PrP 106-126 signal, the non-prion related peptide effects 
would have been observed in addition to the effects of PrP 106-126 interaction with PrPC. In 
Figure 4.7 A, it can be seen that clustering was performed on the individual peptides, shown 
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by the lines on the left side of the heatmap which link the peptides. Though performed 
automatically by the software, this clustering was not considered in the analysis of our data. 
This individual peptide clustering may be a future consideration in the analysis of peptide 
array data. In addition, relative peptide signal intensities are shown on a colour scale from low 
(green) to high (red). This provides a visual indication of the similarities and differences 
between the stimulants. Colours that match across columns indicated peptides of greater 
similarity, while colours that do not match when looking across columns indicated peptides 
which were different. 
The clustering results shown in Figure 4.7 A were supported by a different means of 
clustering based on PCA (Figure 4.7 B). PCA clustering is explained in detail in Section 
1.2.4.4.2 and Figure 1.5. The data were broken down into principal components represented 
by the axes PC1, PC2 and PC3. PC1 incorporated the most variation between data points: 
33.16%. PC2 incorporated 25.05% of the variation, and PC3 incorporated 22.35%. Thus, 
Figure 4.7 B displays 80.56% of the variation between the stimulants on the three axes. The 
PrP 106-126 and scramble control points are close together in the PCA plot. Similarly, the 
6H4 and isotype control monoclonal antibody clustered together relative to the media control 
point. This alternate means of considering the data again indicated there are antibody-specific 
and peptide-specific effects which led to this close clustering. These effects had to be taken 
into account by comparing the stimulant signal with the relevant control. Factoring in relevant 
controls was done for all subsequent analyses.  
The pseudo-image of the normalized, merged data from peptide- and antibody-
stimulated neuronal cells revealed that distinct phosphorylation events occurred with each 
stimulus (Figure 4.8). The figure shows a graphic representation of an array block. The left 
side of each spot shows the normalized, specificity-control-corrected signal when peptide 
stimulated. The right side of each spot shows corresponding antibody signal. Signal is shown 
as a scale of significantly phosphorylated (red) to significantly dephosphorylated (green) 
relative to control. The spots can be organized into three groups: both stimulants causing 
phosphorylation (all red) on the left, both stimulants causing dephosphorylation (all green) in 
the middle and the largest group showing differential phosphorylation (one side green and one 
side red) on the right. While there were some peptides that showed conserved patterns of 
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phosphorylation, indicated by spots which are all red or all green, there was a substantial 
subset of peptides which shows distinct responses with each stimulant.     
The level of differential phosphorylation between the peptide and antibody stimulation 
became even more apparent when considering both the unique and common peptides for each 
stimulant (Figure 4.9). Sixty-eight peptides were uniquely phosphorylated when cells were 
stimulated with peptide. Seventy-five peptides were uniquely phosphorylated when cells were 
stimulated with antibody. Forty-three peptides displayed significant phosphorylation when 
stimulated with either peptide or antibody. Following further inspection of these shared 
peptides, only 15 peptides were phosphorylated in the same direction relative to control. By 
contrast, 28 peptides were phosphorylated in opposite directions. Thus, of the 186 peptides 
that displayed differential phosphorylation relative to controls, only 15 were common and 
phosphorylated in the same direction. This is a noteworthy result, considering that the two 
stimulants targeted the same extracellular protein and the controls used should have 
eliminated as much signal noise as possible. This differential phosphorylation between 
stimulants indicated possibly significant variation in the signalling abilities of PrPC.       
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A) 
 
 
  B) 
 
Figure 4.7. Phosphorylation heatmap and clustering. A) The background-corrected raw 
data collected from the peptide arrays were VSN-transformed, and a heatmap/clustering of the 
data was produced using the Complete Linkage + Euclidian Distance method. The lines at the 
top of the heatmap indicate the relative similarity between the stimulants indicated at the 
bottom of the heatmap. The shorter the lines, the more similar the two connected stimulants. 
The lines on the left side of the heatmap indicate the relative similarity in signal between the 
300 individual peptides on the array. The coloured lines indicate the relative degree of 
phosphorylation of each peptide from strongly phosphorylated (red) to non-phosphorylated 
(green) as indicated by a Z-score. B) Shown here is the 3D Principal Component Analysis of 
the five treatments. Relative distance on the three axes indicates level of similarity or 
difference among the treatments. PrP refers to PrP 106-126 peptide. Scram refers to scramble 
control peptide. 6H4 refers to the PrP-specific antibody. Iso refers to the IgG1 isotype control 
antibody. Media refers to media control. 
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Figure 4.8. Peptide array pseudo-image. Shown is a pseudo-image of a peptide array block 
combining the prion stimulation data. Transformed data for PrP 106-126 was compared to 
scramble control peptide data, and a significance value was determined based on a significant 
increase or decrease in phosphorylation between the two. This process was also performed for 
6H4 antibody stimulated and isotype control antibody. The relative intensity of each spot 
indicates the level of significance of the phosphorylation of that spot. The left side of each 
spot is the response to PrP 106-126 stimulation. The right side of each spot indicates 6H4 
stimulation response. Grey spots represent inconsistent peptides between array peptide 
replicates as determine by Χ2 test (Section 3.12.1.2). 
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Figure 4.9. Comparison of peptide phosphorylation following PrP 106-126 and 6H4 
stimulation. Peptides displaying differential phosphorylation following the two stimulations 
were compared. The majority of the significantly differentially phosphorylated peptides were 
unique to one stimulant or the other. A minority of the peptides were common to both PrP 
106-126 and 6H4. Common Direction of Phosphorylation refers to peptides displaying either 
increased or decreased phosphorylation following both stimulations. Opposite Direction of 
Phosphorylation refers to one stimulation resulting in an increased phosphorylation, while the 
other stimulation results in a decrease.  
 
 
 
 4.3.4 Pathway Analysis 
 The processed kinome data were subject to pathway over-representation analysis using 
the InnateDB database. To ensure the identified pathways represented conserved and 
consistent biological responses, input data were limited to peptides with a consistent pattern 
of phosphorylation across the technical replicates and significant changes in phosphorylation 
levels relative to the relevant control treatment (p <0.20). Significant pathways (p <0.05) for 
each stimulation condition are shown (Table 4.5). 
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Table 4.5. InnateDB-generated pathway list. 
  
  
 PrP 106-126 6H4 
  
Pathway 
Up/ 
Down p-value 
         
# p-value # 
VEGF signalling pathway Up 0.01 22 0.83 14 
Class I PI3K signalling events Up 0.02 5 0.77 3 
TGFBR Down 0.02 10 0.97 3 
Phosphoinositides and their downstream targets Up 0.02 5 0.99 1 
Regulation of nuclear SMAD2/3 signalling Down 0.04 6 0.94 1 
EGF receptor (ErbB1) signalling pathway Down 0.79 2 0.05 5 
Signalling by EGFR Down 0.66 2 0.05 5 
Growth 
Factor 
Signalling 
Signalling by PDGF Down 1 0 0.05 5 
Integrin alphaIIbbeta3 signalling Up 0.04 4 0.68 2 Integrin 
Signalling Integrin cell surface interactions Up 0.04 4 0.68 2 
IL-7 signalling pathway(JAK1 JAK3 STAT5) Up 0.04 20 0.69 15 
IL12-mediated signalling events Down 0.02 9 0.60 5 
IL12 and STAT4 dependent signalling pathway in 
Th1 development 
 
Down 0.02 5 0.90 1 
IL23-mediated signalling events Down 0.04 6 0.47 4 
JAK-STAT signalling pathway Down 0.03 8 0.78 4 
Cytokine 
Signalling 
Chemokine signalling pathway Up 0.95 6 0.01 19 
Erk1/Erk2 mapk signalling pathway Down 0.93 1 0.01 5 
Role of Erk5 in neuronal survival pathway Down 1 0 0.02 6 
Signalling by insulin receptor Down 1 0 0.03 4 
Signalling to RAS Down 0.73 1 0.03 4 
Sprouty regulation of tyrosine kinase signals Down 1 0 0.03 4 
Insulin receptor signalling cascade Down 1 0 0.03 4 
IRS-mediated signalling Down 1 0 0.03 4 
MAPK 
Signalling 
IRS-related events Down 1 0 0.03 4 
Cell Cycle Cell cycle Down 0.04 6 0.36 9 
NFkB signalling Up 0.98 1 0.03 7 NFkB 
Signalling IKK-NFkB cascade Up 0.91 2 0.05 6 
Signalling pathway from G-protein families Down 0.76 2 0.03 4 
Regulation of splicing through Sam68 Down 0.46 1 0.03 4 
Roles arrestin dependent recruitment of Src Down 0.46 1 0.03 4 
Alpha-synuclein signaling Down 0.93 1 0.03 4 
Axon guidance Down 0.66 2 0.03 8 
TrkA signalling from the plasma membrane Down 0.93 2 0.04 10 
NOTCH Down 0.002 8 0.64 3 
Glucocorticoid receptor regulatory network Down 0.01 8 0.78 4 
Akt (PKB) Bad signaling Up 0.04 20 0.77 14 
EPHA forward signaling Up 0.04 4 0.97 1 
Other 
Platelet aggregation (Plug Formation) Up 0.04 4 0.68 2 
 
Transformed phosphorylation data obtained from the peptide arrays were uploaded into 
InnateDB. This table lists all pathways indicated for both treatments with a p-value of <0.05. 
Up/Down describes whether InnateDB indicated an up regulation or down regulation of the 
pathway. p-value describes p-value of the pathway calculated by InnateDB. # indicates the 
number of significant peptides on the array which are in a given pathway. 
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   4.3.4.1 PrP 106-126 Stimulation 
 In PrP 106-126 treated cells, VEGF, PI3K and additional growth factor related 
signalling pathways were identified by pathway over-representation analysis. The pathways 
shown in Table 4.5 can be linked together in putative pathways collected from the peptide 
array data (Figure 4.10). VEGF has been linked to neuroplasticity and a variety of 
neurodegenerative diseases (Storkebaum, 2004), making it an interesting receptor to consider 
in the context of prion function. Cell viability assays carried out in the presence of the prion-
specific stimulants, with and without recombinant VEGF, provided supporting evidence for 
this pathway’s involvement in prion function (Section 4.3.6). While it is possible the VEGF 
receptor (VEGFR) is an interacting partner with PrPC, it is also possible that PrPC interacts 
with growth factor receptors more generally, considering that transforming growth factor beta 
receptor (TGFBR) was also implicated by the data (Table 4.5). It would also be possible to 
consider other specific receptors which showed significant phosphorylation, including 
fibroblast growth factor receptor (FGFR) (p 0.06), nerve growth factor receptor (NGFR) (p 
0.13) and PDGFRB (p 0.06) (Table A1). The downstream-signalling of these growth-factor 
receptors was similar and may implicate any of them as potential candidates in prion function.  
 Cell survival and apoptosis have been strongly implicated as potential functions of 
PrPC (Roucou and LeBlanc, 2005). There have been numerous studies that have attempted to 
describe the mechanism by which the prion protein induces an apoptotic response in cells 
(O’Donovan, et al., 2001; Paitel, et al., 2003). However, many of the studies that purport to 
explain apoptosis signalling in prion-stimulated cells have provided contradictory results 
(Roucou and LeBlanc, 2005). The peptide array data in this study indicated that cell death via 
apoptosis is carried out through signalling involving Caspase-3 (Figure 4.10 and Table A1). 
Caspase-3 activation could occur due to the following phosphorylation events: Akt (Asselin, 
et al., 2001) or calcium related signalling and nuclear factor of activated T-cells (NFAT). 
 As mentioned, calcium-related signalling appears to be a key aspect of PrPC function. 
Calcium signalling and the prion protein have been linked for over a decade (Kristensson, et 
al., 1993). The peptide array data indicated that the mechanism which initiated calcium 
release was phospholipase C gamma (PLCγ) activity. Analysis of peptide-stimulated cells 
revealed PLCγ1 phosphorylation at residue Y771 with a p-value of 0.02 and a fold change of 
1.86. By contrast, antibody stimulation by 6H4 was associated with phosphorylation at 
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residue Y771 with a p-value of 0.16 and a fold change of -1.58 (Table A1). Downstream 
effects may subsequently affect calcineurin and NFAT (Figure 4.10) (Chow, et al., 1997). 
Calcium release upon cell stimulation with PrP 106-126 was confirmed with a calcium release 
assay (Section 4.3.7). 
 The signalling induced by the PrP 106-126 peptide, taken together with the fact that it 
has been used extensively as a model of prion disease, provides possible insights into prion 
disease state signalling. The key pathways uncovered by pathway over-representation analysis 
of peptide array data were growth factor related signalling, calcium signalling and PI3K 
signalling. These pathways are all directly linked to cell death/survival functionality. 
Alteration of these signalling pathways can lead to cells undergoing apoptosis, and the 
possible subversion of these pathways when PrPC is altered to become PrPSc could ultimately 
result in loss of neurons. 
 Pathway over-representation analysis strongly implicated integrin-related signaling. 
There is no literature to support a direct interaction between prion and integrin; however, 
there has long been a link between laminin and the prion protein (Graner, et al., 2000), 
specifically the 37 kDa laminin (Rieger, et al., 1997). Since integrin receptors are receptors 
for laminin, these results may provide supporting evidence for these previously reported 
results.      
            
   4.3.4.2 Antibody Stimulation 
 Following PrPC cross-linking with antibody, a group of pathways was identified that 
can broadly be represented as MAPK-related signalling. MAPK signalling is central to many 
key cellular functions including cell proliferation, cell cycle, differentiation, immunity and 
apoptosis (Chang and Karin, 2001). Therefore, it could have been expected that MAPK-
related signalling played a role in PrPC biology, though interestingly it appears not in peptide-
induced signalling.  
 Previous prion studies have linked MAPK involvement with apoptosis (Thellung, et 
al., 2002) and iNOS (Fabrizi, et al., 2001), both of which displayed significant differential 
phosphorylation on the peptide arrays. Interestingly, neuronal cells stimulated with PrP 106-
126 also showed iNOS phosphorylation (at targets Y151, S909 and S739) at the highest 
statistical significance levels of any of peptides in this study (p-values of 1.6x10-3, 1.6x10-3 
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and 3.1x10-4, respectively). However, while both antibody and peptide induced iNOS 
differential phosphorylation, it was in opposite directions. Peptide significantly increased 
iNOS phosphorylation at all three sites; conversely, antibody cross-linking induced 
significantly decreased phosphorylation at S909 (Table A1).  
 If we consider growth factor receptors as possible interacting partners with peptide-
stimulated PrPC, then insulin receptor was a contender in antibody-stimulated PrPC (Table 
4.5). Altered insulin receptor function in neuronal cells has been linked to prion function in 
previous studies (Ostlund, et al., 2001). Considerable work has recently focused on the insulin 
receptor of pancreatic β-cells as a possible link between blood sugar regulation and prions 
(Strom, et al., 2007). Thus, the high significance assigned to insulin receptor signalling in 
neuronal cells may be a noteworthy result.  
 
4.3.5 Phosphospecific Antibody Array 
A commercial phosphospecific antibody array was used to validate the kinome results. 
While the peptide array contained target sites which were phosphorylated by active kinases, 
the antibody array contained phosphorylation-specific antibodies bound to the array. If a 
protein had been phosphorylated, and the array contained an antibody complementary to that 
phosphorylated site, the protein would be captured by the antibody and bound to the array. 
Before exposure to the array, the proteins within the cells were labelled with one of two 
colours: blue dye for control samples and red dye for treatment samples. This way, control 
and treatment could be visualized on a single array. This type of data provided information on 
the phosphoproteome of the cell; in effect, it was like doing nearly 1,000 individual western 
blots. These data were distinct from the peptide array data in that it provided information on 
the phosphorylated proteins, rather than the active kinases, within a sample. The antibody 
array technique was limited in a number of ways. The key limitation was the availability of 
phosphospecific antibodies such that only a small portion of the antibodies on the array were 
exact matches for target sites on the peptide array. Antibody array analysis was done on the 
neuronal cells stimulated with PrP 106-126, again using scramble peptide as a control. The 
cells were treated in an identical fashion to those used for peptide array analysis. In much the 
same way as with the peptide arrays, the PrP 106-126 signal was compared to the scramble 
signal for each antibody spot on the array. This provided a fold change value and a direction 
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of phosphorylation, increased or decreased relative to control. The signal confidence was 
indicated for the reported data in a yes/no format. All data presented were shown to have 
positive confidence; that is, the fold change presented was considered statistically significant. 
Table 4.6, which contains only the phosphorylation sites that were identical between peptide 
array and antibody array, indicates strong agreement between the two techniques, both in 
magnitude and direction of phosphorylation relative to control. This provided added 
confidence in the accuracy of the peptide array results. 
 
 
 
Figure 4.10. Signalling pathways linked to PrPC stimulation. Shown is a selection of 
proteins implicated by peptide array data that were organized into interconnected pathways. 
Yellow indicates unique PrP 106-126-related phosphorylation. Orange indicates unique 6H4-
related phosphorylation. Red indicates that both stimulants affect the peptide in the same 
direction of phosphorylation. Green indicates that both stimulants affect the peptide in 
opposite directions. Clear indicates insignificant signal or that the peptide is not present on the 
array.  
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Table 4.6. Phosphorylation of select signalling molecules indicated by peptide array and 
phosphospecific antibody array. 
Name 
Target Amino 
Acid 
Fold Change 
Peptide 
Array p-value 
Fold Change 
Antibody 
Array 
Antibody 
Array 
Spot 
CaMK2-alpha T286 -1.41 0.07 -1.27 
 
 
FAK Y397 1.03 0.47 1.15 
 
 
Fos T232 -1.10 0.38 -1.06 
 
 
HSP27 S78/82/3 -1.76 0.07 -1.87 
 
 
Jak2 Y1007/8 -1.08 0.42 -1.12 
 
 
Jun S73 -1.62 0.02 -1.86 
 
 
NFkB-p65 S276 1.32 0.21 1.19 
 
 
p38-alpha T180/2 -1.21 0.28 -2.12 
 
 
pRb S780 1.23 0.22 1.28 
 
 
STAT3 Y705 -1.44 0.10 -1.52 
 
 
STAT3 S727 1.35 0.32 2.03 
 
 
 
Identical phosphorylation target sites on both the peptide array and the antibody array are 
listed. Fold change was calculated as a ratio of PrP 106-126 treated signal to scramble control 
signal. The fold change and p-value calculated from the peptide array data are indicated. Fold 
change p-value for the antibody array data was not assigned because the significance was 
reported as a binary yes/no. All listed fold changes for the antibody array data were indicated 
to be significant. Antibody Array Spot shows the treated (red) and control (blue) spots on the 
array. 
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4.3.6 Cell Viability Assay, Prion Stimulants and VEGF Treatment 
 Pathway analysis of the kinome data implicated the VEGF signalling pathway as 
being involved in peptide-induced PrPC signalling. In addition, previous studies have 
indicated that VEGFR is an important receptor in neurodegeneration and neuronal cell 
viability (Storkebaum, 2004). The combination of the kinome data and the previous VEGF 
studies led to the consideration of VEGF’s affect on cell viability when also stimulated with 
prion-specific ligands. Neuronal cells were stimulated with peptide, antibody or the respective 
controls and then exposed to recombinant VEGF. The apoptosis inducer camptothecin was 
used as a positive control for cell death. Cell viability results (Figure 4.11) indicated that the 
VEGF plus PrP 106-126-stimulated cells had increased viability compared to PrP 106-126-
stimulated cells. Treating 6H4-stimulated cells with VEGF had no significant impact on cell 
viability. These data agreed with the kinome analysis in that VEGF signalling was implicated 
in the context of peptide stimulation but not antibody stimulation. This differential response 
confirmed the distinct phenotypes which emerged following the PrP-specific stimulations. 
The peptide- and antibody- stimulated neuronal cells showed a significant difference in cell 
viability, with the antibody displaying limited observable effect on viability. There was a 
significant drop in cell viability in the peptide-treated cells. These viability results were 
consistent with peptide-induced effects that model disease and antibody-induced effects that 
model endogenous signalling. A key characteristic of TSEs is neuronal death (O’Donovan, et 
al., 2001; Paitel, et al., 2003). Comparing peptide-stimulated cells, with or without VEGF, 
showed a significant difference in viability. This result confirmed the involvement of VEGFR 
in peptide induced cell death. Taken together, these results were in agreement with the 
conclusion that PrPC is capable of distinct effects, depending on the stimulation given. Figure 
4.11 shows the stimulant/treatment viability compared to respective control. 
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Figure 4.11. Cell viability. Stimulated human neuronal cells were assayed for viability using 
trypan blue dye exclusion and a hemocytometer. Camptothecin refers to the inducer of 
apoptosis. PrP 106-126 refers to the prion peptide fragment. 6H4 refers to the 6H4 antibody. 
PrP 106-126 + VEGF refers to PrP 106-126 peptide plus the addition of recombinant VEGF. 
6H4 + VEGF refers to 6H4 antibody plus recombinant VEGF. To calculate fold change each 
stimulated sample was compared to its respective control sample to keep analyses as similar 
to peptide array analyses as possible. Camptothecin and VEGF counts were compared to 
unstimulated control counts. 6H4 counts were compared to IgG1 isotype control counts. 6H4 
+ VEGF counts were compared to 6H4-stimulated counts. PrP 106-126 counts were 
compared to scramble peptide control counts. PrP 106-126 + VEGF counts were compared to 
PrP 106-126-stimulated counts. Assays were performed in triplicate with fold change and 
standard error presented.   
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4.3.7 Calcium Release 
 Numerous studies indicate that calcium-related signalling is involved in prion function 
(Kristensson, et al., 1993; Whatley, et al., 1995; Ferreiro, et al., 2008). The importance of 
calcium had also been supported by the peptide arrays in that several calcium-related 
signalling molecules, including calmodulin (CaM), NFAT2 and PLCγ, showed significantly 
altered phosphorylation in PrP 106-126-stimulated cells relative to control. Figure 4.10 shows 
where calcium signalling fits into the pathways as indicated by the peptide array data. 
Calcium release induced by PLCγ leads to down stream effects on CaM and NFAT. A 
calcium release assay was conducted following the PrP stimulations. Results indicated a 
significant induction of calcium release when cells were stimulated with PrP 106-126 peptide 
but not antibody (Figure 4.12). In fact, there was a significant increase in calcium release 
relative to both media control and peptide control in PrP 106-126-stimulated cells, while there 
was no statistically significant effect in antibody-stimulated cells. These results confirmed 
that distinct cellular responses were elicited depending on which PrPC ligand was used. This 
result supported the conclusion that PrPC is capable of engaging in multiple distinct responses.  
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Figure 4.12. Intracellular calcium release. Stimulated human neuronal cells were assayed 
for release of intracellular calcium as measured by fluorescence. The assay was performed in 
triplicate. The means of the replicates are presented along with standard error of the means. 
Analysis of variance indicated a p-value of 0.032 between groups. The greater the 
fluorescence signal, the more calcium released. Pairs which showed a statistically significant 
difference in signal of at least p <0.05 are indicated. 
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4.4 MAP Signalling Studies 
4.4.1 MAP Infection of Bovine Monocytes 
Following in vitro MAP infection of purified bovine monocytes, bacteria cytospins 
and acid fast staining were conducted to confirm infection (Figure 4.13). Over three repeated 
infections using a multiplicity of infection of 10:1, an infection efficiency of 93 +/- 4% was 
obtained. This level of infection and the consistency among experiments was well within the 
range required for performing kinome analysis. To optimize sensitivity in detecting changes 
in kinomic signal, a homogenous target cell population and a consistent level of infection or 
treatment was desirable. This way, potential kinase activity was avoided from 
uninfected/untreated cells or from cell types not of interest.   
 
 
                         Uninfected     MAP Infected 
   
 
Figure 4.13. Acid-fast staining of bovine monocytes. Figures show monocytes both infected 
and uninfected following the acid-fast staining technique. Blue indicates bovine monocytes 
and red indicates MAP. Cells were observed under a light microscope using oil immersion 
(100X). An estimate of infection efficiency was obtained based on the co-localization of MAP 
and cells. 
 
 
 
 4.4.2 Peptide Array Experiment 
To minimize the possibility of technical variation among peptide arrays, the raw data 
were collected, and were subsequently normalized and analyzed as a single experiment. The 
experiment consisted of monocytes isolated from the blood of three cattle. Uninfected or 
MAP-infected monocyte samples were treated with IFNγ and subjected to kinome analysis.   
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  4.4.2.1 Animal-Animal Variability 
With outbred populations such as cattle, variability in biological responses to infection 
was anticipated. To ensure that the core conserved biological responses across animals were 
being obtained and to determine the animal-dependent and animal-independent 
phosphorylation events, an animal-to-animal variability analysis was conducted. Under the 
same treatment condition, peptides with p-values of less than 0.01 were considered animal-
dependent. Recall that this was a test of animal-animal variation and not phosphorylation 
significance. In other words, when studying the response of two identically treated animals, if 
a given peptide showed a 99% or greater likelihood of being different, it was discarded. By 
this criterion, only eight peptides appeared to have a response dependent on animal, rather 
than treatment, across all samples. Two-hundred peptides elicited responses that were similar 
across animals within a specific treatment. Ninety-two peptides were inconclusive: under 
some treatment conditions they appeared animal-dependent, while under other treatment 
conditions, the various animals displayed a similar response.  
Within the three treatment/infection conditions, relative to control, the results showed 
that significant animal-dependent responses were observed in 52 peptides following IFNγ 
treatment, 43 peptides following MAP infection, and 37 peptides following MAP infection 
and IFNγ treatment. Interestingly, this indicated that there was more variation in the animals’ 
responses to IFNγ stimulation than to MAP infection. This may be due to the proportion of 
phosphorylation events represented on the peptide array being affected by treatment with 
IFNγ as compared to MAP infection. An infection with MAP will likely induce more changes 
in a wider variety of kinases than treatment with IFNγ, which acts on a smaller, specific 
subset of pathways. Thus, the remaining kinases that were peripherally affected by treatment 
with IFNγ or infection with MAP will be active at a more variable level, possibly due to the 
natural biological background activity of the animal. For example, IFNγ treatment of cells 
will induce specific phosphorylation events related to the IFNγ receptor. These 
phosphorylation events induced by IFNγ will represent a limited subset of the peptides found 
on the array. Other phosphorylation events, represented by peptides on the array, that are part 
of pathways connected to the IFNγ response may be affected in a more animal-dependent 
manner. MAP infection will induce immune responses and general stress reponses which 
represent a larger subset of the peptides on the array. There are then fewer peptides on the 
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array that are peripheral to these pathways that may be affected in a more animal dependent 
way. It would be expected that MAP-infected-IFNγ-treated samples would affect the largest 
proportion of peptides on the array due to the numerous phosphorylation events involved. The 
more phosphorylation events specifically affected by the treatment/infection, the less 
peripheral phosphorylation events which may respond in an animal-dependent manner.     
 
   4.4.2.2 Cluster Analysis 
 The kinome datasets from each treatment were subjected to cluster analysis to 
visualize the difference between animals and treatment conditions. PCA was conducted 
before and after subtraction of the control untreated animal-matched datasets. PCA clustering 
is explained in detail in Section 1.2.4.4.2 and in Figure 1.5. The data were broken into 
principal components, as represented by the axes. This enabled comparison of the general 
kinome profiles under the various treatment conditions. 
 PCA clustering without biological control subtraction showed random arrangement of 
animals and treatments (Figure 4.14 A). This random arrangement was expected for the 
complete kinome profile with outbred animals. It was expected because small variations in the 
kinase activity of individual animals, multiplied by the 300 peptides on the array, result in 
substantial variation in total response. Numerous factors can affect the baseline cellular kinase 
activity including genetic, developmental and environmental factors. These factors can also 
affect the dynamic kinase response to stimuli, especially a response as complex as an 
intracellular bacterial infection.    
Following the subtraction of the animal-matched control data, the kinome changes that 
were induced by the treatment/infection were more apparent in the PCA plot. These data 
represent the dynamic response of the monocytes from each animal to given treatment 
conditions: IFNγ-, MAP-, or MAP and IFNγ-treated (Figure 4.14 B). Clustering based 
predominantly on animal-to-animal variation was still apparent. The animals separated into 
different areas of the plot: animal 89 to the top middle, animal 136 to the bottom left and 
animal 148 to the bottom right. While this animal-based clustering seems contradictory given 
that the animal-to-animal analysis indicated 200 of the 300 peptides were animal-independent, 
this combined dataset is still relatively large. Subtle variations in the phosphorylation levels of 
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individual peptides across animals following subtraction still combined to result in the 
individual animal clustering distinctly.  
The clustering by animal was confirmed by hierarchical clustering (Figure 4.15). This 
clustering highlights the similarities between animals and treatments by how closely they 
group together. The lines above the heatmap indicate the relative similarity between the 
biological control subtracted treatments. By observing how close together the groups are, a 
hierarchy of difference is presented. In Figure 4.15, it can be seen that clustering was 
performed on the individual peptides, as shown by the lines on the left side of the heat map 
linking the peptides. The clustering of the peptides was performed automatically by the 
software, and was not considered in the analysis of our data. This may be a future 
consideration in the analysis of peptide array data. In addition, relative peptide signal 
intensities are shown on a colour scale from low (green) to high (red). This provides a visual 
indication of the similarities and differences between the stimulants. Colours that match 
across the columns indicate peptides of greater similarity, while colours that do not match 
when looking across the columns indicate peptide differences.  
While animal-based clustering was clearly observed, there was also clustering 
corresponding to individual treatment conditions, as observed in Figure 4.14 B. The 
monocytes treated with IFNγ cluster near the centre of the plot as a separate group. A box was 
drawn around these points to illustrate the relative proximity of the IFNγ-treated monocytes 
following biological control subtraction. This indicated that, despite the cumulative baseline 
differences among animals, there was a conserved and consistent response to IFNγ across the 
biological replicates. Similarly, in the hierarchical clustering, there was a pattern to the 
treatments within the animal clusters (Figure 4.15). In two of the three animals, MAP-
infected monocytes and MAP-infected monocytes treated with IFNγ cluster together. The 
close clustering within animals indicated that there were limited differences in response to 
these two treatments. MAP had inhibited the IFNγ response from taking place in the infected 
cells.  
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Figure 4.14. PCA of kinome data. Kinome datasets were subjected to 2D PCA cluster 
analysis. The data were broken into principal components, as represented by the axes. The X-
axis represents principle component 1, and the Y-axis represents principal component 2. 
Datasets for each animal are colour coded: Animal 89 (red), Animal 136 (green) and Animal 
148 (blue). Treatment/infection conditions are coded by shape: monocyte control (squares), 
MAP (triangles), IFNγ (circles) and MAP-infected-IFNγ-treated (stars). The black box 
indicates a conserved clustering of responses of uninfected monocytes to IFNγ stimulation 
following biological control subtraction. A) This plot shows treatments/animals prior to 
subtraction of biological control. B) This plot shows treatments/animals with subtraction of 
biological control. 
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Figure 4.15. Clustering and heatmap of MAP kinome data. The background-corrected raw 
data collected from the peptide arrays were VSN-transformed, and respective control signal 
was subtracted. The heatmap/clustering of the data was produced using the Average Linkage 
+ (1 - Pearson Correlation) method. The lines at the top of the heatmap indicate the relative 
similarity between the treatment conditions indicated at the bottom of the heatmap. The 
shorter the lines, the more similar the two connected columns. The animal codes are indicated 
below the treatment conditions. The lines on the left side of the heatmap indicate the relative 
similarity in signal between the 300 individual peptides on the array. The coloured lines 
indicate the relative degree of phosphorylation of each peptide from strongly phosphorylated 
(red) to non-phosphorylated (green) as indicated by a Z-score.  
 
 
4.4.2.3 Pathways Implicated 
 To determine which peptides displayed significant changes in phosphorylation state 
under the various treatment conditions, the peptide signals were subjected to paired treatment-
treatment variability t-tests. IFNγ-treated monocytes and MAP-infected monocytes treated 
with IFNγ were both compared to monocytes alone. IFNγ-treated monocytes were used as the 
Animal 136 Animal 89 Animal 148 
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baseline because an induction of IFNγ response was required in order to see any subsequent 
lack of response in MAP-infected-IFNγ-treated cells.  
Pathway over-representation analysis was carried out to determine the cellular 
pathways/processes that were activated/inactivated by the treatments. To ensure that the 
pathways identified were of conserved and consistent biological relevance, only those 
peptides which were identified as consistent (p >0.01) across the three biological replicates in 
one of the treatment conditions were considered. In addition, only those peptides which 
displayed a certain level of statistical significance (p <0.2) were input into the database. The 
data from the three animals were merged to produce a single representative bovine dataset 
before input into InnateDB. 
 When the monocytes treated with IFNγ were compared to control monocytes, several 
pathways were up-regulated with a high degree of statistical confidence (p <0.05). Notably, 
five of these pathways were related to JAK-STAT signalling (Table 4.7). According to 
InnateDB, the peptide arrays used in this experiment contained 25 peptides that could be 
directly attributed to the canonical JAK-STAT signalling pathway. Of these 25 peptides, 16 
were significantly (p <0.20) differentially phosphorylated relative to control untreated cells. 
Fifteen peptides showed increased phosphorylation, and one showed decreased 
phosphorylation (Table 4.7).   
 JAK-STAT is a well-defined pathway involved in the cellular response to IFNγ 
stimulation (Bach, et al., 1997; Darnell, 1997). Because this pathway was so strongly 
implicated by InnateDB, it provided a level of confidence that the peptide arrays were 
detecting real biological responses. The confidence level for the JAK-STAT pathway 
indicated by InnateDB (p 0.002) was the highest significance level obtained in the experiment 
(Table 4.7). By contrast, when MAP-infected monocytes treated with IFNγ were compared to 
the monocyte control, only four peptides indicated increased differential phosphorylation, and 
the pathway confidence level was negligible (p 0.83). This indicated that the treatment of 
MAP-infected monocytes with IFNγ did not induce the JAK-STAT signalling cascade.             
 In addition to JAK-STAT, a number of secondary signalling pathways were activated 
following IFNγ treatment of monocytes. These pathways included cytokine/chemokine 
signalling and activation of the pro-inflammatory TLR pathway. Many of these pathways 
share signalling intermediates with JAK-STAT, and they overlap downstream function. The 
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activation of these secondary IFNγ responses were not observed in MAP-infected monocytes 
treated with IFNγ. MAP appeared to block IFNγ responsiveness in monocytes. This blocking 
must occur upstream in the IFNγ response pathway; otherwise, a certain portion of the 
signalling cascade observed in IFNγ-treated cells would also be observed in MAP-infected-
IFNγ-treated cells. Repression of these signalling responses may facilitate intracellular 
survival and immune evasion by MAP. 
As numerous points along the JAK-STAT pathway were represented on the array, it 
was possible to investigate the specific point at which MAP influenced the ability of the 
monocytes to respond to IFNγ. IFNγ treatment of uninfected monocytes resulted in the 
differential phosphorylation of numerous isoforms of JAK, STAT and other signalling 
intermediates (Table 4.8). In general, it can be stated that there was an increased differential 
phosphorylation of key signalling peptides in the IFNγ-treated monocytes, while there was 
decreased phosphorylation of these important peptides in the MAP-infected-IFNγ-treated 
monocytes (Table 4.8). This decreased phosphorylation was also observed for IFNγ receptor 
1 (IFNGR1), indicating that this repression of the JAK-STAT pathway appears to be 
occurring at the level of the receptor. A representation of the signalling network highlights the 
differences in response between IFNγ-treated monocytes (Figure 4.16 A) and the reduced 
signalling in the MAP-infected-IFNγ-treated samples (Figure 4.16 B).   
 Interestingly, the suppression of cytokine signalling (SOCS) expression pathway was 
also implicated in the pathway analysis of IFNγ-treated cells. SOCS is a natural repressor of 
JAK-STAT signalling, which modulates the activity of that pathway. An increase in the 
expression of SOCS would inhibit JAK-STAT signaling (Pauli, et al., 2008). This may be the 
detection of the compensatory activation of SOCS to modulate JAK-STAT, thus, keeping the 
system in balance by inhibiting excess JAK-STAT signalling. 
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Table 4.7. Pathway analysis of bovine monocytes and MAP-infected bovine monocytes in 
response to IFNγ stimulation. 
Monocytes  MAP-Infected 
Monocytes  
 
Up 
Regulated 
Down 
Regulated 
Up 
Regulated 
Down 
Regulated 
 Pathway  ↕ ↑ p  ↓ p  ↑ p  ↓ p  
JAK-STAT 
signalling pathway  16 15 0.002 
 
1 0.999 
 
4 
 
0.831 
 
7 
 
0.309 
JAK-STAT 
pathway/ 
regulation  12 11 0.006 
 
 
1 0.998 
 
 
1 
 
 
0.840 
 
 
2 
 
 
0.532 
Gene expression of 
SOCS  6 6 0.025 
 
0 1 
 
1 
 
0.915 
 
3 
 
0.340 
Gene expression of 
SOCS1  6 6 0.025 
 
0 1 
 
1 
 
0.915 
 
3 
 
0.340 
JAK-STAT 
Signalling  
Gene expression of 
SOCS3  6 6 0.025 
 
0 1 
 
1 
 
0.915 
 
3 
 
0.340 
IL27-mediated 
signalling events  6 6 0.025 
 
0 1 
 
1 
 
0.915 
 
3 
 
0.340 
IL12-mediated 
signalling events  14 12 0.013 
 
2 0.990 
 
2 
 
0.910 
 
5 
 
0.251 
IL22 soluble 
receptor signalling  5 5 0.047 
 
0 1 
 
1 
 
0.915 
 
3 
 
0.340 
AndrogenReceptor  11 10 0.081 1 0.999 4 0.247 2 0.919 
Cytokine/  
Chemokine  
Signalling  
IFN beta enhancer 
information 
processing  6 6 0.025 
 
 
0 1 
 
 
0 
 
 
1 
 
 
0 
 
 
1 
TGF-beta 
(canonical)  8 7 0.139 
 
1 0.990 
 
3 
 
0.236 
 
1 
 
0.952 
TGF-beta 
signalling pathway  5 5 0.045 
 
0 1 
 
2 0.425 
 
1 
 
0.895 
TGFB 
Signalling  
TGFBR  15 11 0.273 4 0.957 5 0.061 0 1 
NFkB  
Signalling  Nfkb activation 10 9 0.012 
 
2 0.994 
 
2 
 
0.425 
 
1 
 
0.895 
Other Toll-like receptor 
signalling pathway 25 18 0.044 
 
3 0.999 
 
5 
 
0.373 
 
4 
 
0.802 
 
InnateDB assigned pathways from input transformed peptide array data. Pathways were 
assigned a probability value (p) based on the number of proteins present for a particular 
pathway. Output included the number of peptides associated with a particular pathway and 
the subset of those which are differentially phosphorylated. For our investigation, peptide 
significance cut-offs were set at p <0.2. ↕ indicates the number of peptides on the array 
relating to the pathway. ↑ and ↓ indicate the number of peptides with increased or decreased 
phosphorylation, respectively, as compared to the control condition. 
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Table 4.8 Differential phosphorylation of peptides of the JAK-STAT pathway following 
IFNγ stimulation of monocytes and MAP-infected monocytes. 
 
 Monocytes MAP-Infected 
Monocytes 
Phosphoprotein Fold 
Change 
p-value Fold 
Change 
p-value 
IFNAR1 1.14 0.04 -1.17 0.23 
IFNGR1 1.09 0.26 -1.07 0.27 
IL10RA 1.11 0.19 -1.14 0.15 
IL16 1.20 0.10 1.17 0.16 
IL2RB 1.10 0.24 -1.09 0.27 
IL4R 1.16 0.14 1.08 0.31 
IL6ST 1.14 0.14 1.04 0.33 
IL7R 1.56 0.07 1.16 0.18 
JAK1 1.03 0.42 -1.16 0.12 
JAK2 -1.01 0.44 -1.08 0.22 
JAK3 -1.02 0.36 -1.27 0.02 
STAT1 1.22 0.08 1.20 0.14 
STAT2 1.13 0.06 -1.15 0.08 
STAT3 1.16 0.05 -1.12 0.16 
STAT4 1.17 0.09 -1.06 0.34 
STAT5B 1.14 0.05 1.00 0.49 
STAT6 1.22 0.01 -1.40 0.14 
Tyk2 1.04 0.16 -1.03 0.43 
 
Phosphoprotein indicates the name of the protein which corresponds to the peptide 
phosphorylation target site on the array. Fold Change is the relative change calculated by 
comparing the background-corrected and normalized signal values of these IFNγ-treated cells 
to the media control cells. p-values correspond to the level of significant difference between 
these IFNγ-treated cells and media control cells. 
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A) B) 
 
 
 
Figure 4.16. Signalling within the JAK-STAT pathway in bovine monocytes and MAP-
infected bovine monocytes in response to IFNγ stimulation. Shown are proteins identified 
as belonging to the JAK-STAT pathway. The lines connecting each node are putative 
interactions according to the Cytoscape database. Protein members of the JAK-STAT 
pathway are colour coded with respect to direction of fold change using IFNγ treated 
monocytes as control. Red indicates increased phosphorylation, green indicates decreased 
phosphorylation and white indicates no change. A) Differential phosphorylation of JAK-
STAT intermediates following IFNγ treatment of bovine monocytes is shown. B) Differential 
phosphorylation of MAP-infected monocytes treated with IFNγ is shown.  
 
 
 
 4.4.3 TNFα ELISA 
The pathway analysis and signalling data indicated that MAP inhibited the ability of 
cells to respond to IFNγ stimulation. This appeared to occur at the level of the receptor as 
phosphorylation was decreased in MAP-infected cells from the level of the INFGR down 
through the pathway (Table 4.8). IFNγ-induced expression of TNFα is a well established 
response in macrophages (Collart, et al., 1986). Treatment of bovine monocytes with 10 
ng/mL recombinant bovine IFNγ induced significant release of TNFα (Figure 4.17). 
However, when MAP-infected monocytes were treated in the identical way, there was 
minimal release of TNFα. These results provided a functional confirmation that MAP 
infection could block signalling through the IFNGR, as observed in the kinome data. 
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Figure 4.17. IFNγ-stimulated production of TNFα in MAP-infected and non-infected 
bovine monocytes. Monocytes, IFNγ-treated and untreated, and MAP-infected monocytes, 
IFNγ-treated and untreated, were cultured in growth media. This media was then collected, 
and the level of TNFα in culture supernatant was quantified with a capture ELISA. Cell 
samples were taken from a single representative animal. Statistical analysis was through a 
paired t-test of signal from the ELISA replicates. A standard curve of known TNFα 
concentrations was used to determine sample TNFα concentrations. 
 
 
 
 4.4.4 INFGR and SOCS Gene Expression 
 The absence of early JAK-STAT signalling in MAP-infected monocytes in response to 
IFNγ stimulation indicated that suppression of the signalling cascade was occurring at or near 
the IFNγ receptor. This could reflect suppression of receptor auto-phosphorylation, 
suppression of IFNγ receptor expression, suppression of JAK or STAT phosphorylation, 
suppression of JAK or STAT expression, or an increase in inhibitory factors silencing the 
JAK-STAT phosphorylation/activation at the level of the receptor. Both receptor-expression 
inhibition and increased expression of signalling inhibitors have been observed for other 
mycobacteria (Hussain, et al., 1999). qRT-PCR results indicated that MAP reduced 
expression of IFNGR1 and INFGR2, while it increased the expression of the JAK-STAT 
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suppressor SOCS (Figure 4.18). An approximately four-fold decrease in both IFNGRs’ 
expression was observed at the 18-hour time point, while no appreciable decrease in either 
IFNGRs’ expression was seen at the 1-hour time point. In Figure 4.18, it is apparent that soon 
after infection, at the 1-hour time point, there was a significant increase in both SOCS1 and 
SOCS3 expression, and SOCS expression was further elevated at the 18-hour time point post-
infection. 
 
 
 
   
 
Figure 4.18. Altered expression of SOCS1, SOCS3, IFNGR1 and 2 in response to MAP 
infection. MAP-infected bovine monocytes were assayed in triplicate for relative expression 
of select genes as determined through qRT-PCR. Cultured bovine monocytes taken from a 
single representative animal were infected. RNA was extracted from cells collected at 1-hour 
and 18-hour time points. Cells were taken from three separate culture wells. The control 
sample was time-matched uninfected monocytes. The graph indicates fold change which was 
determined compared to control, as calculated by the 2-∆∆CT method, along with standard 
deviation. 
 
 
 
111 
 
5.0 DISCUSSION 
5.1 Cell Signalling, Disease and Kinome Analysis 
 To date, a large portion of the work done on peptide arrays, kinome analysis and 
kinase-based treatment has focused on cancer. This is understandable as cancer is recognized 
as a disease with altered cell signalling and is of great importance to human health, especially 
in the western world. The techniques developed and refined through the study of cancer are 
now being applied in other areas of biology and health. These techniques include high-
throughput kinomic techniques such as peptide arrays. The development of genus-specific 
peptide arrays and computer techniques to mine the data will enable further expansion of this 
area of research. Disorders of protein function, such as TSEs, are diseases for which kinomics 
may provide a unique perspective. In these diseases, there is no pathogen to target, only 
internal cellular-level processes that become disordered. The disease may be treated by 
targeting the correct site of disorder. In the same vein, infectious diseases that effectively 
evade the immune system, such as MAP, and can hide from or adapt to current treatment 
regimes are problematic to treat. These infections need to be treated in a more elegant way, by 
either reactivating the suppressed immune responses or eliminating the pathogen effectors 
which cause the suppression. This project incorporates all of the aspects mentioned above: to 
enhance the utility of a kinome technology, to study an endogenous protein-based disorder 
involved in extracellular signal transduction and to study an intracellular pathogen that 
disrupts host signalling. These are diverse topics that all relate to kinomics.    
 
5.2 Genus-Specific Peptide Arrays 
 The degree of genus difference in the sequences shown in Table 4.2 highlights the 
importance of developing genus-specific arrays rather than relying on potential kinase cross 
reactivity between diverse genera. Even genera which display significant evolutionary 
proximity to humans, such as other mammals, can have significant differences in kinase target 
recognition sequences. Genus-specific peptide arrays should allow for a better match between 
kinase and peptide target sequence, allowing a greater likelihood of successful kinase 
recognition. It appears that the differences between genera are multiplied at the level of 
peptide sequence as compared to the genetic level. Humans and cattle share approximately 
95% genetic similarity (Zimin, et al., 2009); however, in the scope our peptide array design, 
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22% of peptides compared between human and bovine displayed no sequence homology as 
they corresponded to entirely different proteins (Table 1.3)      
While some groups have taken the extreme step of using human peptide arrays to 
study genera as evolutionarily distinct as Arabidopsis plants (Ritsema, et al., 2007), the results 
shown in Table 4.2 provide a vivid illustration of why this may be inappropriate. For 
example, 99.69% of human phosphorylation target sites have no sequence homology in the 
rice plant. It is not a case of a cross-genus peptide array generating incorrect data but rather 
less significant data. For example, Ritsema et al. (2007) studied the plant Arabidopsis using a 
human peptide array. They generated 15 significant peptide phosphorylation events out of 
184. These 15 peptides may have been the only human peptides with enough similarity to 
plant kinases to be phosphorylated. Meanwhile, in the prion study described here, use of 
human cells and a bovine-specific array showed that well over 100 peptides out of 300 were 
significantly phosphorylated. With a human array, perhaps even more peptides may have been 
considered significant. One of the benefits of PIIKA was the additional data points considered 
significant; this same benefit may result from genus-specific arrays. In addition, the method 
described of using human sequences as a basis for finding the equivalent sequence in the 
genus of interest works well in an evolutionarily proximal genus. Complications arise when 
the differences are greater, such as between humans and insects. A linear approach from 
human peptide sequence with assigned function to honey bee or wheat plant may not be 
possible. For these cases, it may be necessary to find a well-characterized genus of less 
evolutionary distance and then use these data as a starting point to develop an array for the 
genus of interest. Since using well-characterized human kinome data to develop bovine arrays 
was a successful approach, it may be a more straight forward bioinformatics process to take 
the well-characterized rice plant database, Rice Kinome Database 
(phylomics.ucdavis.edu/kinase/), to develop a wheat array, or a Drosophila database, such as 
www.phosphopep.org, to develop a bee array. 
 
5.3 PIIKA Advances in the Peptide Array Technique  
  5.3.1 Data Normalization and Statistical Analysis 
As an early adopter of high throughput microarray technology, genomics has been the 
dominant force in the development of mathematical and computational methods for data 
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analysis. When peptide arrays were developed, and specifically peptide arrays for kinome 
analysis, it was assumed that the data analysis methods developed for nucleotide-based arrays 
could be applied directly to this new technology. As the use of peptide arrays has become 
more wide-spread, it is becoming apparent that these approaches are not allowing the full 
potential of the peptide arrays to be realized, perhaps due to fundamental differences between 
the nature of the nucleotide and peptide arrays. In part, this relates to the distinct nature of the 
signals which are generated. Nucleotide-based arrays produce an output signal based on 
nucleotide hybridization reactions; however, peptide arrays are phosphorylated by transferring 
a phosphate group from ATP (or GTP) to the target sequence printed on the array. This 
creates two difficulties: the question of where to set a cut-off threshold and the issue of 
variance in signal increasing with phosphorylation. Since many statistical tests are based on 
the assumption of constant variance, data normalization is required before these tests can be 
conducted. The normalization method used to analyze the data needs to reflect the unique 
characteristics of peptide array data. Another difference between the two techniques is that the 
typical nucleotide array contains many more targets than the typical peptide array, possibly up 
to 100 times more. This requires a relatively less-stringent cut-off for the discarding of targets 
based on statistical significance. Too many discarded data points will limit the ability to 
identify clusters based on functional associations. 
 The data analysis pipeline that was developed, PIIKA, deals with the above-mentioned 
issues and unique characteristics of the peptide array data. Following a comprehensive 
comparison, PIIKA was found to be superior to the standard nucleotide array techniques that 
are commonly used. The key factors to consider when choosing an analysis method are that 
the data transformation does not alter the data in any way that may affect biological relevance 
(Figure 4.3) and that it enhances the amount of data that are considered statistically 
significant (Table 4.3). The increase in significant data is probably the greatest asset of 
PIIKA. Between the three treatments tested (CpG, LPS and IFNγ), PIIKA produced 273 
significant peptides compared to 20 for VSN + limma and 44 for QNorm + limma (Table 
4.3). This larger dataset allows more data mining and greater significance in the pathway 
analysis (Table 4.4). A large peptide array experiment containing multiple treatments that 
produces 20 significant peptides is not a large improvement over traditional methods such as 
phosphospecific antibodies and western blot, considering the time and cost. However, a 
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technique that generates significant signal from 273 peptides in the same experiment is a large 
advantage over traditional methods. Without this advancement, much of the high throughput 
nature of the peptide arrays would be lost. Additional data points allow effective use of 
PIIKA’s higher-order data clustering, as well as pathway association using databases like 
InnateDB. 
 In determining which peptides are to be considered for further analysis, PIIKA uses 
the t-statistic generated p-value. It has been left up to the individual researcher to consider 
either fold change or p-value as the criterion for whether a gene, in the case of nucleotide 
arrays, or a peptide, in the case of peptide arrays, is distinct from control. Witten and 
Tibshirani (2007) made several observations contributing to this discussion. They compared 
the use of fold change and t-statistic in the generation of differential gene lists from 
microarray data. They concluded that the use of either fold change or t-statistic should be 
based on biological rather than mathematical considerations. However, they found that the use 
of fold change artificially enhances the perceived importance of noisy genes over those with 
true differential expression. This elimination of noisy genes is an important feature of the t-
statistic, though the t-statistic does enhance the perceived importance of replicate consistency 
over magnitude of signal difference between treatment and control. With our experience 
analyzing peptide array data, we found that the t-statistic is the best means of peptide 
selection considering both the noise associated with replicate peptide phosphorylation and the 
negative phosphorylation values generated. 
 If considering the t-statistic as a cut-off, it is important to decide the confidence level 
that will be applied to the data. Peptide array data have a number of unique characteristics that 
distinguish it from nucleotide array data and make assigning a t-statistic cut-off difficult. A 
major characteristic of peptide array data is that there is substantially less data generated, 
potentially up to 100 times fewer data points per array than nucleotide array data. For this 
reason alone, a less stringent p-value cut-off is desirable for peptide array data. In a nucleotide 
array containing 30,000 oligos, a p-value cut-off of 0.05 would produce 1,500 significant data 
points by random chance. A peptide array of 300 peptides with a similar cut-off would 
produce 15 significant data points by random chance. For the reason above, a strict 
significance cut-off is a necessity in nucleotide array data. Another characteristic of peptide 
array data is the potentially large variation in signal between intra-array replicates due to 
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variations in staining and peptide phosphorylation level across the array. This variation could 
result in many more data points being eliminated when using a stringent t-statistic cut-off. In 
addition, the MicroArray Quality Control project conducted a large study on numerous 
microarray datasets and recommended using a less stringent p-value cut-off to enhance the 
reproducibility of gene lists generated from array data (Shi, et al., 2008). Considering these 
characteristics, we have chosen a relatively liberal cut-off for peptide significance: p-value < 
0.2.      
  
5.3.2 Clustering and Pathway Analysis 
 As with any high throughput experimental methodology, a large amount of data are 
generated; thus, there is the problem of mining the data for biologically relevant information. 
Taking a systemic approach and applying higher-order analyses, such as clustering and 
functional associations, has become common in nucleotide-array studies. These types of 
analyses have not been a part of most kinome studies in the past. Many groups have simply 
used the kinome arrays as a means to find specific phosphorylation events, which are then 
further characterized by more classical methods. This approach, however, disregards the 
potential to do higher order analysis from such a large pool of data.  
In this project, it has been shown that clustering of treatments and pathway analysis 
have added value to peptide array data analysis. It has been shown that some treatments are 
more similar than others and indicated which pathways are activated or deactivated under 
given conditions. For instance, in the prion study, clustering occurred based on the type of 
stimulant. This stimulant-type-dependent response had to be controlled so prion-specific 
effects could be observed. Subsequently, pathway analysis showed that the two prion ligands 
displayed unique pathway (de)activation, implicating multiple-pathway interactions between 
the cell-surface prion protein and the intracellular signalling environment. The MAP study 
showed the importance of biological controls, especially in outbred animal populations. Once 
biological variability was taken into account, clear treatment- and infection-specific patterns 
emerged. Following pathway analysis, a lack of JAK-STAT and secondary-pathway 
signalling was observed in MAP-infected cells treated with IFNγ. This was a clear indication 
that MAP inhibits the JAK-STAT pathway to suppress immune responses. These conclusions 
were later confirmed by additional experimental methods.  
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The results shown in this project clearly illustrate the utility of applying these higher 
order methods to peptide array kinome analysis.      
 
 5.4 Prion Signalling 
  5.4.1 The PrP Protein’s Distinct Signalling Potential 
 While numerous studies have looked at signalling events associated with PrPC, this 
study is the first to take a broad approach at the level of the kinome. The results confirm many 
of the individual results from previous studies and also point to a unique aspect of PrPC that, 
until now, had not been fully considered: its multifarious signalling potential. 
 When treated with two PrP-specific ligands, distinct pathways and distinct 
(de)activation dichotomies are observed. The distinct pathways which are activated by the two 
stimulations may lead to different functions of the PrP protein based on conformation. PrP 
106-126-induced cellular responses are a model of disease, and this peptide has been used in 
various in vivo prion disease studies (Tagliavini, et al., 1993; Fabrizi, et al., 2001; 
O’Donovan, et al., 2001; Thellung, et al., 2002; Carimalo, et al., 2005; Pietri, et al., 2006). 
PrP antibody-based stimulation has been used to model signalling and results in a milder cell 
phenotypic response (Mouillet-Richard, et al., 2000; Schneider, et al., 2003; Solforosi, et al., 
2004). Figure 4.10 shows how the various pathways that were implicated by the kinome data 
can be linked, revealing how several diverse functions may have been assigned to the prion 
protein previously. When only a small part of the prion signalling pathway is considered, it is 
understandable why different investigators assigned different functions to the prion protein. 
  The priority of the kinome investigation of PrP function was to take a more global 
perspective when analyzing PrPC signalling. Many of the signalling events observed had been 
reported previously by other groups in various individual studies. The peptide array data 
indicated calcium response, growth factor signalling, and PI3K, all of which have been shown 
previously (Kristensson, et al., 1993; Thellung, et al., 2002; Vassallo, et al., 2005). In 
addition, Thellung, et al., (2002) showed PrP 106-126-dependent activation of Caspase 3 in 
human neuroblastoma cells, a response also identified in our study (Figure 4.10 and Table 
A1). By analyzing multiple protein phosphorylation events within a single experiment, the 
combined dataset was able to implicate possible upstream cell-surface interacting partners for 
PrPC. The most significant of these cell-surface receptor pathways, based on InnateDB 
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pathway-significance values, were VEGFR and TGFBR (Table 4.5).  Previous studies have 
also implicated laminin receptors as possible PrPC interactors (Rieger, et al., 1997; Graner et 
al., 2000), and the array data indicated that integrin receptors, a type of laminin receptor, may 
be linked to peptide-stimulated PrPC.  
 Signalling events induced by antibody stimulation agreed with many of the previously 
published reports and demonstrated a signalling response that was distinct from the peptide. 
MAPK-related signalling was evident from pathway analysis, and this had been shown 
previously in antibody-treated neuronal cells (Mouillet-Richard, et al., 2000). MAPK also 
appeared in peptide-treated cells, but the direction of phosphorylation was opposite, 
depending on treatment. This indicated an activation/deactivation response between the two 
stimulations. Based on pathway analysis and moving upstream of the pathway, insulin 
receptor was implicated as a possible cell-surface interactor, again, a previously reported 
result (Ostlund, et al., 2001). 
 Confirmation of signalling implicated by the peptide array data analysis was obtained 
with a number of independent validation assays. Antibodies on the phosphospecific antibody 
array, which were exact matches to the printed array peptides, agreed in terms of direction of 
phosphorylation and magnitude of fold change (Figure 4.6). This result provided evidence 
that the phosphorylation of peptides on the array were correlated to phosphorylation of 
substrate proteins within the cells. Calcium release was indicated by the array data upon 
stimulation with PrP 106-126 but not antibody. This result was confirmed with a calcium- 
release assay (Figure 4.2). Previously published data had shown a strong apoptosis induction 
and cell death caused by PrP 106-126 (O’Donovan, et al., 2001; Paitel, et al., 2003). This 
study produced results showing that cell-viability was significantly decreased upon 
stimulation with the peptide (Figure 4.11). Peptide array data indicated a role for VEGFR 
signalling in peptide-stimulated but not antibody-stimulated cells. Both of these results were 
confirmed by viable cell counts with and without the addition of recombinant VEGF. A 
significant reduction in cell viability was observed following stimulation with peptide while 
no reduction was observed due to the antibody. Moreover, the addition of VEGF restored cell 
viability in PrP 106-126-stimulated cells but had no significant effect on antibody-treated 
cells (Figure 4.11). Considering the validation assays and that many results from the peptide 
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array study were confirmed by others using low throughput methods, there can be confidence 
in the array results.  
PrPC has the ability to differentially affect multiple signalling pathways based on the 
stimulation given, possibly as a result of different interacting partners on the cell surface. 
These differences are readily observed; for example, when stimulated with peptide, the PI3K 
and calcium responses were significant but were not apparent when the neuronal cells were 
treated with antibody. Antibody stimulation revealed MAPK signalling responses distinct 
from those in peptide-stimulated cells. In addition, Erk is significantly differentially 
phosphorylated when treated with antibody but not peptide. The NFκB pathway is another 
example where antibody affects a pathway, while peptide does not (Table 4.5).  
 Within the literature, it is rare to find examples of receptors that have the ability to 
elicit unique and unrelated phenotypes depending on the ligand bound. However, there are 
examples of receptor-modulating proteins that can alter receptor phenotype; these are referred 
to as receptor activity modifying proteins (RAMPs) (Sexton, et al., 2001). Originally 
discovered in interaction with calcitonin receptor and the calcitonin receptor-like receptor, 
RAMPs interact with a much wider cross-section of receptors (Christopoulos, et al., 2002). 
These proteins can bind at various sites on the receptor, affecting receptor trafficking, 
glycosylation and direct receptor activity through the interaction with the ligand binding 
domain (Sexton, et al., 2001). Perhaps due to misfolding, PrP appears to share a similar 
ability to interact with more than one receptor on the cell surface. Multi-receptor interaction 
may explain prion’s ability to elicit distinct signalling events within a given cell.     
 A reason the function of PrPC has been so difficult to determine may be its 
multifarious signalling ability. Variable signalling pathway activation, resulting from the 
different experimental techniques and models that have been employed, activate different 
potential functions of the protein. This may be a reason that various studies have shown 
different PrPC functions. It may be necessary to take a more global approach to elucidate a 
more complete interaction network for PrPC in order to understand its variable cell signalling 
characteristics.   
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 5.5 MAP Related Signalling 
 The host response to infection is often based on phosphorylation-mediated changes in 
normal cell function. A lack of activation of an immune response can lead to chronic 
infection; however, an aggressive immune response can lead to damaging inflammation or 
autoimmunity. Mycobacteria species display a pathogenic mechanism involving the 
production of bacterially encoded, eukaryotic-like protein phosphatases which play a role in 
virulence (Alber, 2009). The presence of these phosphatases underscores the importance of 
phosphorylation to these bacteria. Given this importance, the understanding of host-pathogen 
interaction related to cell signalling in MAP infections may be central to understanding the 
disease pathogenesis. Considering the widespread availability and success of kinase inhibitors 
to fight disease (Schreiber, et al., 2009), MAP may be a natural fit for this treatment 
paradigm.   
 
  5.5.1 IFNγ Receptor and Immune Response 
When comparing monocytes treated with IFNγ to MAP-infected monocytes treated 
with IFNγ, pathway analysis clearly revealed MAP’s ability to block IFNγ-induced JAK-
STAT signalling. In monocytes treated with IFNγ, activation of the JAK-STAT pathway, 
cytokine/chemokine pathways and TLR signalling were all observed. In MAP-infected 
monocytes, none of these pathways displayed any level of activation. Observing a number of 
JAK-STAT pathway intermediates, phosphorylation status indicated that this lack of 
signalling was occurring throughout the pathway up to the level of the receptor. As IFNγ is an 
important immune modulating molecule, the suppression of this pathway would give an 
intracellular pathogen, such as MAP, an advantage in establishing a chronic infection. 
Gene expression experiments showed that the expression of IFNGR1 and IFNGR2 
decreased, and expression of SOCS1 and SOCS3 increased in a time-dependent manner 
following MAP infection. SOCS are inhibitors of JAK-STAT signalling, so their induced 
expression by MAP would result in a loss of IFNγ response. A number of viruses have been 
shown to reduce IFNγ responsiveness through the action of SOCS, including Influenza A 
(Pauli, et al., 2008), Herpes Simplex Virus 1 (Yokota, et al., 2005), Hepatitis C Virus (Bode, 
et al., 2003), Severe Acute Respiratory Syndrome coronavirus (Okabayashi, et al., 2006) and 
Respiratory Syncytial Virus (Zhao, et al., 2007). While a detectable increase in the expression 
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of SOCS1 and 3 was observed as early as 1 hour post infection, a significant decrease in 
IFNGR1 and 2 expressions required up to 18 hours to be observed. By contrast, SOCS 
expression was substantially increased at a very early time-point post infection. SOCS1 
expression eventually increased approximately 10-fold and SOCS3 increased approximately 
3-fold relative to uninfected cells (Figure 4.18). These results indicated that MAP suppresses 
the JAK-STAT pathway by inducing SOCS expression early in infection, which may provide 
a rapid way to suppress IFNγ responses prior to down-regulating IFNGR protein levels. 
Subsequently, for long-term immune suppression, MAP inhibits the expression of the IFNγ 
receptors. Other pathogens have been known to have a similar affect on IFNGR1 and 2 
(Kierszenbaum, et al., 1995; Ray, et al., 2000) including Mycobacterium avium, a bacterium 
closely related to MAP (Hussain, et al., 1999). However, in Mycobacterium tuberculosis, the 
inhibition of IFNγ signalling is not based on the suppression of STAT signalling (Ting, et al., 
1999).  
This MAP study has offered insight into the pathogenic mechanisms of MAP. It also 
characterizes the nature of MAP’s blockage of IFNγ signalling, specifically the redundant 
nature of the blockage both by signalling suppression via decreased receptor expression and 
pathway suppressor activation.    
 
 5.6 Future Directions 
5.6.1 The Kinome 
 In the future, the characterization of the complex interplay between pathogen and host 
for the discovery of novel and specific therapeutic targets of treatment will be a growing field 
of research. The importance of phosphorylation in cellular activity and the growing body of 
evidence implicating signalling in varied diseases show how key disruptions of signalling are 
critical. This means that kinome analysis will be important as a means of developing 
treatments. An increasing number of “endogenous” diseases such as cancer, Alzheimer’s 
disease, genetic disorders and protein misfolding diseases are becoming increasingly relevant 
to human health. In addition, high throughput technology and data analysis techniques are 
constantly improving while more targeted therapies are being demanded. Considering all of 
the above, kinomic research should receive much attention. 
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    5.6.2 Prion 
   5.6.2.1 The Multifarious Prion Function 
 Despite the huge amount of work that has already gone into understanding PrPC, the 
function of this prion protein is still a mystery. Putative functions seem to fall into and out of 
favour within the research community, with no clear consensus emerging. A more global 
analysis or meta-analysis may be in order. This prion study indicates that taking a broader 
approach to understanding prion function may be a critical step to finally assigning a function 
to this protein. It is possible that PrPC is able to interact with multiple partners, thus affecting 
multiple signalling pathways with varied functions. Adding further complexity to the 
understanding of PrPC is that its function may be subverted or altered upon misfolding. Since 
the search for a single interactor or pathway has yet to be successful, the source of this 
variability should be studied.  
 A first step in the study of PrP functional variability is the prion study described here, 
which takes a more global approach to prion activities in the context of the kinome. With the 
advent of multiple high-throughput techniques involving various “omes” (genomes, 
transcriptomes, proteomes, kinomes, metabolomes and interactomes), perhaps the prion 
protein exemplifies the need for a systems biology approach to certain biological questions. 
Systems biology could incorporate and integrate the individual omics approaches. The prion 
protein is a protein without a clear function. PrP may have the potential for multiple 
interactions which alter its function. A linear approach, considering a single protein-protein 
interaction or looking at genetic answers to protein function, has failed to provide the answer. 
The variation encountered in the study of PrP function may describe a problem which a 
systems approach could more effectively address.  
 
   5.6.2.2 Misfolding Diseases 
 With the success of science in curing infectious disease since the advent of antibiotics 
and vaccination, new diseases of concern appear increasingly to be diseases without an 
obvious infectious trigger. Genetic disorders, degenerative disorders and now misfolding 
diseases are becoming increasingly prevalent as more infectious diseases are cured or 
successfully treated. The first protein misfolding disease to be characterized as such was the 
prion disease scrapie (Pruisner, 1982). This expanded to other prion diseases such as Kuru, 
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Creutzfeldt-Jakob disease, bovine spongiform encephalopathy and chronic wasting disease. 
There is now more evidence that other diseases such as Alzheimer’s disease, Huntington’s 
disease and Parkinson’s disease are caused by the misfolding of key proteins (Aguzzi, 2009). 
The ability to treat these diseases may not come from the classical methods applied to 
infectious disease, or the hope of effective gene therapy; rather, treatment may involve 
targeting misfolding or correcting the physiological disorder resulting from misfolding. This 
“protein only” paradigm is relatively new.  In many of the cases of these misfolding diseases, 
no genetic component has been determined; in fact, the protein misfolding appears 
independent of the genome. The current misfolding disease field is dominated by Alzheimer’s 
disease and prion diseases; however, it may become a much broader field in the future. 
Diseases that result from protein misfolding could become even more important as we realize 
there are limits to what genes can tell us.    
 
  5.6.3 MAP 
   5.6.3.1 Treatment of MAP’s Effects on the Immune System 
 MAP’s ability to not only evade the immune system but also survive and grow inside 
immune cells meant to destroy it makes it a model bacterium for kinome studies. It is clear 
that MAP survives and is able to cause chronic infection, at least in part, due to its specific 
targeting of immune signalling. Thus, it is possible that an effective treatment of MAP 
infection can come from a signalling approach. For the first time, this study points to events 
affecting the IFNγ receptor that leads to the loss of JAK-STAT signalling and downstream 
immune response. Possible treatments may include reactivation of a key phosphorylation 
event in the JAK-STAT pathway, use of an inhibitor designed to stop the activation of SOCS 
or a combination of the two. Alternatively, if the bacteria-produced molecular effector which 
carries out this JAK-STAT suppression were identified, then this molecule may be a target for 
vaccination. If effective, such treatments are of great interest to the cattle industry as they 
could lead to a substantial increase in production and improved animal health. 
 While MAP has been inconclusively linked to human disease, other mycobacteria, like 
M. tuberculosis, are important causes of human disease. MAP and M. tuberculosis share many 
common immune-evasion characteristics. It is possible that effective treatment for MAP 
infections could be helpful in advancing the research for M. tuberculosis treatments.   
123 
 
   5.6.3.2 MAP and its Tyrosine Phosphatases 
 MAP, like other Mycobacterium species, produce two tyrosine phosphatases: PtpA 
and PtpB. Since, 1) MAP contains no tyrosine kinases, 2) its internal signalling is based on 
serine/threonine phosphorylation and 3) these phosphatases are secreted, it is believed that 
these phosphatases are designed to interfere with host cell signalling. Given the importance of 
phosphorylation-mediated signalling and the amount of time bacteria have co-evolved with 
host animals, it is not surprising that they would develop means of affecting cell signalling. 
However, this is a relatively new area of infectious disease research and an opportunity for 
disease treatment. If this pathogen-specific signalling disruption is a widespread strategy of 
infectious disease, the kinase- and phosphatase-based treatments used for cancer may be more 
widely applicable. Diseases which affect signalling by the production of phosphatases or 
kinases to alter host signalling will be among the first to be treated by this signalling 
modulation approach. 
     
  5.6.4 Peptide Arrays 
 Peptide arrays, and specifically peptide arrays for kinome analysis, have been around 
for a number of years. The technology has now advanced to a point where more is expected of 
it, and new tools need to be developed for the technology to truly achieve its full potential. In 
the past, the peptide arrays were used as a hypothesis-generating technique. These hypotheses 
could then be tested and validated by other more classical techniques. Increasingly, peptide-
array kinome analysis is standing on its own, much the way nucleotide-array based work is. 
Two key aspects of the future of peptide arrays are described below: mining as much data out 
of the arrays as possible and producing arrays for more evolutionarily diverse genera. 
 
   5.6.4.1 Analysis Techniques and Enhanced Data Mining 
 When peptide arrays were first used for kinome analysis, a limited amount of data 
were produced and used. An array of 300 or more peptides would be used to observe a few 
phosphorylation events. These results were then validated by western blot or other classical 
methods (Diks, et al., 2004; Lowenberg, et al., 2006). The remaining data were discarded as 
characterizing a single protein phosphorylation event in the context of a disease or treatment 
was an adequate goal. Now, much like nucleotide arrays, a more integrated approach is being 
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adopted. It was clear that looking at a limited number of genes on an array containing 30,000 
potential hybridization events was a waste of potentially important data. Databases such as 
KEGG and InnateDB were first developed to organize gene expression data into pathways 
and functional associations. The same is occurring for peptide arrays. Analysis pipelines such 
as PIIKA and the adaptation of InnateDB for use with phosphorylation data is only the start of 
this trend.  
 The data mining that we achieved is better than what was done previously, but much 
more can be done. One example of possible additional data mining is that peptide arrays could 
generate two potential data points per spot. One data point is the phosphorylation of the 
protein phosphorylation target sites modeled by the peptides on the array, which can be 
matched to proteins found in the cell. This phosphorylation site analysis is what was done in 
this project. The second potential data point is the identity of the kinases, which are active 
within a cell under the experimental conditions. To date, only a peptide which represents a 
protein has been studied, but it is equally valid to consider the kinase recognizing and 
phosphorylating the target site. Considering the fact that there are now thought to be 518 
kinases in the human genome (Manning, et al., 2002), it is theoretically possible to design a 
universal kinase array containing 518 spots corresponding to the consensus sequence of each 
kinase. This array could then be used for any human kinome experiment. The problems of 
kinase specificity, multiple kinases phosphorylating the same spot and varying kinase activity 
would need to be addressed. In addition, peptide arrays that include a larger number of target 
peptides would enhance kinome coverage. With improved printing and experimental 
techniques, it may be possible to have thousands of kinase target peptides on an array. This 
would enhance the high-throughput, global nature of the technology.   
 Another potential direction for kinomics is the profiling of groups or individuals. As 
we observed in the MAP study, individual outbred animals display unique kinome profiles 
which can be used to separate and organize them. Using kinome profiles, it may be possible to 
screen for disease susceptibility or resistance and environmental effects based on the profile 
generated. This has begun with our work on cancer profiles (Van den Brooke, et al., 2011). 
For example, if a cancer cell line is more like a normal cell than a tumour cell growing in an 
animal, it may be inappropriate to use cell lines such as these for signalling studies that 
purport to model cancer.   
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 Kinome profiles can be incorporated into a wider systems biology approach. It may be 
invaluable to incorporate kinomics with the other “omics”, such as genomics, transcriptomics, 
proteomics and metabolomics, to obtain a more comprehensive view of biology. Again, this 
will require data-analysis techniques and data-mining approaches of increased sophistication. 
It will be the work of biologists and bioinformaticians to combine their skills and produce 
biologically relevant, mathematically sound analysis methods.  
 
   5.6.4.2 Novel Genera 
 The interest in performing peptide array kinome analysis on genera other than human 
and mouse has become clear. Some groups have already attempted to profile plants with 
human peptide arrays (Ritsema, et al., 2007). Our group has taken a more exact approach by 
designing arrays which are customized and genus-specific, based on bioinformatic techniques 
(Jalal, et al., 2009). The desire to use this approach has been shown by groups which have 
approached us to design arrays. To date, bovine, chicken, pig, bee and soy bean arrays are in 
development. The challenge of designing arrays for genera that are evolutionarily distant from 
humans, such as bee and soy bean, is significant. Computer-based techniques which automate 
the process are able to run through tens of thousands of proteins and link them to known 
phosphorylation events. This will be a key advancement in the genus-specific array technique.  
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6.0 CONCLUSIONS 
Phosphorylation-mediated cellular signalling represents the central mechanism for 
regulation of cell function. Kinases are a class of enzyme which phosphorylates protein 
through the transfer of a phosphate group, usually from the donor ATP, to the target protein. 
The study of kinases has led to the development of peptide-array technology which exploits 
the kinase recognition site sequences on proteins. These sequences are printed onto array 
surfaces and are recognized and phosphorylated by active kinases. Our development of 
custom-designed genus-specific peptide arrays has allowed for kinomic studies of genera 
besides human and mouse. Specifically, the study of bovine response to various pathogens 
and ligands has been the main focus thus far. 
 The limitations of the mathematical analysis and mining of peptide array data have 
impeded further development of this technology. Historically, peptide array data were 
analyzed in much the same way that nucleotide-based array data were. However, due to the 
numerous differences between the two types of data, sharing analysis methods was not ideal. 
Therefore, a data-analysis pipeline called PIIKA was developed to both analyze and mine 
peptide array data more effectively and efficiently. A comparison with other standard 
microarray analysis techniques confirmed the increased efficacy of PIIKA. PIIKA enables 
analysis of data by a method purpose-adapted to peptide arrays. It also allows for a higher-
order analysis of peptide array data, organizing it into clusters based on similarity and the 
output can be used to query pathway databases based on the phosphorylation signal generated.  
 Peptide arrays and PIIKA were applied to the biological question of prion function. 
The properly folded form of the prion protein known as PrPC is highly conserved in various 
cell types and species. Upon misfolding to the scrapie-like form (PrPSc), the protein causes 
neurodegenerative disease. There is little known about the function of prion, but there is 
ample evidence that it is a cell-surface signalling molecule. The prion protein’s GPI anchor, 
location within lipid rafts and required linkage to the cell surface for disease pathogenesis all 
point to a role as a signalling molecule. Two PrP-specific stimulants were used to induce 
signalling in neuronal cells. One stimulant was a fragment of the prion protein containing 
amino acids 106-126, considered to be an inducer of responses modelling prion disease. The 
second PrP stimulant was the prion-specific antibody 6H4, considered to be an inducer of 
responses modelling endogenous signalling. Kinome results showed a distinct set of 
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signalling events based on the two treatments, displaying a variable signalling ability. Prion 
function may be difficult to determine, as it may be ligand-dependent or interacting partner 
dependent. 
 The host-pathogen interaction and immune-evasion abilities of MAP were another cell 
signalling problem studied in this project. MAP has the ability to evade immune responses 
and grow inside of the phagosome of macrophages, a place where bacteria are normally 
destroyed. Kinome analysis indicated that MAP is able to inhibit the IFNγ-induced JAK-
STAT signalling pathway, thus, eliminating the activation of downstream effectors. The 
MAP-induced pathway inhibition occurred at the level of the IFNγ receptor. MAP also caused 
the activation of JAK-STAT suppressor molecules known as SOCS. Both receptor-level 
inhibition and SOCS activation are novel findings in the study of MAP pathogenesis. In 
addition, long-term MAP immune suppression may occur due to the suppression of IFNγ 
receptor gene expression. While SOCS expression is upregulated in as little as 1 hour, a 
significant decrease in the expression of IFNγ receptor is observed at 18 hours. This 
suppression is another indication that MAP targets the receptor to eliminate IFNγ immune 
signalling. 
 This project has increased the efficacy of peptide array experimental techniques, data 
analysis and data mining. Comprehensive comparisons of other array analysis methods show 
a clear benefit over these previously used methods. These advances have allowed the study of 
prion signalling and the description of prion’s multifarious signalling ability. The project has 
advanced the characterization and understanding of IFNγ-based immune suppression by MAP 
infection. These results prove custom-designed genus-specific peptide arrays, in conjunction 
with customized data analysis methods, represent a valuable strategy to determine host 
signalling responses induced by a variety of stimuli, including infection. 
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8.0 APPENDIX 
Table A1. Transformed peptide array data: prion project. 
   PrP vs Scram 6H4 vs IgG1 
Name ID Target p-value Fold Change p-value Fold change 
4E-BP1  Q13541 T46 0.295 1.214 0.233 -1.491 
4E-BP1  Q13541 T37 0.359 -1.124 0.132 -1.543 
Akt1 P31749 T308 0.438 -1.031 0.327 1.240 
Akt1 P31749 S473 0.491 1.007 0.076 -1.709 
Akt1  P31749 S124/9 0.386 -1.148 0.149 1.344 
Akt1  P31749 Y326 0.319 -1.196 0.195 1.453 
Akt3  Q9Y243 T447 0.451 -1.053 0.139 1.588 
Akt3  Q9Y243 S120 0.223 -1.401 0.496 -1.004 
APE1 P27695 S289 0.197 1.266 0.102 1.492 
A-Raf P10398 Y301 0.062 1.658 0.404 1.116 
ASK1  Q99683 S1033 0.429 1.068 0.222 1.241 
ASK1  Q99683 S83 0.355 1.216 0.422 1.050 
ASK1  Q99683 S966 0.102 1.504 0.272 -1.338 
ATF-2  P15336 T51/3/5 0.200 1.314 0.015 2.156 
ATF-2  P15336 S44 0.190 1.321 0.207 1.311 
ATF-4  P18848  S245 0.333 1.206 0.202 -1.505 
axin-1  O15169 S486 0.422 -1.074 0.148 1.492 
Bad  Q92934 S118 0.343 -1.155 0.175 -1.693 
BATF  Q16520 T48 0.271 1.223 0.067 -1.501 
BCAP  Q6ZUJ8 Y17 0.154 1.495 0.409 -1.062 
BCAP  Q6ZUJ8 Y281 0.333 1.104 0.173 -1.283 
Bid  P55957 T59 0.446 -1.035 0.414 1.106 
BLNK  Q8WV28 Y72 0.290 -1.169 0.164 1.544 
BLNK  Q8WV28 Y96 0.364 1.099 0.240 1.306 
B-Raf P15056 T598 0.263 -1.191 0.034 2.142 
Btk  Q06187 Y223 0.164 1.208 0.418 1.091 
Btk  Q06187 Y551 0.291 1.121 0.167 -1.449 
Calmodulin  P62158 Y99 0.468 -1.021 0.359 -1.193 
CaMK2-
alpha  Q9UQM7 T286 0.074 -1.406 0.011 2.384 
Casp3  P42574 S150 0.078 1.306 0.461 -1.039 
Casp8  Q14790 S347 0.408 -1.063 0.372 1.102 
CBP  Q92793 S2063 0.260 1.250 0.469 -1.036 
CCR2  P41597  Y139 0.436 -1.079 0.118 1.456 
CCR5  P51681  S336/7 0.439 1.065 0.488 -1.012 
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CCR7  P32248 S356/7 0.240 -1.420 0.361 1.127 
CCR7  P32248 T372/3/4/5/7 0.326 1.144 0.448 -1.047 
CD28  P10747 Y206/9 0.378 -1.109 0.147 1.404 
CD45  P08575 S999/02/03 0.416 1.066 0.372 -1.221 
CD45  P08575 Y1216 0.258 1.176 0.097 -1.978 
Cdc25A  P30304 S82 0.205 1.424 0.295 1.235 
Cdc25A  P30304 S88 0.067 1.904 0.063 -2.058 
Cdc42  P60953 Y64 0.092 -1.437 0.490 1.012 
CDK2  P24941 T160 0.166 -1.320 0.287 -1.272 
CDK2  P24941 T14/5 0.181 -1.241 0.271 -1.227 
CDK7  P50613 T170 0.027 -1.452 0.409 1.083 
Cot  P41279 S400 0.375 1.101 0.500 1.000 
CREB  P16220 S110/1 0.453 1.031 0.087 -1.844 
CREB  P16220 S129 0.407 1.103 0.047 -2.207 
Crk  P46108 Y221 0.255 -1.212 0.173 1.477 
CSFR  P07333  Y561 0.437 1.061 0.425 1.062 
CSFR  P07333  Y809 0.437 1.051 0.446 -1.050 
CSK  P41240 Y184 0.457 -1.040 0.277 1.258 
CTLA-4  P16410 Y201 0.017 -1.822 0.320 -1.185 
CTNNB1 P35222 T41/45 0.405 1.087 0.131 1.404 
CTNNB1 P35222 S33/37 0.066 1.998 0.489 -1.010 
CTNNB1 P35222 Y142 0.147 -1.330 0.126 -1.264 
CTNNB1 P35222 S675 0.333 -1.098 0.050 -1.522 
CXCR4  P61073 Y157 0.258 -1.155 0.438 1.067 
cyclin D1  P24385 T286/8 0.276 -1.193 0.351 -1.153 
cyclin E1  P24864 T395 0.410 -1.071 0.012 -2.052 
DAPK1  P53355 S308 0.323 1.187 0.370 -1.118 
DAPK1  P53355 S735 0.372 -1.161 0.100 -1.487 
DAPK3 O43293 T225 0.139 -1.243 0.147 1.419 
DAPK3 O43293 T180 0.176 1.415 0.167 -1.519 
DAPP1  Q9UHF2 Y139 0.230 -1.164 0.361 -1.127 
Daxx  Q9UER7 S668/71 0.057 -1.305 0.385 1.157 
DNA-PK  P78527 T2609 0.333 -1.095 0.423 -1.061 
DNA-PK  P78527 T2638 0.364 -1.108 0.341 -1.116 
DOCK2 Q5XG91 Y221/4 0.227 -1.216 0.451 1.039 
Elk-1  P19419 T417 0.343 1.201 0.476 1.020 
Elk-1  P19419 S389 0.101 1.656 0.429 -1.082 
eNOS  P29474 S1176 0.403 1.056 0.013 -1.398 
EphA1  P21709 Y781 0.356 -1.120 0.385 1.081 
148 
 
EphA2  P29317 Y594 0.398 1.107 0.231 -1.288 
EphA2  P29317 Y772 0.176 1.572 0.163 -1.412 
EphA2  P29317 Y588 0.146 1.372 0.035 -1.718 
ERK1  P27361 T202/4 0.356 1.140 0.334 1.119 
ERK2  P28482 Y205 0.434 -1.103 0.145 -1.222 
ERK3  Q16659 S189 0.292 -1.119 0.234 -1.287 
Etk  P51813 Y40 0.376 -1.159 0.019 -3.704 
Ezrin P15311 T566 0.146 1.313 0.167 1.334 
FADD  Q13158 S194 0.489 -1.008 0.393 1.111 
FADD  Q13158 S196 0.203 -1.332 0.079 -2.115 
FAK  Q05397 Y397 0.470 1.029 0.182 1.473 
Fas  P25445 Y232 0.479 1.016 0.414 -1.092 
Fas  P25445 Y291 0.139 -1.481 0.201 -1.482 
Fes  P07332 Y713 0.230 -1.283 0.434 -1.105 
FGFR1  P11362 Y653/4 0.495 -1.003 0.099 1.559 
FGFR1  P11362 Y154 0.211 -1.216 0.127 1.346 
FGFR1  P11362 Y463 0.055 1.859 0.280 -1.186 
FGFR3  P22607 Y724 0.364 1.110 0.496 1.004 
FGFR3  P22607 Y760 0.292 1.221 0.283 -1.352 
FGFR4  P22455 Y754 0.224 1.296 0.255 1.199 
FLT3  P36888 Y589/91 0.397 1.093 0.096 1.486 
FLT3  P36888 Y597/9 0.192 -1.435 0.109 -1.494 
Fos  P01100 T232 0.382 -1.102 0.319 1.239 
FRS2  Q8WU20 Y196 0.329 1.148 0.288 -1.409 
FRS2  Q8WU20 Y436 0.412 1.029 0.029 -2.826 
FRS3  Q8WU20 Y416 0.196 -1.302 0.220 -1.516 
gp130  P40189 S782 0.325 -1.196 0.247 1.299 
gp130  P40189 Y814 0.345 -1.104 0.474 1.035 
gp130  P40189 Y767 0.240 1.236 0.371 -1.091 
Grb10  Q13322 S150 0.354 1.090 0.029 2.310 
GSK3-beta  P49840 S9 0.431 -1.048 0.290 1.223 
GSK3-beta  P49840 Y216 0.102 1.471 0.435 1.069 
HIF1A  Q16665 T796 0.234 1.279 0.294 -1.212 
HIF2A  Q99814 T840 0.120 -1.572 0.123 1.369 
HMGA1  P17096  T52 0.291 -1.226 0.327 -1.118 
H-Ras-1  P01112 T35 0.253 1.413 0.256 1.433 
HSP27  P04792 S78/82/3 0.067 -1.765 0.413 -1.075 
HSP70  P08107 Y525/6 0.197 -1.335 0.285 1.241 
IFNAR1  P17181 S535 0.408 1.096 0.340 1.080 
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IFNAR1  P17181 Y466 0.254 1.161 0.059 -2.249 
IFNGR1  P15260 Y479 0.338 1.125 0.322 1.162 
IFNGR1  P15260 Y457 0.034 -1.922 0.493 -1.004 
IGF1R  P08069  Y1166 0.323 1.269 0.007 -3.497 
IkB-alpha  P25963  S32/36 0.318 1.184 0.136 1.915 
IkB-alpha  P25963  Y42 0.134 1.794 0.285 -1.337 
IkB-beta  Q15653 S313/15 0.321 1.160 0.109 1.748 
IkB-beta  Q15653 T19/23 0.430 1.083 0.435 -1.106 
IkB-epsilon O00221 S18/22 0.168 -1.483 0.353 1.196 
IKK-alpha  O15111 T23 0.047 1.486 0.117 1.502 
IKK-alpha  O15111 S180 0.215 1.431 0.286 -1.168 
IKK-beta  O14920 Y199 0.489 -1.011 0.077 1.879 
IKK-beta  O14920 Y188 0.084 -1.436 0.219 1.501 
IKK-gamma  Q9Y6K9 S31 0.021 -1.551 0.216 -1.222 
IKK-gamma  Q9Y6K9 S43 0.043 1.280 0.038 -1.466 
IL-10R-A  Q13651 Y496 0.346 1.173 0.467 1.040 
IL-16  Q14005 S143/4 0.438 1.066 0.257 1.158 
IL1A  P01583 S87 0.463 1.045 0.298 1.283 
IL2RB  P14784 Y364 0.248 1.228 0.466 -1.041 
IL2RB  P14784 Y536 0.031 -1.920 0.321 -1.231 
IL4R  P24394 Y713 0.253 -1.340 0.001 2.635 
IL7R  P16871 Y449 0.486 -1.013 0.139 1.415 
IL-8R B  P25025 S351/2/3 0.143 1.615 0.052 2.795 
IL-8R B  P25025 S347 0.180 1.460 0.447 -1.089 
iNOS  P35228 S739 0.001 2.844 0.326 1.201 
iNOS  P35228 Y151 0.002 3.450 0.370 1.146 
iNOS  P35228 S909 0.002 1.305 0.151 -1.515 
IRAK1  P51617 T209 0.282 1.383 0.172 1.482 
IRAK1  P51617 S376 0.253 -1.320 0.427 -1.058 
IRAK1  P51617 T387 0.300 -1.178 0.377 -1.146 
IRAK1  P51617 S568 0.027 1.486 0.349 -1.264 
IRAK1  P51617 T100 0.427 1.080 0.153 -1.630 
IRF-3  Q14653 S396/8 0.078 -1.979 0.050 1.636 
IRF-3  Q14653 S385/6 0.269 -1.173 0.105 1.258 
IRF-3  Q14653 S402/5 0.043 -2.020 0.129 1.647 
IRF-5  Q13568 S437 0.220 1.387 0.415 -1.094 
ITK  Q08881 Y512 0.366 1.134 0.040 1.929 
Jak1  P23458 Y1022/3 0.120 1.701 0.065 1.835 
Jak2  O60674 Y1007/8 0.420 -1.077 0.401 -1.098 
150 
 
Jak3  P52333 Y981 0.090 1.699 0.436 -1.065 
JIP1  Q9UQF2 T103 0.043 1.297 0.330 1.175 
JNK1 P45983 Y185 0.291 1.217 0.024 -2.219 
JNK1  P45983  S377 0.021 -2.023 0.017 2.750 
JNK2  P45984 S129 0.427 1.058 0.342 1.242 
JNK2  P45984 T404/7 0.415 -1.049 0.355 1.277 
JNK3  P53779 T131 0.174 1.406 0.315 1.356 
Jun  P05412 S73 0.021 -1.622 0.033 1.645 
Jun  P05412 S63 0.474 1.023 0.308 1.173 
Kit  P10721 Y721 0.132 -1.341 0.170 1.377 
Kit  P10721 S821 0.136 -1.349 0.384 -1.109 
LEF-1 Q9UJU2 T155 0.372 1.052 0.042 1.812 
LEF-1 Q9UJU2 S166 0.381 1.110 0.138 -1.452 
LRRFIP1  O75766 S497 0.457 -1.031 0.440 -1.052 
LRRFIP1  O75766 S690 0.378 -1.136 0.240 -1.302 
Lyn  P07948 Y507 0.161 1.300 0.008 -2.498 
MEK1  Q02750 S217 0.288 1.303 0.056 -1.894 
MEK2  P36507 Y216 0.488 1.010 0.137 -1.647 
MEK5  Q13163  S311/15 0.193 1.319 0.169 -1.621 
MEKK1  Q13233 T1383 0.417 -1.073 0.316 -1.273 
Met  P08581 Y1234/5 0.246 1.383 0.234 -1.373 
Met  P08581 Y1349 0.070 1.531 0.120 -1.522 
MKK3 P46734 T222 0.320 1.237 0.497 1.003 
MKP-1  P28562 S296 0.403 -1.044 0.000 3.743 
MKP-1  P28562 S359 0.112 -1.432 0.463 -1.024 
MKP-1  P28562 S323 0.300 -1.172 0.341 -1.139 
MLK3  Q16584  T277 0.010 2.142 0.207 -1.350 
Mos  P00540 S25 0.409 -1.053 0.438 -1.051 
MSK1  O75582  T581 0.308 -1.172 0.496 -1.003 
MSK2  O75676 S347 0.366 -1.103 0.226 1.607 
MSK2  O75676 S196 0.231 1.370 0.300 1.265 
mucin 1  P15941  T1224/7/9 0.037 1.722 0.005 2.689 
NFAT1  Q13469  S168 0.223 -1.310 0.375 1.132 
NFAT1  Q13469 S326 0.481 1.016 0.396 1.081 
NFAT2  O95644 S294 0.007 -1.953 0.152 -1.191 
NFAT2  O95644 S245 0.032 -1.608 0.121 -1.530 
NFAT4  Q12968 S163/5 0.450 -1.031 0.069 1.361 
NFkB-p100  Q00653 S865 0.199 -1.648 0.064 1.522 
NFkB-p100  Q00653 S869/71 0.010 -2.012 0.165 1.396 
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NFkB-p105  P19838 S337 0.331 -1.176 0.132 1.211 
NFkB-p105  P19838 S907 0.117 -1.394 0.474 -1.020 
NFkB-p65  Q04206 S276 0.213 1.320 0.110 1.369 
NFkB-p65  Q04206 S311 0.169 -1.415 0.382 1.138 
NFkB-p65  Q04206 S536 0.049 -1.709 0.450 1.059 
NGFR  P08138  Y336 0.126 1.371 0.317 1.236 
Nik  Q99558 T559 0.192 1.259 0.449 -1.067 
Notch 2  Q04721 S2070 0.121 -1.353 0.261 -1.158 
Notch 2  Q04721 T1808 0.411 -1.094 0.057 -1.729 
p300  Q09472  S893 0.040 -1.421 0.486 1.011 
p300  Q09472  S1834 0.217 -1.239 0.340 -1.174 
P38 gamma P53778 T183/5 0.322 -1.251 0.427 1.116 
p38-alpha  Q16539 Y323 0.118 -1.549 0.472 1.020 
p38-alpha  Q16539 T180/2 0.280 -1.211 0.489 -1.009 
p40phox  P14598 T154 0.069 -1.588 0.430 1.053 
p47phox  P14598 S370 0.364 -1.095 0.103 1.649 
p53  P04637 S6/9 0.438 1.102 0.178 1.399 
p53  P04637 S215 0.258 -1.395 0.140 -1.460 
p70S6Kb  Q9UBS0 S473/4 0.477 1.020 0.388 1.135 
PDGFRb  P09619  Y579/81 0.058 -1.372 0.076 1.559 
PDGFRb  P09619  Y740 0.073 1.733 0.196 1.284 
PIK3R1  P27986 S608/7 0.374 -1.114 0.341 -1.117 
PKACa  P17612 T195/7 0.386 1.094 0.131 1.577 
PKACa  P17612 S338 0.422 1.052 0.204 1.283 
PKCA  P17252 Y658 0.188 1.349 0.330 1.109 
PKCA  P17252 S656 0.047 -1.714 0.367 1.180 
PKCA  P17252 T637 0.137 -1.585 0.265 -1.272 
PKCB  P05771 S15/T16 0.346 -1.220 0.355 1.168 
PKCB  P05771 T323 0.479 1.022 0.233 -1.339 
PKCE  Q02156 T710 0.077 1.522 0.294 -1.273 
PKCE  Q02156 S729 0.380 -1.116 0.029 -2.446 
PKCT  Q04759 T219 0.473 -1.030 0.300 1.204 
PKCT  Q04759 Y90 0.201 1.443 0.314 1.192 
PKG1  Q13976 T58 0.374 -1.061 0.320 -1.195 
PKR  P19525 T451 0.001 -2.411 0.371 -1.115 
PKR  P19525 T446 0.320 -1.091 0.327 -1.128 
PLCB1  Q9NQ66  S887 0.310 -1.129 0.012 2.358 
PLCB1  Q9NQ66  S887 0.155 1.556 0.099 1.606 
PLCG1  P19174 Y472 0.369 1.101 0.172 -1.448 
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PLCG1  P19174 Y771 0.021 1.863 0.162 -1.582 
PLCG1  P19174 Y783 0.489 -1.011 0.000 -2.902 
PPARG  P37231 S112 0.459 -1.041 0.477 -1.009 
PPP2CA  P67775 T304/7 0.068 1.529 0.434 -1.071 
PTP1B  P18031 S50 0.041 1.882 0.458 -1.033 
PXN P49023  Y31 0.121 -1.698 0.188 1.505 
Pyk2  Q14289 Y402 0.013 -2.401 0.490 -1.007 
RAC1  P63000 S71 0.498 -1.001 0.065 1.367 
Raf1  P04049 S499 0.217 -1.330 0.409 -1.097 
Raf1  P04049 S259 0.217 -1.410 0.402 -1.130 
RasGAP  P20936 Y460 0.350 1.145 0.261 1.446 
Rb  P06400 S780 0.223 1.226 0.124 -1.554 
Rb  P06400 S795 0.484 -1.010 0.069 -2.440 
RelB  Q01201 S573 0.291 1.150 0.116 -1.284 
RhoA   P61586 S188 0.253 1.294 0.124 -1.918 
RIPK1  Q13546 Y384/7/9 0.098 1.340 0.006 -2.602 
ROCK2  O75116 S1134/7 0.321 -1.132 0.077 -1.531 
SEK1  P45985 S80 0.314 -1.190 0.355 1.225 
SEK1  P45985 S257/0 0.479 -1.023 0.128 -1.833 
Shc1 P29353 Y349/0 0.277 1.245 0.496 1.003 
Smad1  Q15797 S462/3/5 0.145 -1.209 0.265 -1.160 
Smad2  Q15796 S250 0.471 -1.021 0.102 1.772 
Smad2  Q15796 S255 0.022 -1.966 0.177 1.425 
Smad2  Q15796 T8 0.024 -1.852 0.427 -1.035 
Smad3  P84022 S208 0.156 -1.300 0.331 1.123 
Smad3  P84022 S422/3/5 0.272 -1.094 0.494 1.002 
Smad4 Q13485 T277 0.046 -1.746 0.430 -1.044 
smMLCK  Q15746 S1773 0.419 1.068 0.116 1.770 
Src  P12931  S96 0.200 1.282 0.486 1.014 
Src  P12931  S74 0.188 1.236 0.167 -1.453 
SRF  P11831 S77/79 0.138 1.500 0.415 -1.100 
STAT1  P42224 S727 0.099 -1.421 0.461 1.026 
STAT1  P42224 Y701 0.202 -1.194 0.188 -1.332 
STAT2  P52630 Y690 0.082 -1.520 0.110 1.264 
STAT3  P40763 Y705 0.104 -1.440 0.300 -1.177 
STAT3  P40763 S727 0.321 1.346 0.166 -1.407 
STAT4  Q14765 Y693 0.218 -1.234 0.255 -1.205 
STAT4  Q14765 S721 0.090 -1.636 0.177 -1.321 
STAT5B  P51692 Y699 0.481 1.024 0.473 -1.024 
153 
 
STAT5B  P51692 S731 0.240 1.212 0.464 -1.032 
STAT6  P42226 Y641 0.288 -1.250 0.319 -1.095 
STMN1  P16949  S62 0.265 -1.168 0.043 1.456 
STMN1  P16949  S15 0.364 1.113 0.395 1.094 
Syk  P43405 Y525/6 0.039 1.647 0.313 1.282 
TAK1  O43318 S192 0.328 1.168 0.019 1.758 
TAK1  O43318 T184 0.443 1.059 0.458 1.046 
TBK1  Q9UHD2 S172 0.427 1.043 0.492 1.008 
TNF-R1  P19438 S274 0.266 -1.288 0.497 -1.003 
TNFRSF5  P25942 T254 0.438 1.056 0.231 1.440 
TNIK  Q9UKE5  T987 0.240 1.160 0.328 -1.200 
TNIK  Q9UKE5  S764 0.017 2.053 0.237 -1.265 
TPH1  P17752 S58 0.405 -1.090 0.111 1.878 
TRAF6 Q9Y4K3 T 0.182 -1.374 0.274 1.305 
TRAF6 Q9Y4K3 T 0.009 -1.830 0.440 -1.086 
TRAF6 Q9Y4K3 T 0.121 1.276 0.363 -1.174 
TRAF6 Q9Y4K3 T 0.087 -1.236 0.300 -1.211 
TRAF6 Q9Y4K3 S 0.026 1.688 0.266 -1.164 
TRAF6 Q9Y4K3 S 0.017 1.682 0.006 -2.309 
TRAF6 Q9Y4K3 S 0.316 1.169 0.002 -1.705 
TrkB  Q16620  Y706/7 0.130 -1.271 0.053 -2.665 
TrkC  Q16288  Y516 0.055 1.496 0.280 -1.427 
Tyk2  P29597  Y1054/5 0.176 -1.440 0.126 1.717 
VASP  P50552 S156 0.197 1.372 0.219 1.344 
VEGFR-1  P17948 Y1169 0.052 1.677 0.443 -1.060 
VEGFR-2  P35968 Y1214 0.297 1.290 0.137 -1.476 
VEGFR3  P35916 Y130/1 0.418 -1.046 0.455 1.051 
VEGFR3  P35916 Y1265 0.076 -1.395 0.438 -1.090 
WASP  P42768 Y291 0.052 -1.839 0.494 1.007 
XIAP  P98170 S87 0.302 1.227 0.309 1.054 
 
Peptide array data which has been transformed with p-value and fold change calculated based 
on the comparisons listed. Name indicates name of protein corresponding to peptide target 
sequence printed. ID refers to protein UniProt identification number. p-value refers to 
significance value calculated between two treatments indicated. Fold change refers to the 
differences between the two treatments indicated. 
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Table A2. Transformed peptide array data: MAP project. 
   IFN+MAP vs Monocytes 
IFN+Monocytes vs 
Monocytes 
Name ID Target p-value Fold Change p-value Fold Change 
4E-BP1  Q13541 T46 0.067 1.234 0.439 1.014 
4E-BP1  Q13541 T37 0.361 1.053 0.265 -1.068 
ADCY8 P40145 Y406 0.224 -1.090 0.013 -1.104 
Akt1 P31749 S473 0.445 1.017 0.384 -1.023 
Akt1 P31749 T308 0.213 -1.083 0.046 -1.149 
Akt1  P31749 Y326 0.175 1.157 0.030 1.302 
Akt1  P31749 S124/9 0.487 -1.005 0.392 -1.042 
Akt3  Q9Y243 T447 0.259 1.145 0.108 1.174 
Akt3  Q9Y243 S120 0.404 1.027 0.458 1.013 
APE1 P27695 S289 0.059 -1.245 0.153 -1.185 
Aplp1 P51693 Y643 0.122 -1.327 0.158 1.104 
ApoE P02649 S314 0.488 1.003 0.002 -1.273 
A-Raf P10398 Y301 0.253 1.085 0.279 1.023 
ASK1  Q99683 S966 0.147 -1.171 0.266 1.063 
ASK1  Q99683 S1033 0.263 -1.082 0.010 -1.232 
ASK1  Q99683 S83 0.289 -1.074 0.008 -1.238 
ATF-2  P15336 T51/3/5 0.472 -1.016 0.054 1.169 
ATF-2  P15336 S44 0.385 1.048 0.404 1.023 
ATF-4  P18848  S245 0.462 -1.033 0.033 1.392 
axin-1  O15169 S486 0.303 -1.053 0.482 -1.002 
Bad  Q92934 S118 0.028 1.259 0.069 1.140 
BATF  Q16520 T48 0.027 -1.207 0.207 -1.077 
BCAP  Q6ZUJ8 Y281 0.377 1.030 0.113 1.095 
BCAP  Q6ZUJ8 Y17 0.311 -1.057 0.094 -1.112 
Bcl-2 P10415 S70 0.469 1.026 0.041 1.263 
Bcl-2 P10415 T56 0.421 1.043 0.419 1.024 
Bid  P55957 T59 0.481 -1.005 0.047 -1.120 
BLNK  Q8WV28 Y96 0.209 -1.098 0.133 1.102 
BLNK  Q8WV28 Y72 0.336 1.035 0.250 1.043 
B-Raf P15056 T598 0.411 -1.044 0.166 1.090 
Btk  Q06187 Y223 0.489 1.004 0.061 1.163 
Btk  Q06187 Y551 0.253 1.078 0.068 1.107 
Calmodulin  P62158 Y99 0.117 1.144 0.470 -1.007 
CaMK2-alpha  Q9UQM7 T286 0.241 -1.085 0.129 1.204 
Casp3  P42574 S150 0.116 -1.103 0.406 1.015 
Casp8  Q14790 S347 0.060 -1.184 0.150 1.075 
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caveolin-1 Q2TNI1 Y14 0.420 -1.013 0.068 -1.128 
Cbl P22681 Y371 0.205 -1.139 0.095 -1.113 
CBP  Q92793 S2063 0.265 -1.090 0.024 1.203 
CCR2  P41597  Y139 0.474 -1.012 0.315 1.094 
CCR5  P51681  S336/7 0.108 -1.146 0.161 -1.124 
CCR7  P32248 S356/7 0.177 -1.186 0.166 -1.128 
CCR7  P32248 T372/3/4/5/7 0.215 -1.071 0.132 -1.114 
CD28  P10747 Y206/9 0.276 1.082 0.398 1.021 
CD45  P08575 S999/02/03 0.271 1.137 0.062 -1.162 
CD45  P08575 Y1216 0.491 1.003 0.053 -1.175 
Cdc25A  P30304 S88 0.398 -1.047 0.207 1.108 
Cdc25A  P30304 S82 0.270 1.087 0.312 -1.052 
Cdc42  P60953 Y64 0.236 -1.071 0.001 -1.227 
CDK2  P24941 T14/5 0.199 1.141 0.166 1.127 
CDK2  P24941 T160 0.386 1.034 0.237 1.098 
CDK7  P50613 T170 0.147 1.119 0.293 1.057 
Cot  P41279 S400 0.116 -1.183 0.343 1.072 
CREB  P16220 S129 0.422 -1.023 0.063 -1.124 
CREB  P16220 S110/1 0.222 1.065 0.058 -1.110 
Crk  P46108 Y221 0.151 1.057 0.133 -1.083 
CSFR  P07333  Y809 0.226 1.067 0.236 -1.045 
CSFR  P07333  Y561 0.241 1.041 0.188 -1.063 
CSK  P41240 Y184 0.034 1.247 0.060 1.149 
CTLA-4  P16410 Y201 0.297 -1.081 0.364 1.054 
CTNNB1 P35222 T41/45 0.153 1.234 0.135 1.114 
CTNNB1 P35222 Y142 0.094 1.322 0.264 1.038 
CTNNB1 P35222 S675 0.222 1.041 0.102 -1.120 
CTSB P07858 Y219 0.129 1.210 0.358 1.033 
CXCR4  P61073 Y157 0.221 1.134 0.252 1.114 
cyclin D1  P24385 T286/8 0.413 1.033 0.344 1.046 
cyclin E1  P24864 T395 0.354 1.136 0.297 1.067 
Cystatin S P01036 S132 0.288 1.102 0.086 -1.124 
DAPK1  P53355 S735 0.306 1.109 0.128 -1.111 
DAPK1  P53355 S308 0.065 -1.249 0.009 -1.238 
DAPK3 O43293 T180 0.438 -1.024 0.334 1.032 
DAPK3 O43293 T225 0.004 1.348 0.375 1.017 
DAPP1  Q9UHF2 Y139 0.497 -1.001 0.060 1.159 
Daxx  Q9UER7 S668/71 0.464 -1.020 0.487 -1.008 
DNA-PK  P78527 T2609 0.500 1.000 0.192 1.110 
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DNA-PK  P78527 T2638 0.484 1.008 0.429 1.022 
Elk-1  P19419 T417 0.426 -1.025 0.038 1.284 
Elk-1  P19419 S389 0.121 -1.108 0.320 1.054 
eNOS  P29474 S1176 0.325 1.070 0.126 1.088 
EphA1  P21709 Y781 0.244 1.088 0.412 -1.015 
EphA2  P29317 Y588 0.169 1.171 0.055 1.245 
EphA2  P29317 Y772 0.042 1.185 0.195 1.089 
EphA2  P29317 Y594 0.173 1.090 0.302 1.025 
ERK1  P27361 T202/4 0.304 -1.069 0.403 1.019 
ERK2  P28482 Y205 0.019 -1.102 0.088 1.126 
ERK3  Q16659 S189 0.037 -1.175 0.094 1.233 
Etk  P51813 Y40 0.121 1.139 0.015 1.130 
Ezrin P15311 T566 0.446 1.014 0.048 -1.264 
FADD  Q13158 S194 0.402 1.018 0.090 1.104 
FADD  Q13158 S196 0.111 1.087 0.015 -1.217 
FAK  Q05397 Y397 0.416 1.020 0.405 -1.015 
Fas  P25445 Y291 0.130 -1.187 0.192 -1.107 
Fas  P25445 Y232 0.480 -1.007 0.009 -1.163 
Fes  P07332 Y713 0.433 -1.012 0.002 -1.280 
FGFR1  P11362 Y154 0.495 -1.002 0.363 1.023 
FGFR1  P11362 Y653/4 0.297 1.068 0.440 1.009 
FGFR1  P11362 Y463 0.451 1.014 0.008 -1.171 
FGFR3  P22607 Y724 0.213 1.094 0.500 1.000 
FGFR3  P22607 Y760 0.247 -1.114 0.303 -1.055 
FGFR4  P22455 Y754 0.191 -1.136 0.382 -1.025 
FLT3  P36888 Y589/91 0.471 1.012 0.427 1.030 
FLT3  P36888 Y597/9 0.377 1.036 0.242 -1.051 
Fos  P01100 T232 0.332 -1.051 0.106 1.147 
FRS2  Q8WU20 Y196 0.478 1.007 0.447 -1.014 
FRS2  Q8WU20 Y436 0.119 -1.151 0.087 -1.179 
FRS3  Q8WU20 Y416 0.390 -1.038 0.135 -1.134 
Fyn P06241 Y420 0.463 1.005 0.361 -1.019 
Fyn P06241 Y531 0.266 1.035 0.040 -1.164 
GCAP2 Q9UMX6 S200 0.264 -1.117 0.098 1.103 
gp130  P40189 S782 0.326 1.040 0.141 1.143 
gp130  P40189 Y767 0.355 1.063 0.167 1.152 
gp130  P40189 Y814 0.360 1.032 0.448 1.012 
Grb10  Q13322 S150 0.281 -1.058 0.148 1.091 
Grb2 P62993 Y209 0.416 -1.033 0.312 -1.035 
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GSK3-beta  P49840 Y216 0.449 -1.017 0.044 1.149 
GSK3-beta  P49840 S9 0.348 -1.047 0.067 1.284 
HIF1A  Q16665 T796 0.354 1.041 0.397 -1.022 
HIF2A  Q99814 T840 0.341 -1.047 0.457 -1.013 
HMGA1  P17096  T52 0.344 1.085 0.090 1.093 
H-Ras-1  P01112 T35 0.284 -1.065 0.018 -1.247 
HSP27  P04792 S78/82/3 0.355 -1.067 0.194 1.117 
HSP60 P10809 Y227 0.159 1.110 0.049 -1.115 
HSP70  P08107 Y525/6 0.123 1.127 0.147 1.087 
IFNAR1  P17181 Y466 0.228 -1.170 0.044 1.141 
IFNAR1  P17181 S535 0.411 -1.038 0.246 -1.073 
IFNGR1  P15260 Y479 0.467 -1.011 0.243 1.079 
IFNGR1  P15260 Y457 0.273 -1.070 0.260 1.092 
IGF1R  P08069  Y1166 0.119 -1.148 0.284 1.068 
IkB-alpha  P25963  Y42 0.404 -1.031 0.114 -1.121 
IkB-alpha  P25963  S32/36 0.406 1.026 0.006 -1.206 
IkB-beta  Q15653 S313/15 0.091 1.189 0.357 -1.017 
IkB-beta  Q15653 T19/23 0.324 -1.072 0.319 -1.025 
IKK-alpha  O15111 T23 0.225 1.067 0.335 -1.028 
IKK-beta  O14920 Y199 0.272 1.068 0.086 1.223 
IKK-beta  O14920 Y188 0.267 -1.078 0.156 1.103 
IKK-gamma  Q9Y6K9 S31 0.289 1.215 0.004 1.366 
IKK-gamma  Q9Y6K9 S43 0.326 1.059 0.225 1.065 
IL-10R-A  Q13651 Y496 0.146 -1.144 0.192 1.114 
IL-16  Q14005 S143/4 0.165 1.174 0.101 1.205 
IL1A  P01583 S87 0.245 1.145 0.147 1.135 
IL2RB  P14784 Y536 0.272 -1.089 0.237 1.098 
IL2RB  P14784 Y364 0.181 -1.119 0.314 1.050 
IL4R  P24394 Y713 0.314 1.082 0.140 1.158 
IL7R  P16871 Y449 0.178 1.161 0.073 1.156 
IL-8R B  P25025 S347 0.451 1.007 0.067 -1.119 
IL-8R B  P25025 S351/2/3 0.234 -1.065 0.026 -1.148 
iNOS  P35228 Y151 0.089 -1.181 0.027 -1.258 
iNOS  P35228 S909 0.305 -1.082 0.016 -1.198 
iNOS  P35228 S739 0.180 -1.097 0.001 -1.236 
IRAK1  P51617 T100 0.246 -1.134 0.028 1.203 
IRAK1  P51617 S376 0.468 1.029 0.296 1.049 
IRAK1  P51617 T387 0.310 -1.065 0.453 -1.015 
IRAK1  P51617 T209 0.268 1.080 0.275 -1.041 
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IRAK1  P51617 S568 0.439 -1.031 0.200 -1.088 
IRF-3  Q14653 S385/6 0.483 -1.005 0.105 1.123 
IRF-3  Q14653 S402/5 0.483 -1.003 0.201 1.054 
IRF-3  Q14653 S396/8 0.492 1.002 0.258 1.049 
IRF-5  Q13568 S437 0.333 1.043 0.010 1.121 
ITK  Q08881 Y512 0.430 1.017 0.372 -1.023 
Jak1  P23458 Y1022/3 0.122 -1.161 0.415 1.029 
Jak2  O60674 Y1007/8 0.222 -1.085 0.443 -1.010 
Jak3  P52333 Y981 0.022 -1.269 0.355 -1.020 
JIP1  Q9UQF2 T103 0.478 1.005 0.013 -1.148 
JNK1 P45983 Y185 0.277 -1.101 0.070 -1.153 
JNK1  P45983  S377 0.380 1.047 0.186 1.149 
JNK2  P45984 T404/7 0.193 1.066 0.483 1.003 
JNK2  P45984 S129 0.311 -1.069 0.312 -1.046 
JNK3  P53779 T131 0.223 1.093 0.079 -1.120 
Jun  P05412 S63 0.245 -1.077 0.060 1.332 
Jun  P05412 S73 0.392 -1.045 0.395 1.038 
Kit  P10721 Y721 0.176 1.096 0.291 1.042 
Kit  P10721 S821 0.139 -1.144 0.264 -1.090 
LEF-1 Q9UJU2 T155 0.195 1.131 0.246 1.072 
LEF-1 Q9UJU2 S166 0.087 -1.159 0.188 -1.055 
LRRFIP1  O75766 S690 0.175 1.047 0.449 -1.010 
LRRFIP1  O75766 S497 0.226 -1.049 0.185 -1.065 
Lyn  P07948 Y507 0.281 1.069 0.074 -1.150 
MEK1  Q02750 S217 0.068 -1.255 0.429 1.019 
MEK2  P36507 Y216 0.276 1.129 0.063 1.332 
MEK5  Q13163  S311/15 0.383 -1.046 0.264 -1.076 
MEKK1  Q13233 T1383 0.445 1.015 0.371 -1.032 
Met  P08581 Y1349 0.440 1.028 0.233 1.075 
Met  P08581 Y1234/5 0.167 1.140 0.453 1.011 
MKP-1  P28562 S359 0.066 -1.134 0.049 1.335 
MKP-1  P28562 S323 0.221 1.107 0.090 1.172 
MKP-1  P28562 S296 0.345 -1.117 0.300 -1.042 
MLK3  Q16584  T277 0.417 1.052 0.201 -1.108 
Mos  P00540 S25 0.088 -1.319 0.368 -1.036 
MSK1  O75582  T581 0.200 -1.139 0.078 -1.095 
MSK2  O75676 S347 0.345 1.051 0.072 -1.058 
MSK2  O75676 S196 0.399 -1.031 0.008 -1.158 
mucin 1  P15941  T1224/7/9 0.367 1.036 0.042 -1.172 
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NFAT1  Q13469 S326 0.453 1.024 0.051 1.150 
NFAT1  Q13469  S168 0.134 -1.168 0.303 1.053 
NFAT2  O95644 S294 0.046 1.137 0.137 1.137 
NFAT4  Q12968 S163/5 0.439 -1.017 0.228 -1.095 
NFkB-p100  Q00653 S865 0.164 1.208 0.086 1.123 
NFkB-p100  Q00653 S869/71 0.387 -1.047 0.265 -1.120 
NFkB-p105  P19838 S337 0.382 1.045 0.043 1.210 
NFkB-p105  P19838 S907 0.330 1.094 0.200 1.110 
NFkB-p65  Q04206 S276 0.283 1.152 0.003 1.229 
NFkB-p65  Q04206 S311 0.371 -1.071 0.022 1.258 
NFkB-p65  Q04206 S536 0.397 1.044 0.235 1.070 
NGFR  P08138  Y336 0.275 -1.084 0.399 1.034 
Nik  Q99558 T559 0.494 1.001 0.385 1.017 
Notch 2  Q04721 T1808 0.446 -1.011 0.420 1.021 
Notch 2  Q04721 S2070 0.418 -1.018 0.297 -1.046 
p300  Q09472  S893 0.449 1.049 0.054 1.130 
p300  Q09472  S1834 0.062 1.212 0.096 1.074 
P38 gamma P53778 T183/5 0.296 1.070 0.091 1.097 
p38-alpha  Q16539 Y323 0.234 1.095 0.493 -1.001 
p38-alpha  Q16539 T180/2 0.222 1.107 0.329 -1.032 
p40phox  P14598 T154 0.376 -1.049 0.268 -1.058 
p47phox  P14598 S370 0.498 -1.001 0.447 1.011 
p53  P04637 S6/9 0.245 1.060 0.052 -1.135 
p53  P04637 S215 0.328 -1.059 0.035 -1.266 
p70S6Kb  Q9UBS0 S473/4 0.297 1.060 0.173 -1.092 
PDGFRb  P09619  Y579/81 0.175 1.141 0.111 1.100 
PDGFRb  P09619  Y740 0.276 1.076 0.415 -1.015 
PIK3R1  P27986 S608/7 0.394 -1.042 0.353 -1.038 
PKACa  P17612 T195/7 0.121 1.174 0.033 1.165 
PKACa  P17612 S338 0.279 1.081 0.246 1.078 
PKCA  P17252 S656 0.208 -1.091 0.042 -1.220 
PKCA  P17252 T637 0.268 -1.076 0.003 -1.227 
PKCB  P05771 T323 0.117 1.190 0.265 -1.075 
PKCB  P05771 S15/T16 0.355 1.070 0.162 -1.108 
PKCE  Q02156 T710 0.284 1.092 0.416 -1.012 
PKCE  Q02156 S729 0.098 -1.179 0.036 -1.213 
PKCT  Q04759 T219 0.419 -1.028 0.059 -1.163 
PKCT  Q04759 Y90 0.095 -1.191 0.003 -1.293 
PKG1  Q13976 T58 0.193 -1.154 0.074 -1.220 
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PKR  P19525 T451 0.472 -1.009 0.162 1.084 
PKR  P19525 T446 0.049 1.370 0.182 1.093 
PLCB1  Q9NQ66  S887 0.437 1.027 0.078 1.097 
PLCB1  Q9NQ66  S887 0.215 1.196 0.366 1.043 
PLCG1  P19174 Y783 0.376 -1.042 0.022 1.137 
PLCG1  P19174 Y472 0.490 -1.002 0.407 1.022 
PLCG1  P19174 Y771 0.293 -1.057 0.049 -1.103 
PPARG  P37231 S112 0.460 1.011 0.047 -1.128 
PPP2CA  P67775 T304/7 0.002 -1.730 0.022 -1.328 
PTP1B  P18031 S50 0.243 -1.179 0.083 1.146 
PXN P49023  Y31 0.241 1.096 0.096 1.122 
Pyk2  Q14289 Y402 0.460 1.016 0.238 1.086 
RAC1  P63000 S71 0.372 1.037 0.436 1.006 
Raf1  P04049 S499 0.249 1.051 0.018 -1.187 
Raf1  P04049 S259 0.297 -1.056 0.012 -1.347 
RasGAP  P20936 Y460 0.240 -1.093 0.022 -1.106 
Rb  P06400 S780 0.230 1.108 0.241 1.080 
Rb  P06400 S795 0.286 1.079 0.298 1.025 
RelB  Q01201 S573 0.457 -1.014 0.042 1.196 
RhoA   P61586 S188 0.465 1.020 0.090 1.296 
RIPK1  Q13546 Y384/7/9 0.126 1.173 0.021 1.293 
ROCK2  O75116 S1134/7 0.408 -1.022 0.298 -1.067 
SEK1  P45985 S257/0 0.441 1.014 0.187 1.080 
SEK1  P45985 S80 0.410 1.038 0.298 1.099 
Shc1 P29353 Y349/0 0.478 -1.007 0.029 -1.159 
Smad1  Q15797 S462/3/5 0.278 1.164 0.041 1.220 
Smad2  Q15796 T8 0.479 -1.013 0.043 1.330 
Smad2  Q15796 S255 0.265 1.101 0.043 1.230 
Smad3  P84022 S208 0.153 1.163 0.013 1.240 
Smad3  P84022 S422/3/5 0.321 1.110 0.123 1.119 
smMLCK  Q15746 S1773 0.327 1.068 0.345 1.046 
SOD1 P00441 S98 0.290 -1.068 0.267 -1.052 
Src  P12931  S96 0.426 -1.033 0.393 -1.029 
Src  P12931  S74 0.299 1.044 0.057 -1.129 
SRF  P11831 S77/79 0.074 1.116 0.052 -1.098 
STAT1  P42224 Y701 0.142 1.203 0.078 1.221 
STAT1  P42224 S727 0.207 1.092 0.283 1.050 
STAT2  P52630 Y690 0.080 -1.154 0.062 1.133 
STAT3  P40763 S727 0.459 -1.018 0.032 1.361 
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STAT3  P40763 Y705 0.157 -1.116 0.046 1.157 
STAT4  Q14765 Y693 0.448 1.017 0.065 1.261 
STAT4  Q14765 S721 0.337 -1.060 0.094 1.172 
STAT5B  P51692 Y699 0.493 1.003 0.054 1.140 
STAT5B  P51692 S731 0.468 1.011 0.450 1.016 
STAT6  P42226 Y641 0.139 -1.398 0.004 1.220 
STMN1  P16949  S62 0.345 1.049 0.176 1.156 
STMN1  P16949  S15 0.208 -1.071 0.410 1.022 
Syk  P43405 Y525/6 0.354 -1.036 0.097 1.117 
TAK1  O43318 T184 0.325 1.037 0.028 1.120 
TAK1  O43318 S192 0.209 1.177 0.283 1.081 
TBK1  Q9UHD2 S172 0.377 -1.040 0.224 -1.056 
TNF-R1  P19438 S274 0.424 -1.018 0.005 -1.185 
TNFRSF5  P25942 T254 0.348 -1.052 0.037 -1.091 
TNIK  Q9UKE5  T987 0.218 -1.094 0.005 -1.260 
TNIK  Q9UKE5  S764 0.182 -1.135 0.004 -1.353 
TPH1  P17752 S58 0.009 -1.407 0.033 -1.239 
TrkB  Q16620  Y706/7 0.117 1.155 0.119 1.080 
TrkC  Q16288  Y516 0.355 1.081 0.413 1.028 
Tyk2  P29597  Y1054/5 0.425 -1.030 0.155 1.040 
VASP  P50552 S156 0.305 1.144 0.340 -1.068 
VEGFR-1  P17948 Y1169 0.178 -1.203 0.455 1.007 
VEGFR-2  P35968 Y1214 0.491 -1.002 0.012 1.215 
VEGFR3  P35916 Y130/1 0.437 -1.036 0.032 1.359 
VEGFR3  P35916 Y1265 0.063 -1.176 0.121 -1.081 
VIM P08670 S39 0.203 1.077 0.047 -1.146 
WASP  P42768 Y291 0.206 -1.075 0.188 1.058 
XIAP  P98170 S87 0.169 -1.119 0.018 1.149 
 
Peptide array data which has been transformed with p-value and fold change calculated based 
on the comparisons listed. Name indicates name of protein corresponding to peptide target 
sequence printed. ID refers to protein UniProt identification number. p-value refers to 
significance value calculated between two treatments indicated. Fold change refers to the 
differences between the two treatments indicated. 
